score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.169	71.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	BLCA_VARSCAN2	TCGA-YF-AA3L-01A-11D-A38G-08	TCGA-YF-AA3L-10A-01D-A38J-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.375	16.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-DK-AA77-01A-11D-A391-08	TCGA-DK-AA77-10A-01D-A394-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.5217	23.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-CF-A9FM-01A-11D-A38G-08	TCGA-CF-A9FM-10A-01D-A38J-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.R248C	0.6667	18.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.R248C (Missense)		BLCA_VARSCAN2	TCGA-CF-A47Y-01A-11D-A23U-08	TCGA-CF-A47Y-10A-01D-A23U-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.Y373C	0.9057	265.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.Y373C (Missense)		BLCA_VARSCAN2	TCGA-DK-A6B0-01A-11D-A31L-08	TCGA-DK-A6B0-10A-01D-A31J-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.8548	62.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AG-01A-11D-A13W-08	TCGA-DK-A1AG-10A-01D-A13W-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.8718	156.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-CF-A47V-01A-11D-A23U-08	TCGA-CF-A47V-10A-01D-A23U-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.R248C	0.1364	44.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.R248C (Missense)		BLCA_VARSCAN2	TCGA-FJ-A3ZE-01A-11D-A23M-08	TCGA-FJ-A3ZE-10A-01D-A23K-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.1458	48.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-FJ-A3ZE-01A-11D-A23M-08	TCGA-FJ-A3ZE-10A-01D-A23K-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.R248C	0.44	25.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.R248C (Missense)		BLCA_VARSCAN2	TCGA-BT-A0S7-01A-11D-A10S-08	TCGA-BT-A0S7-10A-01D-A10S-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.Y373C	0.4833	240.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.Y373C (Missense)		BLCA_VARSCAN2	TCGA-E7-A5KF-01A-11D-A289-08	TCGA-E7-A5KF-10A-01D-A289-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.5862	29.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-2F-A9KR-01A-11D-A38G-08	TCGA-2F-A9KR-10A-01D-A38J-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.Y373C	0.8131	107.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.Y373C (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RE-01A-11D-A38G-08	TCGA-ZF-A9RE-10A-01D-A38J-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.561	41.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-H4-A2HQ-01A-11D-A17V-08	TCGA-H4-A2HQ-10A-01D-A17V-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.7273	22.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA83-01A-11D-A391-08	TCGA-4Z-AA83-10A-01D-A394-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.5625	16.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-GU-AATQ-01A-11D-A391-08	TCGA-GU-AATQ-10A-01D-A394-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.Y373C	0.713	223.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.Y373C (Missense)		BLCA_VARSCAN2	TCGA-BT-A42C-01A-11D-A23M-08	TCGA-BT-A42C-10A-01D-A23K-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.5143	35.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-CF-A9FF-01A-11D-A38G-08	TCGA-CF-A9FF-10A-01D-A38J-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.G370C	0.5329	167.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.G370C (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4U-01A-11D-A38G-08	TCGA-ZF-AA4U-10A-01D-A38J-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.375	16.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-GU-A763-01A-11D-A32B-08	TCGA-GU-A763-10A-01D-A329-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.325	40.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-E7-A7XN-01A-11D-A34U-08	TCGA-E7-A7XN-10A-01D-A34X-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.4167	36.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-E5-A2PC-01A-11D-A202-08	TCGA-E5-A2PC-10B-01D-A202-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.7843	51.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-GU-A42R-01A-11D-A23M-08	TCGA-GU-A42R-10A-01D-A23K-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.8846	26.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R2-01A-11D-A391-08	TCGA-ZF-A9R2-10A-01D-A394-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.Y373C	0.4626	147.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.Y373C (Missense)		BLCA_VARSCAN2	TCGA-2F-A9KQ-01A-11D-A38G-08	TCGA-2F-A9KQ-11A-11D-A38J-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.4878	41.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-CF-A27C-01A-11D-A16O-08	TCGA-CF-A27C-10A-01D-A16O-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.G370C	0.5882	119.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.G370C (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6P-01A-11D-A391-08	TCGA-DK-AA6P-10A-01D-A394-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.2973	37.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SM-01A-11D-A22Z-08	TCGA-FD-A3SM-10A-01D-A22Z-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.7586	29.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-CU-A72E-01A-12D-A339-08	TCGA-CU-A72E-10A-01D-A339-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.3	20.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-XF-A8HI-01A-11D-A38G-08	TCGA-XF-A8HI-10A-01D-A38J-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.4545	22.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-XF-A9SV-01A-21D-A42E-08	TCGA-XF-A9SV-10A-01D-A42H-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.G370C	0.5913	208.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.G370C (Missense)		BLCA_VARSCAN2	TCGA-E7-A7DU-01A-11D-A32B-08	TCGA-E7-A7DU-10A-01D-A329-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.551	49.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-FD-A43X-01A-11D-A23U-08	TCGA-FD-A43X-10A-01D-A23U-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.725	40.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-GC-A3BM-01A-11D-A22Z-08	TCGA-GC-A3BM-10A-01D-A22Z-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.G370C	0.4659	264.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.G370C (Missense)		BLCA_VARSCAN2	TCGA-CF-A5U8-01A-11D-A289-08	TCGA-CF-A5U8-10A-01D-A289-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	1.0	18.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-LT-A8JT-01A-11D-A364-08	TCGA-LT-A8JT-10A-01D-A362-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.Y373C	0.6	135.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.Y373C (Missense)		BLCA_VARSCAN2	TCGA-DK-AA71-01A-31D-A391-08	TCGA-DK-AA71-10A-01D-A394-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.4706	17.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA89-01A-11D-A391-08	TCGA-4Z-AA89-10A-01D-A394-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.2667	15.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-E7-A519-01A-11D-A26M-08	TCGA-E7-A519-10A-01D-A26K-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.3333	24.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-CF-A7I0-01A-22D-A34U-08	TCGA-CF-A7I0-10A-01D-A34X-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.7419	31.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-E7-A3X6-01A-12D-A22Z-08	TCGA-E7-A3X6-10A-01D-A22Z-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.Y373C	0.4579	107.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.Y373C (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R5-01A-12D-A42E-08	TCGA-ZF-A9R5-10A-01D-A42H-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.Y373C	0.479	119.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.Y373C (Missense)		BLCA_VARSCAN2	TCGA-CF-A47W-01A-11D-A23U-08	TCGA-CF-A47W-10A-01D-A23U-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.G370C	0.3548	248.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.G370C (Missense)		BLCA_VARSCAN2	TCGA-E7-A3Y1-01A-11D-A22Z-08	TCGA-E7-A3Y1-10A-01D-A22Z-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.3235	34.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-E7-A7DV-01A-11D-A339-08	TCGA-E7-A7DV-10A-01D-A339-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.9692	65.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7Y-01A-11D-A391-08	TCGA-4Z-AA7Y-10A-01D-A394-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.4286	21.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-2F-A9KT-01A-11D-A38G-08	TCGA-2F-A9KT-10A-01D-A38J-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.5714	28.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		BLCA_VARSCAN2	TCGA-E7-A678-01A-11D-A30E-08	TCGA-E7-A678-10A-01D-A30H-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.5909	22.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	BLCA_VARSCAN2	TCGA-CF-A47X-01A-31D-A23U-08	TCGA-CF-A47X-10A-01D-A23U-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.8627	51.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	BLCA_VARSCAN2	TCGA-XF-AAN7-01A-11D-A42E-08	TCGA-XF-AAN7-10A-01D-A42H-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.5398	113.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-AA54-01A-11D-A391-08	TCGA-ZF-AA54-10A-01D-A394-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12C	0.4038	52.0	0.0	0.0		Putatively Actionable	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12C (Missense)	1	BLCA_VARSCAN2	TCGA-G2-AA3C-01A-21D-A391-08	TCGA-G2-AA3C-10A-01D-A394-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.7826	69.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	BLCA_VARSCAN2	TCGA-UY-A8OC-01A-11D-A364-08	TCGA-UY-A8OC-10A-01D-A362-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.4314	51.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	BLCA_VARSCAN2	TCGA-XF-AAMH-01A-11D-A42E-08	TCGA-XF-AAMH-10A-01D-A42H-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12D	0.3065	62.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Putatively Actionable	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12D (Missense)	1	BLCA_VARSCAN2	TCGA-XF-A9SU-01A-31D-A391-08	TCGA-XF-A9SU-10A-01D-A394-08
Putatively Actionable	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12C	0.5455	33.0	0.0	0.0		Putatively Actionable	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12C (Missense)	1	BLCA_VARSCAN2	TCGA-CF-A5UA-01A-11D-A289-08	TCGA-CF-A5UA-10A-01D-A289-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4706	102.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	BLCA_VARSCAN2	TCGA-XF-A8HB-01A-11D-A364-08	TCGA-XF-A8HB-10A-01D-A362-08
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.1941	170.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61R (Missense)	1	BLCA_VARSCAN2	TCGA-G2-A2EF-01A-12D-A18F-08	TCGA-G2-A2EF-10A-01D-A18F-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.7037	27.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-E7-A4IJ-01A-31D-A26M-08	TCGA-E7-A4IJ-10A-01D-A26K-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.4681	47.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-DK-AA77-01A-11D-A391-08	TCGA-DK-AA77-10A-01D-A394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.2619	42.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-K4-A54R-01A-11D-A26M-08	TCGA-K4-A54R-10A-01D-A26K-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.8108	37.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-XF-AAMG-01A-11D-A42E-08	TCGA-XF-AAMG-10A-01D-A42H-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.5283	53.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A1AG-01A-11D-A13W-08	TCGA-DK-A1AG-10A-01D-A13W-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.2597	77.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-G2-A2EO-01A-11D-A17V-08	TCGA-G2-A2EO-11A-21D-A17V-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.4143	70.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-GD-A76B-01A-11D-A32B-08	TCGA-GD-A76B-10A-01D-A329-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.1053	57.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-A9RG-01A-21D-A42E-08	TCGA-ZF-A9RG-10A-01D-A42H-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.2294	109.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-G2-A3VY-01A-11D-A22Z-08	TCGA-G2-A3VY-10A-01D-A22Z-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.4314	51.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-2F-A9KR-01A-11D-A38G-08	TCGA-2F-A9KR-10A-01D-A38J-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.1449	69.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A5C1-01A-11D-A289-08	TCGA-FD-A5C1-10A-01D-A289-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.G1049R	0.4	100.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.G1049R (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-A9RE-01A-11D-A38G-08	TCGA-ZF-A9RE-10A-01D-A38J-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.1579	57.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-XF-A9T8-01A-11D-A391-08	TCGA-XF-A9T8-10A-01D-A394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.4118	51.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-GU-AATQ-01A-11D-A391-08	TCGA-GU-AATQ-10A-01D-A394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.3208	53.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	BLCA_VARSCAN2	TCGA-CF-A9FF-01A-11D-A38G-08	TCGA-CF-A9FF-10A-01D-A38J-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.M1043I	0.1404	57.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.M1043I (Missense)	1	BLCA_VARSCAN2	TCGA-UY-A78P-01A-12D-A364-08	TCGA-UY-A78P-11A-11D-A362-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.3286	70.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	BLCA_VARSCAN2	TCGA-K4-A4AB-01B-12D-A289-08	TCGA-K4-A4AB-10A-01D-A289-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.3939	33.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.2105	38.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-BT-A20Q-01A-11D-A14W-08	TCGA-BT-A20Q-11A-11D-A14W-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.35	20.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-E5-A2PC-01A-11D-A202-08	TCGA-E5-A2PC-10B-01D-A202-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.1765	51.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A3B5-01A-11D-A20D-08	TCGA-FD-A3B5-10A-01D-A20D-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.1208	149.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A43N-01A-11D-A23U-08	TCGA-FD-A43N-10A-01D-A23U-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.7119	59.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-DK-AA6Q-01A-11D-A391-08	TCGA-DK-AA6Q-10A-01D-A394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.1975	81.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-BT-A20R-01A-12D-A16O-08	TCGA-BT-A20R-11A-11D-A16O-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.1556	45.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-BT-A20O-01A-21D-A14W-08	TCGA-BT-A20O-11A-11D-A14W-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.2632	38.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-DK-AA6X-01A-12D-A42E-08	TCGA-DK-AA6X-10A-01D-A42H-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.3704	27.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-CU-A72E-01A-12D-A339-08	TCGA-CU-A72E-10A-01D-A339-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.5	36.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-XF-A8HI-01A-11D-A38G-08	TCGA-XF-A8HI-10A-01D-A38J-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545Q	0.1333	45.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545Q (Missense)	1	BLCA_VARSCAN2	TCGA-HQ-A5NE-01A-12D-A289-08	TCGA-HQ-A5NE-10A-01D-A289-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Q546K	0.4103	39.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Q546K (Missense)	1	BLCA_VARSCAN2	TCGA-CU-A5W6-01A-11D-A289-08	TCGA-CU-A5W6-10A-01D-A289-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545Q	0.4	35.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545Q (Missense)	1	BLCA_VARSCAN2	TCGA-E7-A7DU-01A-11D-A32B-08	TCGA-E7-A7DU-10A-01D-A329-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047L	0.3167	60.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047L (Missense)	1	BLCA_VARSCAN2	TCGA-UY-A78M-01A-21D-A34U-08	TCGA-UY-A78M-10A-01D-A34X-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545Q	0.2162	74.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545Q (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A3B6-01A-21D-A20D-08	TCGA-FD-A3B6-10A-01D-A20D-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.2712	59.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-H4-A2HO-01A-11D-A17V-08	TCGA-H4-A2HO-10A-01D-A17V-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545A	0.2424	33.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545A (Missense)	1	BLCA_VARSCAN2	TCGA-GC-A6I3-01A-11D-A31L-08	TCGA-GC-A6I3-10A-01D-A31J-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.2188	64.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-K4-A3WS-01A-11D-A22Z-08	TCGA-K4-A3WS-10A-01D-A22Z-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.5714	35.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A3SN-01A-12D-A22Z-08	TCGA-FD-A3SN-10A-01D-A22Z-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.3333	51.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-5N-A9KI-01A-31D-A42E-08	TCGA-5N-A9KI-10A-01D-A42H-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.5538	65.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-XF-A8HD-01A-11D-A364-08	TCGA-XF-A8HD-10A-01D-A362-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047L	0.4271	96.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047L (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A3SJ-01A-12D-A22Z-08	TCGA-FD-A3SJ-10A-01D-A22Z-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.62	50.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-DK-AA71-01A-31D-A391-08	TCGA-DK-AA71-10A-01D-A394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.4925	67.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-AA56-01A-31D-A391-08	TCGA-ZF-AA56-10A-01D-A394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.M1043I	0.3452	84.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.M1043I (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A1AB-01A-11D-A13W-08	TCGA-DK-A1AB-10A-01D-A13W-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.2174	46.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.3421	38.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-AA53-01A-11D-A391-08	TCGA-ZF-AA53-10A-01D-A394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.9362	47.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-GD-A6C6-01A-21D-A31L-08	TCGA-GD-A6C6-10A-01D-A31J-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.5172	58.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-GU-AATO-01A-11D-A391-08	TCGA-GU-AATO-10A-01D-A394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.1957	46.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-XF-A8HE-01A-11D-A364-08	TCGA-XF-A8HE-10A-01D-A362-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.3226	93.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-XF-AAN2-01A-11D-A42E-08	TCGA-XF-AAN2-10A-01D-A42H-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.1892	74.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	BLCA_VARSCAN2	TCGA-4Z-AA7W-01A-11D-A391-08	TCGA-4Z-AA7W-10A-01D-A394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.5303	66.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-XF-A8HG-01A-11D-A364-08	TCGA-XF-A8HG-10A-01D-A362-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.3095	42.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-2F-A9KW-01A-11D-A38G-08	TCGA-2F-A9KW-10A-01D-A38J-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.3797	79.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-GV-A3JX-01A-11D-A20D-08	TCGA-GV-A3JX-10A-01D-A20D-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.5122	41.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-XF-AAN0-01A-11D-A42E-08	TCGA-XF-AAN0-10A-01D-A42H-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.3396	53.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-G2-AA3B-01A-11D-A391-08	TCGA-G2-AA3B-10A-01D-A394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.4242	66.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A1AC-01A-11D-A13W-08	TCGA-DK-A1AC-10A-01D-A13W-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.5319	47.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-4Z-AA7Y-01A-11D-A391-08	TCGA-4Z-AA7Y-10A-01D-A394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545G	0.5435	46.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545G (Missense)	1	BLCA_VARSCAN2	TCGA-4Z-AA7Y-01A-11D-A391-08	TCGA-4Z-AA7Y-10A-01D-A394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.5556	63.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A6B5-01A-11D-A31L-08	TCGA-DK-A6B5-10A-01D-A31J-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.4375	48.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-AA4X-01A-11D-A38G-08	TCGA-ZF-AA4X-10A-01D-A38J-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.1071	56.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A3SO-01A-11D-A22Z-08	TCGA-FD-A3SO-10A-01D-A22Z-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.129	93.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A3X1-01A-12D-A22Z-08	TCGA-DK-A3X1-10A-01D-A22Z-08
Putatively Actionable	Preclinical			Somatic Variant	AKT1	Missense	p.E17K	0.5122	41.0	0.0	0.0		Putatively Actionable	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.E17K (Missense)	0	BLCA_VARSCAN2	TCGA-E7-A5KF-01A-11D-A289-08	TCGA-E7-A5KF-10A-01D-A289-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.G740E	0.34	50.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.G740E (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R4-01A-11D-A38G-08	TCGA-ZF-A9R4-10A-01D-A38J-08
Putatively Actionable			Guideline	Somatic Variant	SF3B1	Missense	p.R625C	0.3902	82.0	0.0	0.0																Putatively Actionable	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R625C (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AE-01A-11D-A13W-08	TCGA-DK-A1AE-10A-01D-A13W-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.E695Q	0.3295	88.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.E695Q (Missense)	1	BLCA_VARSCAN2	TCGA-XF-AAMY-01A-11D-A42E-08	TCGA-XF-AAMY-10A-01D-A42H-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G469A	0.2353	51.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G469A (Missense)	1	BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.Q262E	0.375	40.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.Q262E (Missense)	1	BLCA_VARSCAN2	TCGA-4Z-AA7M-01A-11D-A391-08	TCGA-4Z-AA7M-10A-01D-A394-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.D594Y	0.3667	30.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.D594Y (Missense)	1	BLCA_VARSCAN2	TCGA-E7-A4XJ-01A-11D-A26M-08	TCGA-E7-A4XJ-10A-01D-A26K-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.S129L	0.3768	69.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.S129L (Missense)	1	BLCA_VARSCAN2	TCGA-G2-A2EL-01A-12D-A18F-08	TCGA-G2-A2EL-10A-01D-A18F-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.T384S	0.1748	103.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.T384S (Missense)	1	BLCA_VARSCAN2	TCGA-E5-A2PC-01A-11D-A202-08	TCGA-E5-A2PC-10B-01D-A202-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.V121F	0.3667	60.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.V121F (Missense)	1	BLCA_VARSCAN2	TCGA-BT-A42E-01A-11D-A23U-08	TCGA-BT-A42E-10A-01D-A23U-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.F359L	0.1912	68.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.F359L (Missense)	1	BLCA_VARSCAN2	TCGA-DK-AA75-01A-11D-A391-08	TCGA-DK-AA75-10A-01D-A394-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.E1079K	0.3333	21.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.E1079K (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.Q390R	0.2353	51.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.Q390R (Missense)	1	BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.E711K	0.2277	101.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.E711K (Missense)	1	BLCA_VARSCAN2	TCGA-DK-AA6L-01A-11D-A391-08	TCGA-DK-AA6L-10A-01D-A394-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.D479H	0.25	36.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.D479H (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TG-01A-11D-A32B-08	TCGA-FD-A6TG-10A-01D-A329-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.P558A	0.2222	72.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.P558A (Missense)		BLCA_VARSCAN2	TCGA-CF-A47X-01A-31D-A23U-08	TCGA-CF-A47X-10A-01D-A23U-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.F145Y	0.1538	65.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.F145Y (Missense)		BLCA_VARSCAN2	TCGA-H4-A2HQ-01A-11D-A17V-08	TCGA-H4-A2HQ-10A-01D-A17V-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.G866E	0.4667	90.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.G866E (Missense)		BLCA_VARSCAN2	TCGA-UY-A9PH-01A-11D-A38G-08	TCGA-UY-A9PH-10A-01D-A38J-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.S271Y	0.2885	52.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.S271Y (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SN-01A-12D-A22Z-08	TCGA-FD-A3SN-10A-01D-A22Z-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH2	Missense	p.G137E	0.269	145.0	0.0	0.0		Investigate Actionability	Enasidenib	IDH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.	Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf								Investigate Actionability	0	More frequent in Acute Myeloid Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					IDH2 p.G137E (Missense)		BLCA_VARSCAN2	TCGA-S5-A6DX-01A-11D-A31L-08	TCGA-S5-A6DX-10A-01D-A31J-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.F667L	0.1136	44.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.F667L (Missense)		BLCA_VARSCAN2	TCGA-LT-A5Z6-01A-11D-A289-08	TCGA-LT-A5Z6-10A-01D-A289-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.V668A	0.3971	68.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.V668A (Missense)		BLCA_VARSCAN2	TCGA-KQ-A41P-01A-12D-A339-08	TCGA-KQ-A41P-10F-01D-A339-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.E720D	0.1591	44.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.E720D (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4W-01A-12D-A38G-08	TCGA-ZF-AA4W-10A-01D-A38J-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.L14R	0.4444	54.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.L14R (Missense)		BLCA_VARSCAN2	TCGA-BT-A3PJ-01A-21D-A21Z-08	TCGA-BT-A3PJ-10A-01D-A21Z-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.R19C	0.3448	29.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.R19C (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AC-01A-11D-A13W-08	TCGA-DK-A1AC-10A-01D-A13W-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH2	Missense	p.M411I	0.1402	164.0	0.0	0.0		Investigate Actionability	Enasidenib	IDH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.	Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf								Investigate Actionability	0	More frequent in Acute Myeloid Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					IDH2 p.M411I (Missense)		BLCA_VARSCAN2	TCGA-E7-A85H-01A-11D-A34U-08	TCGA-E7-A85H-10B-01D-A34X-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.A299V	0.1429	119.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.A299V (Missense)		BLCA_VARSCAN2	TCGA-DK-A3X1-01A-12D-A22Z-08	TCGA-DK-A3X1-10A-01D-A22Z-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.G380R	0.5145	311.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.G380R (Missense)		BLCA_VARSCAN2	TCGA-G2-A2EO-01A-11D-A17V-08	TCGA-G2-A2EO-11A-21D-A17V-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.K650E	0.5385	13.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.K650E (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RG-01A-21D-A42E-08	TCGA-ZF-A9RG-10A-01D-A42H-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S371C	0.9506	162.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S371C (Missense)		BLCA_VARSCAN2	TCGA-CF-A9FH-01A-11D-A38G-08	TCGA-CF-A9FH-10A-01D-A38J-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S371C	0.9043	94.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S371C (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN1-01A-31D-A42E-08	TCGA-XF-AAN1-10A-01D-A42H-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S351C	0.48	50.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S351C (Missense)		BLCA_VARSCAN2	TCGA-GU-AATQ-01A-11D-A391-08	TCGA-GU-AATQ-10A-01D-A394-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.V306I	0.3333	15.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.V306I (Missense)		BLCA_VARSCAN2	TCGA-FJ-A3ZF-01A-11D-A23M-08	TCGA-FJ-A3ZF-10A-01D-A23K-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.G380R	0.4267	382.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.G380R (Missense)		BLCA_VARSCAN2	TCGA-BT-A20T-01A-11D-A14W-08	TCGA-BT-A20T-11A-11D-A14W-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.H349Y	0.7597	129.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.H349Y (Missense)		BLCA_VARSCAN2	TCGA-GU-A42R-01A-11D-A23M-08	TCGA-GU-A42R-10A-01D-A23K-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S351F	0.7895	57.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S351F (Missense)		BLCA_VARSCAN2	TCGA-CU-A72E-01A-12D-A339-08	TCGA-CU-A72E-10A-01D-A339-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S348F	0.1452	62.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S348F (Missense)		BLCA_VARSCAN2	TCGA-XF-A8HE-01A-11D-A364-08	TCGA-XF-A8HE-10A-01D-A362-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.K650E	0.4348	23.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.K650E (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RL-01A-11D-A38G-08	TCGA-ZF-A9RL-10A-01D-A38J-08
Investigate Actionability	FDA-Approved			Somatic Variant	MET	Nonsense	p.S1390*	0.3089	123.0	0.0	0.0		Investigate Actionability	Capmatinib	MET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf																	MET p.S1390* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-A9RL-01A-11D-A38G-08	TCGA-ZF-A9RL-10A-01D-A38J-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.P358L	0.4074	54.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.P358L (Missense)		BLCA_VARSCAN2	TCGA-UY-A78N-01A-12D-A339-08	TCGA-UY-A78N-10A-01D-A339-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.G185R	0.4545	55.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.G185R (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A1AA-01A-11D-A13W-08	TCGA-DK-A1AA-10A-01D-A13W-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E338Q	0.5362	69.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E338Q (Missense)	0	BLCA_VARSCAN2	TCGA-E7-A5KF-01A-11D-A289-08	TCGA-E7-A5KF-10A-01D-A289-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.S783L	0.3582	67.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.S783L (Missense)	0	BLCA_VARSCAN2	TCGA-4Z-AA81-01A-11D-A391-08	TCGA-4Z-AA81-10A-01D-A394-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.T474M	0.4563	103.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.T474M (Missense)	0	BLCA_VARSCAN2	TCGA-GV-A3QH-01A-11D-A21Z-08	TCGA-GV-A3QH-10A-01D-A21Z-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.S1081L	0.2424	132.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.S1081L (Missense)	0	BLCA_VARSCAN2	TCGA-BT-A3PH-01A-11D-A21Z-08	TCGA-BT-A3PH-10A-01D-A21Z-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.R522H	0.25	108.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.R522H (Missense)	0	BLCA_VARSCAN2	TCGA-GV-A3JV-01A-11D-A21Z-08	TCGA-GV-A3JV-10B-01D-A21Z-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.R512Q	0.3415	41.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.R512Q (Missense)	0	BLCA_VARSCAN2	TCGA-XF-AAML-01A-11D-A42E-08	TCGA-XF-AAML-10A-01D-A42H-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E109D	0.4201	219.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E109D (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.D423A	0.4384	73.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.D423A (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E1051K	0.3258	89.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E1051K (Missense)	0	BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.A491T	0.1656	157.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.A491T (Missense)	0	BLCA_VARSCAN2	TCGA-C4-A0F6-01A-11D-A10S-08	TCGA-C4-A0F6-10A-01D-A10S-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.V1084M	0.1176	85.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.V1084M (Missense)	0	BLCA_VARSCAN2	TCGA-XF-A9SY-01A-21D-A42E-08	TCGA-XF-A9SY-10A-01D-A42H-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.E675Q	0.3864	44.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.E675Q (Missense)	0	BLCA_VARSCAN2	TCGA-GV-A3QI-01A-11D-A21Z-08	TCGA-GV-A3QI-10A-01D-A21Z-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.5882	51.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	BLCA_VARSCAN2	TCGA-FJ-A3Z9-01A-11D-A26M-08	TCGA-FJ-A3Z9-10A-01D-A26K-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G13D	0.7752	218.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G13D (Missense)	1	BLCA_VARSCAN2	TCGA-4Z-AA81-01A-11D-A391-08	TCGA-4Z-AA81-10A-01D-A394-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.L19F	0.2727	66.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.L19F (Missense)	1	BLCA_VARSCAN2	TCGA-UY-A78P-01A-12D-A364-08	TCGA-UY-A78P-11A-11D-A362-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.L19F	0.4655	58.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.L19F (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-A9R4-01A-11D-A38G-08	TCGA-ZF-A9R4-10A-01D-A38J-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.Q61H	0.5091	55.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.Q61H (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A5BX-01A-11D-A26M-08	TCGA-FD-A5BX-10A-01D-A26K-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12R	0.7302	63.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12R (Missense)	1	BLCA_VARSCAN2	TCGA-FJ-A871-01A-11D-A34U-08	TCGA-FJ-A871-10A-01D-A34X-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.G12V	0.4545	11.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.G12V (Missense)	1	BLCA_VARSCAN2	TCGA-E7-A4XJ-01A-11D-A26M-08	TCGA-E7-A4XJ-10A-01D-A26K-08
Investigate Actionability	Clinical trial	Clinical trial	Clinical evidence	Somatic Variant	KRAS	Missense	p.A59G	0.5	54.0	0.0	0.0		Investigate Actionability	AMG 510	targets KRAS G12C	Targeted therapy	5/10 NSCLC patients with KRAS G12C variants observed a PR to AMG 510.	J Clin Oncol 37, 2019 (suppl; abstr 3003)	https://abstracts.asco.org/239/AbstView_239_268371.html	Investigate Actionability	Proton-based SBRT	Radiation	Radiation therapy	In a single-arm phase II trial of proton-based SBRT for liver metastases from solid tumors, KRAS mutation in codon 12, 13, or 61 was the strongest predictor of inferior local control.	Hong TS, Wo JY, Borger DR, et al. Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype . 2017; 109(9).	https://doi.org/10.1093/jnci/djx031	Investigate Actionability	0	KRAS mutation G12D is associated with an increased risk of developing advanced pancreatic ductal carcinoma.	Bournet B, Muscari F, Buscail C, et al. KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma. Clin Transl Gastroenterol. 2016;7:e157.	https://doi.org/10.1038/ctg.2016.18					KRAS p.A59G (Missense)	1	BLCA_VARSCAN2	TCGA-E7-A8O8-01A-11D-A364-08	TCGA-E7-A8O8-10A-01D-A362-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.E3022*	0.25	76.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.E3022* (Nonsense)		BLCA_VARSCAN2	TCGA-G2-A3IE-01A-11D-A20D-08	TCGA-G2-A3IE-10A-01D-A20D-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.Q1276*	0.3295	88.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.Q1276* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-AAMG-01A-11D-A42E-08	TCGA-XF-AAMG-10A-01D-A42H-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.Q781*	0.5405	37.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.Q781* (Nonsense)		BLCA_VARSCAN2	TCGA-UY-A8OD-01A-11D-A364-08	TCGA-UY-A8OD-10A-01D-A362-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Frameshift	p.W1026Lfs*22	0.1224	245.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.W1026Lfs*22 (Frameshift)		BLCA_VARSCAN2	TCGA-GV-A40E-01A-12D-A23M-08	TCGA-GV-A40E-10A-01D-A23K-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R1466*	0.4058	138.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R1466* (Nonsense)		BLCA_VARSCAN2	TCGA-4Z-AA84-01A-11D-A391-08	TCGA-4Z-AA84-10A-01D-A394-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.Q1839*	0.9286	14.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.Q1839* (Nonsense)		BLCA_VARSCAN2	TCGA-E7-A5KF-01A-11D-A289-08	TCGA-E7-A5KF-10A-01D-A289-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.K3053*	0.3103	58.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.K3053* (Nonsense)		BLCA_VARSCAN2	TCGA-R3-A69X-01A-22D-A30E-08	TCGA-R3-A69X-10A-01D-A30H-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Splice Site	p.X2326_splice	0.8125	16.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.X2326_splice (Splice Site)		BLCA_VARSCAN2	TCGA-GV-A6ZA-01A-12D-A339-08	TCGA-GV-A6ZA-10A-01D-A339-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Splice Site	p.X1249_splice	0.28	25.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.X1249_splice (Splice Site)		BLCA_VARSCAN2	TCGA-KQ-A41N-01A-11D-A339-08	TCGA-KQ-A41N-10D-01D-A339-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Splice Site	p.X2191_splice	0.7705	61.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.X2191_splice (Splice Site)		BLCA_VARSCAN2	TCGA-FD-A3B5-01A-11D-A20D-08	TCGA-FD-A3B5-10A-01D-A20D-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.Q1636*	0.3488	43.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.Q1636* (Nonsense)		BLCA_VARSCAN2	TCGA-BT-A42E-01A-11D-A23U-08	TCGA-BT-A42E-10A-01D-A23U-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.Q1839*	0.4	60.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.Q1839* (Nonsense)		BLCA_VARSCAN2	TCGA-UY-A9PF-01A-11D-A38G-08	TCGA-UY-A9PF-10A-01D-A38J-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.S403*	0.3571	42.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.S403* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A43Y-01A-21D-A26M-08	TCGA-FD-A43Y-10A-01D-A26K-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.E2272*	0.2051	39.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.E2272* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Splice Site	p.X2643_splice	0.7057	316.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.X2643_splice (Splice Site)		BLCA_VARSCAN2	TCGA-GD-A6C6-01A-21D-A31L-08	TCGA-GD-A6C6-10A-01D-A31J-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Splice Site	p.X1249_splice	0.7647	34.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.X1249_splice (Splice Site)		BLCA_VARSCAN2	TCGA-E7-A8O8-01A-11D-A364-08	TCGA-E7-A8O8-10A-01D-A362-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.R1875*	0.4412	34.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.R1875* (Nonsense)		BLCA_VARSCAN2	TCGA-E7-A8O8-01A-11D-A364-08	TCGA-E7-A8O8-10A-01D-A362-08
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Nonsense	p.E2221*	0.3393	112.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																	ATM p.E2221* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A43P-01A-31D-A23U-08	TCGA-FD-A43P-10A-01D-A23U-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.E337K	0.3793	29.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.E337K (Missense)		BLCA_VARSCAN2	TCGA-G2-A2EO-01A-11D-A17V-08	TCGA-G2-A2EO-11A-21D-A17V-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.A999E	0.2418	91.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.A999E (Missense)		BLCA_VARSCAN2	TCGA-GC-A3YS-01A-11D-A23M-08	TCGA-GC-A3YS-10A-01D-A23K-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.Q2731*	0.619	84.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q2731* (Nonsense)		BLCA_VARSCAN2	TCGA-BT-A42C-01A-11D-A23M-08	TCGA-BT-A42C-10A-01D-A23K-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.S1341*	0.3478	69.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S1341* (Nonsense)		BLCA_VARSCAN2	TCGA-GU-A42R-01A-11D-A23M-08	TCGA-GU-A42R-10A-01D-A23K-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.S1882*	0.3846	39.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S1882* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A6TC-01A-21D-A339-08	TCGA-FD-A6TC-10A-21D-A339-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.D1081H	0.3361	119.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.D1081H (Missense)		BLCA_VARSCAN2	TCGA-GC-A3BM-01A-11D-A22Z-08	TCGA-GC-A3BM-10A-01D-A22Z-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.E2129*	0.5128	39.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E2129* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.Q2870*	0.1905	63.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q2870* (Nonsense)		BLCA_VARSCAN2	TCGA-K4-A3WS-01A-11D-A22Z-08	TCGA-K4-A3WS-10A-01D-A22Z-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.E673K	0.2239	67.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.E673K (Missense)		BLCA_VARSCAN2	TCGA-LT-A5Z6-01A-11D-A289-08	TCGA-LT-A5Z6-10A-01D-A289-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.E884K	0.2245	49.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.E884K (Missense)		BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.E826*	0.1951	41.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E826* (Nonsense)		BLCA_VARSCAN2	TCGA-4Z-AA7W-01A-11D-A391-08	TCGA-4Z-AA7W-10A-01D-A394-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.Q2157*	0.2676	71.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q2157* (Nonsense)		BLCA_VARSCAN2	TCGA-CF-A1HR-01A-11D-A13W-08	TCGA-CF-A1HR-10A-01D-A13W-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.S76*	0.2644	87.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S76* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A6B5-01A-11D-A31L-08	TCGA-DK-A6B5-10A-01D-A31J-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.F998L	0.5849	53.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.F998L (Missense)		BLCA_VARSCAN2	TCGA-UY-A78N-01A-12D-A339-08	TCGA-UY-A78N-10A-01D-A339-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.D92N	0.2407	162.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.D92N (Missense)	1	BLCA_VARSCAN2	TCGA-UY-A9PD-01A-11D-A38G-08	TCGA-UY-A9PD-10A-01D-A38J-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.M111V	0.5417	48.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.M111V (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-A9RL-01A-11D-A38G-08	TCGA-ZF-A9RL-10A-01D-A38J-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61K	0.4825	114.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.Q61K (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-A9R5-01A-12D-A42E-08	TCGA-ZF-A9R5-10A-01D-A42H-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.E49K	0.2366	93.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.E49K (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A43P-01A-31D-A23U-08	TCGA-FD-A43P-10A-01D-A23U-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.E332K	0.5301	83.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.E332K (Missense)		BLCA_VARSCAN2	TCGA-E7-A4IJ-01A-31D-A26M-08	TCGA-E7-A4IJ-10A-01D-A26K-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.T862A	0.1778	90.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.T862A (Missense)		BLCA_VARSCAN2	TCGA-GC-A3OO-01A-11D-A22Z-08	TCGA-GC-A3OO-10C-01D-A22Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V104L	0.4008	237.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V104L (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AA-01A-11D-A13W-08	TCGA-DK-A1AA-10A-01D-A13W-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Nonsense	p.E656*	0.25	16.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.E656* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A1AA-01A-11D-A13W-08	TCGA-DK-A1AA-10A-01D-A13W-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.M91I	0.3478	161.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.M91I (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AG-01A-11D-A13W-08	TCGA-DK-A1AG-10A-01D-A13W-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Nonsense	p.S871*	0.3985	133.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.S871* (Nonsense)		BLCA_VARSCAN2	TCGA-G2-A2EO-01A-11D-A17V-08	TCGA-G2-A2EO-11A-21D-A17V-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.S236P	0.2674	187.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.S236P (Missense)		BLCA_VARSCAN2	TCGA-G2-A2EO-01A-11D-A17V-08	TCGA-G2-A2EO-11A-21D-A17V-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.D821H	0.2581	31.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.D821H (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RG-01A-21D-A42E-08	TCGA-ZF-A9RG-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.S44L	0.209	67.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.S44L (Missense)	0	BLCA_VARSCAN2	TCGA-ZF-A9RG-01A-21D-A42E-08	TCGA-ZF-A9RG-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.V218I	0.2162	37.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.V218I (Missense)	0	BLCA_VARSCAN2	TCGA-XF-A9SX-01A-21D-A391-08	TCGA-XF-A9SX-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.Y72C	0.2283	127.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.Y72C (Missense)	0	BLCA_VARSCAN2	TCGA-4Z-AA84-01A-11D-A391-08	TCGA-4Z-AA84-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.D251H	0.875	96.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.D251H (Missense)		BLCA_VARSCAN2	TCGA-E5-A4TZ-01A-11D-A31L-08	TCGA-E5-A4TZ-10B-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.G419A	0.9211	38.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.G419A (Missense)		BLCA_VARSCAN2	TCGA-E5-A4TZ-01A-11D-A31L-08	TCGA-E5-A4TZ-10B-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Nonsense	p.S163*	0.4054	37.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.S163* (Nonsense)		BLCA_VARSCAN2	TCGA-GU-A766-01A-11D-A32B-08	TCGA-GU-A766-10A-01D-A329-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310Y	0.3	250.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310Y (Missense)		BLCA_VARSCAN2	TCGA-GU-A766-01A-11D-A32B-08	TCGA-GU-A766-10A-01D-A329-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.D951H	0.2386	88.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.D951H (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6S-01A-21D-A391-08	TCGA-DK-AA6S-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.E173K	0.3061	147.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.E173K (Missense)		BLCA_VARSCAN2	TCGA-DK-A3IN-01A-11D-A20D-08	TCGA-DK-A3IN-10A-01D-A20D-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.P583S	0.1717	99.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.P583S (Missense)		BLCA_VARSCAN2	TCGA-XF-A8HH-01A-11D-A38G-08	TCGA-XF-A8HH-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Nonsense	p.E931*	0.95	80.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.E931* (Nonsense)		BLCA_VARSCAN2	TCGA-CF-A9FH-01A-11D-A38G-08	TCGA-CF-A9FH-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.3984	256.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-GC-A3YS-01A-11D-A23M-08	TCGA-GC-A3YS-10A-01D-A23K-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.N238S	0.1515	33.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.N238S (Missense)	0	BLCA_VARSCAN2	TCGA-E7-A97P-01A-11D-A38G-08	TCGA-E7-A97P-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.N238S	0.6842	19.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.N238S (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A1A7-01A-11D-A13W-08	TCGA-DK-A1A7-10A-01D-A13W-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Nonsense	p.S1170*	0.1316	76.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.S1170* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-AA76-01A-11D-A391-08	TCGA-DK-AA76-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.S74L	0.2967	91.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.S74L (Missense)	0	BLCA_VARSCAN2	TCGA-XF-A9SJ-01A-11D-A391-08	TCGA-XF-A9SJ-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.5197	254.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-GC-A4ZW-01A-11D-A26M-08	TCGA-GC-A4ZW-10A-01D-A26K-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S653C	0.3507	134.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S653C (Missense)		BLCA_VARSCAN2	TCGA-GC-A4ZW-01A-11D-A26M-08	TCGA-GC-A4ZW-10A-01D-A26K-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.H228Q	0.2976	168.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.H228Q (Missense)		BLCA_VARSCAN2	TCGA-DK-A3IL-01A-11D-A20D-08	TCGA-DK-A3IL-10A-01D-A20D-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.D951N	0.1846	65.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.D951N (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T8-01A-11D-A391-08	TCGA-XF-A9T8-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.E981D	0.1714	35.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.E981D (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T8-01A-11D-A391-08	TCGA-XF-A9T8-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.H1208Y	0.1316	38.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.H1208Y (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T8-01A-11D-A391-08	TCGA-XF-A9T8-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Nonsense	p.Y185*	0.625	32.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.Y185* (Nonsense)		BLCA_VARSCAN2	TCGA-4Z-AA83-01A-11D-A391-08	TCGA-4Z-AA83-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.E280Q	0.3889	36.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.E280Q (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RF-01A-11D-A38G-08	TCGA-ZF-A9RF-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.H118Y	0.5333	30.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.H118Y (Missense)	0	BLCA_VARSCAN2	TCGA-4Z-AA87-01A-11D-A391-08	TCGA-4Z-AA87-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.8571	224.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-GV-A6ZA-01A-12D-A339-08	TCGA-GV-A6ZA-10A-01D-A339-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.V777L	0.8611	36.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.V777L (Missense)		BLCA_VARSCAN2	TCGA-GV-A6ZA-01A-12D-A339-08	TCGA-GV-A6ZA-10A-01D-A339-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.2353	221.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.G607A	0.2876	153.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.G607A (Missense)	0	BLCA_VARSCAN2	TCGA-CU-A0YR-01A-12D-A10S-08	TCGA-CU-A0YR-10A-01D-A10S-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.2099	343.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-K4-A5RJ-01A-11D-A289-08	TCGA-K4-A5RJ-10A-01D-A289-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.G776S	0.1849	119.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.G776S (Missense)		BLCA_VARSCAN2	TCGA-K4-A5RJ-01A-11D-A289-08	TCGA-K4-A5RJ-10A-01D-A289-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.D1013H	0.2143	126.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.D1013H (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN3-01A-11D-A42E-08	TCGA-XF-AAN3-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.R678Q	0.9955	1764.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.R678Q (Missense)		BLCA_VARSCAN2	TCGA-2F-A9KP-01A-11D-A38G-08	TCGA-2F-A9KP-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Nonsense	p.R692*	0.7209	43.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.R692* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-A9R3-01A-11D-A38G-08	TCGA-ZF-A9R3-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.E332K	0.1829	82.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.E332K (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA81-01A-11D-A391-08	TCGA-4Z-AA81-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Frameshift	p.L45Wfs*17	0.6667	36.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.L45Wfs*17 (Frameshift)		BLCA_VARSCAN2	TCGA-BT-A42C-01A-11D-A23M-08	TCGA-BT-A42C-10A-01D-A23K-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.5182	137.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-XF-A9ST-01A-11D-A42E-08	TCGA-XF-A9ST-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.S246F	0.4444	27.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.S246F (Missense)	0	BLCA_VARSCAN2	TCGA-XF-A9ST-01A-11D-A42E-08	TCGA-XF-A9ST-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Frameshift	p.H279Pfs*20	0.4348	23.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.H279Pfs*20 (Frameshift)		BLCA_VARSCAN2	TCGA-CF-A9FF-01A-11D-A38G-08	TCGA-CF-A9FF-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.L792M	0.1887	53.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.L792M (Missense)		BLCA_VARSCAN2	TCGA-UY-A78P-01A-12D-A364-08	TCGA-UY-A78P-11A-11D-A362-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V104L	0.5723	166.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V104L (Missense)		BLCA_VARSCAN2	TCGA-FJ-A3ZF-01A-11D-A23M-08	TCGA-FJ-A3ZF-10A-01D-A23K-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.M91I	0.2576	66.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.M91I (Missense)		BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.S782F	0.3571	56.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.S782F (Missense)		BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.E606Q	0.3469	49.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.E606Q (Missense)	0	BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.E606Q	0.4634	41.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.E606Q (Missense)	0	BLCA_VARSCAN2	TCGA-XF-A9T0-01A-11D-A391-08	TCGA-XF-A9T0-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S573L	0.3448	29.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S573L (Missense)		BLCA_VARSCAN2	TCGA-BT-A20T-01A-11D-A14W-08	TCGA-BT-A20T-11A-11D-A14W-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.V842I	0.1212	66.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.V842I (Missense)		BLCA_VARSCAN2	TCGA-FD-A5BU-01A-31D-A26M-08	TCGA-FD-A5BU-10A-01D-A26K-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.N238S	0.25	52.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.N238S (Missense)	0	BLCA_VARSCAN2	TCGA-FD-A3N5-01A-11D-A21A-08	TCGA-FD-A3N5-10A-01D-A21A-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.D30H	0.1034	58.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.D30H (Missense)		BLCA_VARSCAN2	TCGA-E7-A7XN-01A-11D-A34U-08	TCGA-E7-A7XN-10A-01D-A34X-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.D297Y	0.4043	324.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.D297Y (Missense)		BLCA_VARSCAN2	TCGA-HQ-A2OE-01A-11D-A202-08	TCGA-HQ-A2OE-10A-01D-A202-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.G675S	0.4684	79.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.G675S (Missense)	0	BLCA_VARSCAN2	TCGA-E5-A2PC-01A-11D-A202-08	TCGA-E5-A2PC-10B-01D-A202-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.V842I	0.8462	312.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.V842I (Missense)		BLCA_VARSCAN2	TCGA-HQ-A2OF-01A-11D-A26M-08	TCGA-HQ-A2OF-10B-01D-A26K-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.M91I	0.287	115.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.M91I (Missense)		BLCA_VARSCAN2	TCGA-BT-A20R-01A-12D-A16O-08	TCGA-BT-A20R-11A-11D-A16O-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.P135L	0.3617	47.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.P135L (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R7-01A-11D-A38G-08	TCGA-ZF-A9R7-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.I767M	0.2903	31.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.I767M (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R7-01A-11D-A38G-08	TCGA-ZF-A9R7-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R475W	0.5948	153.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R475W (Missense)		BLCA_VARSCAN2	TCGA-GU-A42R-01A-11D-A23M-08	TCGA-GU-A42R-10A-01D-A23K-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.S782C	0.792	250.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.S782C (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6P-01A-11D-A391-08	TCGA-DK-AA6P-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Nonsense	p.E577*	0.5116	43.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.E577* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A3SM-01A-11D-A22Z-08	TCGA-FD-A3SM-10A-01D-A22Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.H659Y	0.2568	74.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.H659Y (Missense)	0	BLCA_VARSCAN2	TCGA-BT-A20O-01A-21D-A14W-08	TCGA-BT-A20O-11A-11D-A14W-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.K329E	0.2458	118.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.K329E (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6X-01A-12D-A42E-08	TCGA-DK-AA6X-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.8247	97.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-XF-AAMX-01A-11D-A42E-08	TCGA-XF-AAMX-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.R75K	0.2381	105.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.R75K (Missense)	0	BLCA_VARSCAN2	TCGA-UY-A9PF-01A-11D-A38G-08	TCGA-UY-A9PF-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.E332K	0.3561	132.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.E332K (Missense)		BLCA_VARSCAN2	TCGA-HQ-A5NE-01A-12D-A289-08	TCGA-HQ-A5NE-10A-01D-A289-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Frameshift	p.Y185*	0.4483	58.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.Y185* (Frameshift)		BLCA_VARSCAN2	TCGA-ZF-AA54-01A-11D-A391-08	TCGA-ZF-AA54-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.3025	162.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-XF-A9SM-01A-11D-A42E-08	TCGA-XF-A9SM-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S413L	0.25	32.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S413L (Missense)		BLCA_VARSCAN2	TCGA-G2-AA3C-01A-21D-A391-08	TCGA-G2-AA3C-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.D581H	0.2118	85.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.D581H (Missense)		BLCA_VARSCAN2	TCGA-UY-A9PH-01A-11D-A38G-08	TCGA-UY-A9PH-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.D297Y	0.1905	210.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.D297Y (Missense)		BLCA_VARSCAN2	TCGA-FD-A3B6-01A-21D-A20D-08	TCGA-FD-A3B6-10A-01D-A20D-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.E150K	0.4767	86.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.E150K (Missense)		BLCA_VARSCAN2	TCGA-XF-AAML-01A-11D-A42E-08	TCGA-XF-AAML-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.2035	172.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-XF-AAML-01A-11D-A42E-08	TCGA-XF-AAML-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.R286W	0.36	25.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.R286W (Missense)	0	BLCA_VARSCAN2	TCGA-H4-A2HO-01A-11D-A17V-08	TCGA-H4-A2HO-10A-01D-A17V-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S390L	0.2941	51.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S390L (Missense)		BLCA_VARSCAN2	TCGA-DK-AA75-01A-11D-A391-08	TCGA-DK-AA75-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.I80T	0.4085	71.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.I80T (Missense)	0	BLCA_VARSCAN2	TCGA-DK-AA75-01A-11D-A391-08	TCGA-DK-AA75-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.V104M	0.381	168.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V104M (Missense)		BLCA_VARSCAN2	TCGA-GD-A3OQ-01A-32D-A21Z-08	TCGA-GD-A3OQ-10A-01D-A21Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.Q758E	0.1178	331.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.Q758E (Missense)	0	BLCA_VARSCAN2	TCGA-GD-A3OQ-01A-32D-A21Z-08	TCGA-GD-A3OQ-10A-01D-A21Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Nonsense	p.Q516*	0.55	40.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.Q516* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A1A3-01A-11D-A13W-08	TCGA-DK-A1A3-10A-01D-A13W-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.1728	301.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-DK-A1A3-01A-11D-A13W-08	TCGA-DK-A1A3-10A-01D-A13W-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.Y14C	0.129	31.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.Y14C (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A1A3-01A-11D-A13W-08	TCGA-DK-A1A3-10A-01D-A13W-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.V777L	0.3023	86.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.V777L (Missense)		BLCA_VARSCAN2	TCGA-KQ-A41S-01A-12D-A339-08	TCGA-KQ-A41S-10C-01D-A339-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.D767N	0.4688	64.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.D767N (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SN-01A-12D-A22Z-08	TCGA-FD-A3SN-10A-01D-A22Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.R103Q	0.5091	55.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.R103Q (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SN-01A-12D-A22Z-08	TCGA-FD-A3SN-10A-01D-A22Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.Y72C	0.359	78.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.Y72C (Missense)	0	BLCA_VARSCAN2	TCGA-FD-A3SN-01A-12D-A22Z-08	TCGA-FD-A3SN-10A-01D-A22Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.L74F	0.2577	97.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.L74F (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SJ-01A-12D-A22Z-08	TCGA-FD-A3SJ-10A-01D-A22Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.S44L	0.1895	95.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.S44L (Missense)	0	BLCA_VARSCAN2	TCGA-FT-A3EE-01A-11D-A202-08	TCGA-FT-A3EE-10A-01D-A202-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Nonsense	p.L536*	0.8571	28.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.L536* (Nonsense)		BLCA_VARSCAN2	TCGA-BT-A20P-01A-11D-A14W-08	TCGA-BT-A20P-11A-11D-A14W-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.E1244Q	0.2556	90.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.E1244Q (Missense)		BLCA_VARSCAN2	TCGA-BT-A0YX-01A-11D-A10S-08	TCGA-BT-A0YX-10A-01D-A10S-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.1193	285.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-K4-A83P-01A-11D-A34U-08	TCGA-K4-A83P-10A-01D-A34X-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Frameshift	p.R190Pfs*20	0.3151	73.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.R190Pfs*20 (Frameshift)		BLCA_VARSCAN2	TCGA-ZF-AA53-01A-11D-A391-08	TCGA-ZF-AA53-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.S44L	0.2893	121.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.S44L (Missense)	0	BLCA_VARSCAN2	TCGA-FT-A61P-01A-11D-A30E-08	TCGA-FT-A61P-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.S236L	0.2395	167.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.S236L (Missense)		BLCA_VARSCAN2	TCGA-DK-A6B6-01A-11D-A30E-08	TCGA-DK-A6B6-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.3147	286.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-DK-A6B6-01A-11D-A30E-08	TCGA-DK-A6B6-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.2388	134.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN5-01A-11D-A42E-08	TCGA-XF-AAN5-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.E86Q	0.2121	33.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.E86Q (Missense)	0	BLCA_VARSCAN2	TCGA-G2-A2ES-01A-11D-A17V-08	TCGA-G2-A2ES-11A-31D-A17V-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.G222C	0.6781	146.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.G222C (Missense)		BLCA_VARSCAN2	TCGA-GV-A40G-01A-11D-A23M-08	TCGA-GV-A40G-10A-01D-A23K-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.D769N	0.927	274.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.D769N (Missense)		BLCA_VARSCAN2	TCGA-DK-A1A6-01A-11D-A13W-08	TCGA-DK-A1A6-10A-01D-A13W-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.E1645*	0.3235	68.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E1645* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-AA6R-01A-11D-A42E-08	TCGA-DK-AA6R-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Nonsense	p.E911*	0.9048	126.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.E911* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-A9RL-01A-11D-A38G-08	TCGA-ZF-A9RL-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.3333	336.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN2-01A-11D-A42E-08	TCGA-XF-AAN2-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Nonsense	p.S836*	0.2247	89.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.S836* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A6TB-01A-12D-A339-08	TCGA-FD-A6TB-10A-21D-A339-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.E925Q	0.1654	133.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.E925Q (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TB-01A-12D-A339-08	TCGA-FD-A6TB-10A-21D-A339-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S196F	0.2581	62.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S196F (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TB-01A-12D-A339-08	TCGA-FD-A6TB-10A-21D-A339-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.F409L	0.1282	39.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.F409L (Missense)		BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.D769Y	0.4407	59.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.D769Y (Missense)		BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.H210Q	0.5455	88.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.H210Q (Missense)	0	BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.E554Q	0.4699	83.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.E554Q (Missense)	0	BLCA_VARSCAN2	TCGA-ZF-AA51-01A-21D-A391-08	TCGA-ZF-AA51-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.L755S	0.4103	39.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.L755S (Missense)		BLCA_VARSCAN2	TCGA-CU-A3YL-01A-11D-A22Z-08	TCGA-CU-A3YL-10A-01D-A22Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S138F	0.2323	99.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S138F (Missense)		BLCA_VARSCAN2	TCGA-E7-A541-01A-11D-A26M-08	TCGA-E7-A541-10A-01D-A26K-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.M91I	0.1493	67.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.M91I (Missense)		BLCA_VARSCAN2	TCGA-E7-A541-01A-11D-A26M-08	TCGA-E7-A541-10A-01D-A26K-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Nonsense	p.Q328*	0.6271	59.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.Q328* (Nonsense)		BLCA_VARSCAN2	TCGA-GU-AATP-01A-11D-A391-08	TCGA-GU-AATP-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.1925	265.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4V-01A-11D-A38G-08	TCGA-ZF-AA4V-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.Y72C	0.1987	151.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.Y72C (Missense)	0	BLCA_VARSCAN2	TCGA-ZF-AA4V-01A-11D-A38G-08	TCGA-ZF-AA4V-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.E1189K	0.2553	47.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.E1189K (Missense)		BLCA_VARSCAN2	TCGA-YF-AA3M-01A-11D-A42E-08	TCGA-YF-AA3M-10D-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.T733I	0.9434	106.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.T733I (Missense)		BLCA_VARSCAN2	TCGA-DK-A2I6-01A-12D-A18F-08	TCGA-DK-A2I6-10A-01D-A18F-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.Y209C	0.2593	54.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.Y209C (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A2I6-01A-12D-A18F-08	TCGA-DK-A2I6-10A-01D-A18F-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.R103Q	0.1698	106.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.R103Q (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RC-01A-11D-A38G-08	TCGA-ZF-A9RC-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.Y14C	0.1163	43.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.Y14C (Missense)	0	BLCA_VARSCAN2	TCGA-ZF-A9RC-01A-11D-A38G-08	TCGA-ZF-A9RC-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.A443V	0.5462	119.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.A443V (Missense)	0	BLCA_VARSCAN2	TCGA-E7-A5KE-01A-11D-A289-08	TCGA-E7-A5KE-10A-01D-A289-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.N238S	0.2258	31.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.N238S (Missense)	0	BLCA_VARSCAN2	TCGA-GC-A3RC-01A-11D-A22Z-08	TCGA-GC-A3RC-10B-01D-A22Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R1267Q	0.1897	116.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R1267Q (Missense)		BLCA_VARSCAN2	TCGA-2F-A9KW-01A-11D-A38G-08	TCGA-2F-A9KW-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.A395T	0.3016	63.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.A395T (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4W-01A-12D-A38G-08	TCGA-ZF-AA4W-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Nonsense	p.Q328*	0.3333	102.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.Q328* (Nonsense)		BLCA_VARSCAN2	TCGA-CF-A1HR-01A-11D-A13W-08	TCGA-CF-A1HR-10A-01D-A13W-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S213L	0.2327	159.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S213L (Missense)		BLCA_VARSCAN2	TCGA-K4-A6FZ-01A-11D-A31L-08	TCGA-K4-A6FZ-10A-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.E925Q	0.5085	118.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.E925Q (Missense)		BLCA_VARSCAN2	TCGA-K4-A6FZ-01A-11D-A31L-08	TCGA-K4-A6FZ-10A-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.2331	296.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-K4-A6FZ-01A-11D-A31L-08	TCGA-K4-A6FZ-10A-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.2414	174.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6L-01A-11D-A391-08	TCGA-DK-AA6L-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.S1232I	0.7	20.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.S1232I (Missense)		BLCA_VARSCAN2	TCGA-XF-AAMF-01A-21D-A42E-08	TCGA-XF-AAMF-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.2549	204.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN0-01A-11D-A42E-08	TCGA-XF-AAN0-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.F595L	0.2642	53.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.F595L (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN0-01A-11D-A42E-08	TCGA-XF-AAN0-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.T484M	0.3421	76.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.T484M (Missense)	0	BLCA_VARSCAN2	TCGA-BT-A3PJ-01A-21D-A21Z-08	TCGA-BT-A3PJ-10A-01D-A21Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.N238S	0.35	40.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.N238S (Missense)	0	BLCA_VARSCAN2	TCGA-E7-A677-01A-11D-A30E-08	TCGA-E7-A677-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.R678Q	0.4219	128.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.R678Q (Missense)		BLCA_VARSCAN2	TCGA-CF-A5UA-01A-11D-A289-08	TCGA-CF-A5UA-10A-01D-A289-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.N238S	0.3939	33.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.N238S (Missense)	0	BLCA_VARSCAN2	TCGA-KQ-A41R-01A-21D-A34U-08	TCGA-KQ-A41R-10G-01D-A34X-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R1127C	0.2727	33.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R1127C (Missense)		BLCA_VARSCAN2	TCGA-G2-AA3B-01A-11D-A391-08	TCGA-G2-AA3B-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Frameshift	p.R1603Pfs*12	0.1688	77.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1603Pfs*12 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A1AC-01A-11D-A13W-08	TCGA-DK-A1AC-10A-01D-A13W-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.Y14C	0.3333	39.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.Y14C (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A1AC-01A-11D-A13W-08	TCGA-DK-A1AC-10A-01D-A13W-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.E928K	0.25	104.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.E928K (Missense)		BLCA_VARSCAN2	TCGA-DK-A6B1-01A-12D-A30E-08	TCGA-DK-A6B1-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Frameshift	p.I157Ffs*60	0.619	21.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.I157Ffs*60 (Frameshift)		BLCA_VARSCAN2	TCGA-4Z-AA7Y-01A-11D-A391-08	TCGA-4Z-AA7Y-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.N238S	0.6471	34.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.N238S (Missense)	0	BLCA_VARSCAN2	TCGA-E7-A85H-01A-11D-A34U-08	TCGA-E7-A85H-10B-01D-A34X-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S250F	0.2679	56.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S250F (Missense)		BLCA_VARSCAN2	TCGA-2F-A9KT-01A-11D-A38G-08	TCGA-2F-A9KT-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.N238S	0.4667	30.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.N238S (Missense)	0	BLCA_VARSCAN2	TCGA-UY-A78N-01A-12D-A339-08	TCGA-UY-A78N-10A-01D-A339-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.L313V	0.9675	3478.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.L313V (Missense)		BLCA_VARSCAN2	TCGA-DK-A1A5-01A-11D-A13W-08	TCGA-DK-A1A5-10A-01D-A13W-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.N238S	0.3	20.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.N238S (Missense)	0	BLCA_VARSCAN2	TCGA-XF-A9T3-01A-11D-A42E-08	TCGA-XF-A9T3-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.D939N	0.3636	55.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.D939N (Missense)		BLCA_VARSCAN2	TCGA-XF-A8HC-01A-11D-A364-08	TCGA-XF-A8HC-10A-01D-A362-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.D1327Y	0.2919	161.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.D1327Y (Missense)		BLCA_VARSCAN2	TCGA-XF-A8HC-01A-11D-A364-08	TCGA-XF-A8HC-10A-01D-A362-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.5	210.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		BLCA_VARSCAN2	TCGA-XF-A8HC-01A-11D-A364-08	TCGA-XF-A8HC-10A-01D-A362-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.Q214*	0.5635	126.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Q214* (Nonsense)	1	BLCA_VARSCAN2	TCGA-GV-A40E-01A-12D-A23M-08	TCGA-GV-A40E-10A-01D-A23K-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.E285Kfs*3	0.3947	38.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.E285Kfs*3 (Frameshift)	1	BLCA_VARSCAN2	TCGA-DK-A3IN-01A-11D-A20D-08	TCGA-DK-A3IN-10A-01D-A20D-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.Q17*	0.2273	110.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Q17* (Nonsense)	1	BLCA_VARSCAN2	TCGA-BL-A5ZZ-01A-31D-A30E-08	TCGA-BL-A5ZZ-10A-01D-A30H-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Splice Site	p.X343_splice	0.413	46.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.X343_splice (Splice Site)	1	BLCA_VARSCAN2	TCGA-FJ-A871-01A-11D-A34U-08	TCGA-FJ-A871-10A-01D-A34X-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.Q245*	0.9444	36.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Q245* (Nonsense)	1	BLCA_VARSCAN2	TCGA-G2-A2EL-01A-12D-A18F-08	TCGA-G2-A2EL-10A-01D-A18F-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.Y177*	0.5273	165.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Y177* (Nonsense)	1	BLCA_VARSCAN2	TCGA-KQ-A41R-01A-21D-A34U-08	TCGA-KQ-A41R-10G-01D-A34X-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.Q17*	0.4154	65.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Q17* (Nonsense)	1	BLCA_VARSCAN2	TCGA-UY-A9PE-01A-11D-A38G-08	TCGA-UY-A9PE-10A-01D-A38J-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E299K	0.2617	107.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E299K (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A62P-01A-32D-A30E-08	TCGA-FD-A62P-10A-01D-A30H-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.C199S	0.1509	53.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.C199S (Missense)	1	BLCA_VARSCAN2	TCGA-4Z-AA86-01A-11D-A391-08	TCGA-4Z-AA86-10A-01D-A394-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.G846D	0.3871	31.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.G846D (Missense)	1	BLCA_VARSCAN2	TCGA-KQ-A41N-01A-11D-A339-08	TCGA-KQ-A41N-10D-01D-A339-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.L780F	0.2258	31.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.L780F (Missense)	1	BLCA_VARSCAN2	TCGA-BL-A3JM-01A-12D-A21A-08	TCGA-BL-A3JM-11A-31D-A21A-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.W854C	0.2979	47.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.W854C (Missense)	1	BLCA_VARSCAN2	TCGA-XF-AAML-01A-11D-A42E-08	TCGA-XF-AAML-10A-01D-A42H-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.L235H	0.3766	231.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.L235H (Missense)	0	BLCA_VARSCAN2	TCGA-C4-A0F0-01A-12D-A10S-08	TCGA-C4-A0F0-10A-01D-A10S-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E209K	0.1	60.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.E209K (Missense)	1	BLCA_VARSCAN2	TCGA-G2-AA3B-01A-11D-A391-08	TCGA-G2-AA3B-10A-01D-A394-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.D885N	0.4211	19.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.D885N (Missense)		BLCA_VARSCAN2	TCGA-XF-AAMG-01A-11D-A42E-08	TCGA-XF-AAMG-10A-01D-A42H-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.R292C	0.3676	68.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.R292C (Missense)		BLCA_VARSCAN2	TCGA-5N-A9KM-01A-11D-A42E-08	TCGA-5N-A9KM-10A-01D-A42H-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.R401Q	0.4103	39.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.R401Q (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TE-01A-12D-A339-08	TCGA-FD-A6TE-10A-21D-A339-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E343K	0.3091	110.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.E343K (Missense)		BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P499T	0.5189	106.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P499T (Missense)		BLCA_VARSCAN2	TCGA-GU-AATQ-01A-11D-A391-08	TCGA-GU-AATQ-10A-01D-A394-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.R209C	0.75	40.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.R209C (Missense)		BLCA_VARSCAN2	TCGA-E7-A6ME-01A-22D-A32B-08	TCGA-E7-A6ME-10B-01D-A329-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.R209C	0.25	28.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.R209C (Missense)		BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.E1407K	0.2821	78.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.E1407K (Missense)		BLCA_VARSCAN2	TCGA-GC-A6I3-01A-11D-A31L-08	TCGA-GC-A6I3-10A-01D-A31J-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.R259C	0.1681	119.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.R259C (Missense)		BLCA_VARSCAN2	TCGA-S5-A6DX-01A-11D-A31L-08	TCGA-S5-A6DX-10A-01D-A31J-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.P316R	0.2212	104.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.P316R (Missense)		BLCA_VARSCAN2	TCGA-DK-A2I2-01A-11D-A17V-08	TCGA-DK-A2I2-10A-01D-A17V-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.M1138K	0.1562	32.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.M1138K (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RC-01A-11D-A38G-08	TCGA-ZF-A9RC-10A-01D-A38J-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.R65H	0.4	10.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.R65H (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R5-01A-12D-A42E-08	TCGA-ZF-A9R5-10A-01D-A42H-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.G118D	0.3404	47.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.G118D (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-AA4N-01A-11D-A38G-08	TCGA-ZF-AA4N-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.W552C	0.3333	36.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.W552C (Missense)	1	BLCA_VARSCAN2	TCGA-XF-AAMG-01A-11D-A42E-08	TCGA-XF-AAMG-10A-01D-A42H-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E453K	0.2114	123.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E453K (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-A9RG-01A-21D-A42E-08	TCGA-ZF-A9RG-10A-01D-A42H-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.L752V	0.2637	91.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.L752V (Missense)	1	BLCA_VARSCAN2	TCGA-4Z-AA84-01A-11D-A391-08	TCGA-4Z-AA84-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E1012Q	0.3827	81.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E1012Q (Missense)	1	BLCA_VARSCAN2	TCGA-2F-A9KR-01A-11D-A38G-08	TCGA-2F-A9KR-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E978K	0.66	100.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E978K (Missense)	1	BLCA_VARSCAN2	TCGA-DK-AA76-01A-11D-A391-08	TCGA-DK-AA76-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E600K	0.2927	41.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E600K (Missense)	1	BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Q546P	0.6875	48.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Q546P (Missense)	1	BLCA_VARSCAN2	TCGA-XF-A9T0-01A-11D-A391-08	TCGA-XF-A9T0-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.M1004V	0.4062	64.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.M1004V (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-AA4U-01A-11D-A38G-08	TCGA-ZF-AA4U-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E417K	0.1346	104.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E417K (Missense)	1	BLCA_VARSCAN2	TCGA-GD-A3OP-01A-21D-A21Z-08	TCGA-GD-A3OP-10A-01D-A21Z-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.L956F	0.2421	95.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.L956F (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A6B2-01A-11D-A30E-08	TCGA-DK-A6B2-10A-01D-A30H-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E710Q	0.45	60.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E710Q (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-A9R2-01A-11D-A391-08	TCGA-ZF-A9R2-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E726K	0.4	55.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E726K (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-A9R2-01A-11D-A391-08	TCGA-ZF-A9R2-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Q546R	0.4576	59.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Q546R (Missense)	1	BLCA_VARSCAN2	TCGA-GC-A3WC-01A-31D-A22Z-08	TCGA-GC-A3WC-10A-01D-A22Z-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.S499F	0.5256	78.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.S499F (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R274K	0.359	78.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R274K (Missense)	1	BLCA_VARSCAN2	TCGA-5N-A9KI-01A-31D-A42E-08	TCGA-5N-A9KI-10A-01D-A42H-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E453K	0.1192	151.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E453K (Missense)	1	BLCA_VARSCAN2	TCGA-K4-A83P-01A-11D-A34U-08	TCGA-K4-A83P-10A-01D-A34X-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E365K	0.4746	118.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E365K (Missense)	1	BLCA_VARSCAN2	TCGA-GC-A3I6-01A-11D-A20D-08	TCGA-GC-A3I6-10A-01D-A20D-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.S66C	0.2632	57.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.S66C (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A5BX-01A-11D-A26M-08	TCGA-FD-A5BX-10A-01D-A26K-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E365K	0.2857	35.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E365K (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A5BX-01A-11D-A26M-08	TCGA-FD-A5BX-10A-01D-A26K-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E453Q	0.5438	160.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E453Q (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A1A6-01A-11D-A13W-08	TCGA-DK-A1A6-10A-01D-A13W-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R115L	0.5179	56.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R115L (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-A9RL-01A-11D-A38G-08	TCGA-ZF-A9RL-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.N345K	0.4516	93.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.N345K (Missense)	1	BLCA_VARSCAN2	TCGA-4Z-AA89-01A-11D-A391-08	TCGA-4Z-AA89-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.P471A	0.5333	45.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.P471A (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A3NA-01A-11D-A21A-08	TCGA-FD-A3NA-10A-01D-A21A-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.F909L	0.3013	229.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.F909L (Missense)	1	BLCA_VARSCAN2	TCGA-BT-A20X-01A-11D-A16O-08	TCGA-BT-A20X-11A-12D-A16O-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.G451V	0.229	131.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.G451V (Missense)	1	BLCA_VARSCAN2	TCGA-G2-A2EJ-01A-11D-A17V-08	TCGA-G2-A2EJ-10A-01D-A17V-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Q75E	0.3203	153.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Q75E (Missense)	1	BLCA_VARSCAN2	TCGA-CF-A5UA-01A-11D-A289-08	TCGA-CF-A5UA-10A-01D-A289-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E726K	0.125	40.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E726K (Missense)	1	BLCA_VARSCAN2	TCGA-2F-A9KO-01A-11D-A38G-08	TCGA-2F-A9KO-11A-12D-A38J-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E791Q	0.2414	29.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E791Q (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A1A5-01A-11D-A13W-08	TCGA-DK-A1A5-10A-01D-A13W-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1200*	0.4655	58.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1200* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A2HX-01A-12D-A18F-08	TCGA-DK-A2HX-10A-01D-A18F-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.S1602Rfs*10	0.1071	84.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1602Rfs*10 (Frameshift)		BLCA_VARSCAN2	TCGA-YC-A8S6-01A-31D-A38G-08	TCGA-YC-A8S6-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q944*	0.3012	83.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q944* (Nonsense)		BLCA_VARSCAN2	TCGA-K4-A54R-01A-11D-A26M-08	TCGA-K4-A54R-10A-01D-A26K-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.E1032*	0.2256	164.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E1032* (Nonsense)		BLCA_VARSCAN2	TCGA-K4-A54R-01A-11D-A26M-08	TCGA-K4-A54R-10A-01D-A26K-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.S1182Rfs*24	0.5263	19.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1182Rfs*24 (Frameshift)		BLCA_VARSCAN2	TCGA-BL-A0C8-01A-11D-A271-08	TCGA-BL-A0C8-10A-01D-A271-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.E1060*	0.1194	67.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E1060* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A6TG-01A-11D-A32B-08	TCGA-FD-A6TG-10A-01D-A329-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q878*	0.3143	35.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q878* (Nonsense)		BLCA_VARSCAN2	TCGA-GD-A76B-01A-11D-A32B-08	TCGA-GD-A76B-10A-01D-A329-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q566*	0.1333	240.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q566* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A3B3-01A-12D-A202-08	TCGA-FD-A3B3-10A-01D-A202-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.M918Kfs*19	0.4	55.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.M918Kfs*19 (Frameshift)		BLCA_VARSCAN2	TCGA-4Z-AA84-01A-11D-A391-08	TCGA-4Z-AA84-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.S711*	0.6486	37.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S711* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-AA6W-01A-12D-A391-08	TCGA-DK-AA6W-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.N820Mfs*13	0.1364	44.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.N820Mfs*13 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A3IT-01A-31D-A20D-08	TCGA-DK-A3IT-10A-01D-A20D-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q512*	0.2985	268.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q512* (Nonsense)		BLCA_VARSCAN2	TCGA-GU-A766-01A-11D-A32B-08	TCGA-GU-A766-10A-01D-A329-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1331*	0.3065	124.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1331* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A3IN-01A-11D-A20D-08	TCGA-DK-A3IN-10A-01D-A20D-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q758Rfs*75	0.2653	49.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q758Rfs*75 (Frameshift)		BLCA_VARSCAN2	TCGA-KQ-A41Q-01A-11D-A339-08	TCGA-KQ-A41Q-10D-01D-A339-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.S1085*	0.4118	51.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1085* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A62P-01A-32D-A30E-08	TCGA-FD-A62P-10A-01D-A30H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.S2104Pfs*31	0.4085	71.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S2104Pfs*31 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-A9SZ-01A-11D-A391-08	TCGA-XF-A9SZ-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.M1564Hfs*8	0.1846	65.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.M1564Hfs*8 (Frameshift)		BLCA_VARSCAN2	TCGA-BL-A5ZZ-01A-31D-A30E-08	TCGA-BL-A5ZZ-10A-01D-A30H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R1446*	0.1293	116.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1446* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A5C1-01A-11D-A289-08	TCGA-FD-A5C1-10A-01D-A289-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q802Vfs*32	0.3111	45.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q802Vfs*32 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-AA76-01A-11D-A391-08	TCGA-DK-AA76-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q589*	0.4611	180.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q589* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A1AD-01A-11D-A13W-08	TCGA-DK-A1AD-10A-01D-A13W-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.R1511Sfs*16	0.2	65.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1511Sfs*16 (Frameshift)		BLCA_VARSCAN2	TCGA-FD-A6TK-01A-42D-A339-08	TCGA-FD-A6TK-10A-21D-A339-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P729Vfs*84	0.1892	37.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P729Vfs*84 (Frameshift)		BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.S617*	0.1831	71.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S617* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-A9T5-01A-11D-A42E-08	TCGA-XF-A9T5-10A-01D-A42H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1584*	0.5426	282.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1584* (Nonsense)		BLCA_VARSCAN2	TCGA-FJ-A3Z9-01A-11D-A26M-08	TCGA-FJ-A3Z9-10A-01D-A26K-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.T533M	0.5	18.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.T533M (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T6-01A-11D-A42E-08	TCGA-XF-A9T6-10A-01D-A42H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q2207*	0.4841	126.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q2207* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A3IK-01A-32D-A21A-08	TCGA-DK-A3IK-10A-01D-A21A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q944*	0.6667	75.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q944* (Nonsense)		BLCA_VARSCAN2	TCGA-GU-A42P-01A-11D-A23U-08	TCGA-GU-A42P-10A-01D-A23U-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.S617*	0.1757	74.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S617* (Nonsense)		BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.L964R	0.35	60.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.L964R (Missense)		BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.S1171Rfs*8	0.2308	39.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1171Rfs*8 (Frameshift)		BLCA_VARSCAN2	TCGA-BT-A20Q-01A-11D-A14W-08	TCGA-BT-A20Q-11A-11D-A14W-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.F2141Sfs*59	0.1571	70.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.F2141Sfs*59 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-A9SP-01A-11D-A391-08	TCGA-XF-A9SP-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P1554Hfs*11	0.432	125.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1554Hfs*11 (Frameshift)		BLCA_VARSCAN2	TCGA-FD-A43N-01A-11D-A23U-08	TCGA-FD-A43N-10A-01D-A23U-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R2158*	0.1606	137.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R2158* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A6B2-01A-11D-A30E-08	TCGA-DK-A6B2-10A-01D-A30H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.E1802*	0.3846	39.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E1802* (Nonsense)		BLCA_VARSCAN2	TCGA-BL-A3JM-01A-12D-A21A-08	TCGA-BL-A3JM-11A-31D-A21A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Y500Lfs*123	0.3684	475.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Y500Lfs*123 (Frameshift)		BLCA_VARSCAN2	TCGA-BT-A2LD-01A-12D-A20D-08	TCGA-BT-A2LD-10A-01D-A20D-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q386*	0.2288	118.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q386* (Nonsense)		BLCA_VARSCAN2	TCGA-BT-A20R-01A-12D-A16O-08	TCGA-BT-A20R-11A-11D-A16O-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R1528*	0.2625	80.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1528* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-A9R7-01A-11D-A38G-08	TCGA-ZF-A9R7-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1424*	0.3818	110.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1424* (Nonsense)		BLCA_VARSCAN2	TCGA-GU-A42R-01A-11D-A23M-08	TCGA-GU-A42R-10A-01D-A23K-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.E2035*	0.3421	152.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E2035* (Nonsense)		BLCA_VARSCAN2	TCGA-BT-A3PH-01A-11D-A21Z-08	TCGA-BT-A3PH-10A-01D-A21Z-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.K1815*	0.1552	58.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.K1815* (Frameshift)		BLCA_VARSCAN2	TCGA-BT-A20O-01A-21D-A14W-08	TCGA-BT-A20O-11A-11D-A14W-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.A2234Lfs*33	0.2264	53.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.A2234Lfs*33 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-A9SW-01A-11D-A42E-08	TCGA-XF-A9SW-10A-01D-A42H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1095*	0.1512	86.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1095* (Nonsense)		BLCA_VARSCAN2	TCGA-GD-A2C5-01A-12D-A17V-08	TCGA-GD-A2C5-10A-01D-A17V-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1363*	0.5616	219.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1363* (Nonsense)		BLCA_VARSCAN2	TCGA-GV-A3JV-01A-11D-A21Z-08	TCGA-GV-A3JV-10B-01D-A21Z-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.W2050*	0.5248	101.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.W2050* (Nonsense)		BLCA_VARSCAN2	TCGA-K4-A3WV-01A-11D-A22Z-08	TCGA-K4-A3WV-10A-01D-A22Z-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.R532C	0.3871	31.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.R532C (Missense)		BLCA_VARSCAN2	TCGA-XF-A8HI-01A-11D-A38G-08	TCGA-XF-A8HI-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.S698Vfs*119	0.25	76.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S698Vfs*119 (Frameshift)		BLCA_VARSCAN2	TCGA-HQ-A5NE-01A-12D-A289-08	TCGA-HQ-A5NE-10A-01D-A289-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.S2264*	0.4627	67.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S2264* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-AAML-01A-11D-A42E-08	TCGA-XF-AAML-10A-01D-A42H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.L1694Cfs*9	0.2958	71.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.L1694Cfs*9 (Frameshift)		BLCA_VARSCAN2	TCGA-H4-A2HO-01A-11D-A17V-08	TCGA-H4-A2HO-10A-01D-A17V-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Y551Lfs*72	0.3175	315.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Y551Lfs*72 (Frameshift)		BLCA_VARSCAN2	TCGA-GD-A3OQ-01A-32D-A21Z-08	TCGA-GD-A3OQ-10A-01D-A21Z-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R1989*	0.9515	103.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1989* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P947Hfs*21	0.1009	109.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P947Hfs*21 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A3IU-01A-11D-A20D-08	TCGA-DK-A3IU-10A-01D-A20D-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q393Rfs*3	0.2162	74.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q393Rfs*3 (Frameshift)		BLCA_VARSCAN2	TCGA-FD-A3SN-01A-12D-A22Z-08	TCGA-FD-A3SN-10A-01D-A22Z-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.Q505Hfs*113	0.68	150.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q505Hfs*113 (Frameshift)		BLCA_VARSCAN2	TCGA-ZF-AA5N-01A-11D-A42E-08	TCGA-ZF-AA5N-10A-01D-A42H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.S740_Q743delins*	0.2632	38.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S740_Q743delins* (Nonsense)		BLCA_VARSCAN2	TCGA-5N-A9KI-01A-31D-A42E-08	TCGA-5N-A9KI-10A-01D-A42H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1850Gfs*4	0.5	76.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1850Gfs*4 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-A8HD-01A-11D-A364-08	TCGA-XF-A8HD-10A-01D-A362-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.S1085*	0.2368	38.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1085* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-AA71-01A-31D-A391-08	TCGA-DK-AA71-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.Q980L	0.2018	114.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.Q980L (Missense)		BLCA_VARSCAN2	TCGA-BT-A0YX-01A-11D-A10S-08	TCGA-BT-A0YX-10A-01D-A10S-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q393*	0.1136	132.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q393* (Nonsense)		BLCA_VARSCAN2	TCGA-K4-A83P-01A-11D-A34U-08	TCGA-K4-A83P-10A-01D-A34X-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.S1085*	0.3077	26.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1085* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-AA6R-01A-11D-A42E-08	TCGA-DK-AA6R-10A-01D-A42H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.S634*	0.48	125.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S634* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-AAN2-01A-11D-A42E-08	TCGA-XF-AAN2-10A-01D-A42H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.E2250Vfs*27	0.7073	123.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E2250Vfs*27 (Frameshift)		BLCA_VARSCAN2	TCGA-FJ-A871-01A-11D-A34U-08	TCGA-FJ-A871-10A-01D-A34X-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1536Efs*34	0.131	84.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1536Efs*34 (Frameshift)		BLCA_VARSCAN2	TCGA-FD-A3SP-01A-31D-A22Z-08	TCGA-FD-A3SP-10A-01D-A22Z-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q557*	0.343	277.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q557* (Nonsense)		BLCA_VARSCAN2	TCGA-E7-A4XJ-01A-11D-A26M-08	TCGA-E7-A4XJ-10A-01D-A26K-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.S1242Rfs*16	0.463	54.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1242Rfs*16 (Frameshift)		BLCA_VARSCAN2	TCGA-E7-A4XJ-01A-11D-A26M-08	TCGA-E7-A4XJ-10A-01D-A26K-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q507*	0.5474	380.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q507* (Nonsense)		BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q678*	0.2877	73.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q678* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-AA51-01A-21D-A391-08	TCGA-ZF-AA51-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.E1032*	0.2979	141.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E1032* (Nonsense)		BLCA_VARSCAN2	TCGA-LC-A66R-01A-41D-A30E-08	TCGA-LC-A66R-10A-01D-A30H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.S664*	0.4634	164.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S664* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A3IM-01A-11D-A20D-08	TCGA-DK-A3IM-10A-01D-A20D-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1212*	0.5606	66.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1212* (Nonsense)		BLCA_VARSCAN2	TCGA-4Z-AA7O-01A-31D-A391-08	TCGA-4Z-AA7O-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P598Lfs*21	0.2787	122.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P598Lfs*21 (Frameshift)		BLCA_VARSCAN2	TCGA-E7-A519-01A-11D-A26M-08	TCGA-E7-A519-10A-01D-A26K-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.P508Afs*112	0.1597	144.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P508Afs*112 (Frameshift)		BLCA_VARSCAN2	TCGA-YF-AA3M-01A-11D-A42E-08	TCGA-YF-AA3M-10D-01D-A42H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q393*	0.3264	144.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q393* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A62O-01A-11D-A30E-08	TCGA-FD-A62O-10A-01D-A30H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q611*	0.2159	88.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q611* (Nonsense)		BLCA_VARSCAN2	TCGA-GC-A3RC-01A-11D-A22Z-08	TCGA-GC-A3RC-10B-01D-A22Z-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.S634*	0.9643	56.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S634* (Nonsense)		BLCA_VARSCAN2	TCGA-G2-A2EL-01A-12D-A18F-08	TCGA-G2-A2EL-10A-01D-A18F-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.D1850Gfs*4	0.496	125.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1850Gfs*4 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A1AE-01A-11D-A13W-08	TCGA-DK-A1AE-10A-01D-A13W-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.G1097C	0.1845	103.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.G1097C (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4W-01A-12D-A38G-08	TCGA-ZF-AA4W-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q515*	0.3664	655.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q515* (Nonsense)		BLCA_VARSCAN2	TCGA-BT-A3PJ-01A-21D-A21Z-08	TCGA-BT-A3PJ-10A-01D-A21Z-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.M1318Dfs*5	0.234	94.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.M1318Dfs*5 (Frameshift)		BLCA_VARSCAN2	TCGA-G2-A2EK-01A-22D-A18F-08	TCGA-G2-A2EK-10A-01D-A18F-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.N1471Kfs*20	0.5652	69.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.N1471Kfs*20 (Frameshift)		BLCA_VARSCAN2	TCGA-E7-A85H-01A-11D-A34U-08	TCGA-E7-A85H-10B-01D-A34X-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.S552*	0.5102	98.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S552* (Nonsense)		BLCA_VARSCAN2	TCGA-G2-AA3F-01A-12D-A42E-08	TCGA-G2-AA3F-10A-01D-A42H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q678*	0.1622	74.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q678* (Nonsense)		BLCA_VARSCAN2	TCGA-2F-A9KO-01A-11D-A38G-08	TCGA-2F-A9KO-11A-12D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Frameshift	p.N1040Sfs*6	0.2688	93.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.N1040Sfs*6 (Frameshift)		BLCA_VARSCAN2	TCGA-BL-A13I-01A-11D-A271-08	TCGA-BL-A13I-10A-01D-A271-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q479*	0.3216	426.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q479* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A6B5-01A-11D-A31L-08	TCGA-DK-A6B5-10A-01D-A31J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1363*	0.3253	83.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1363* (Nonsense)		BLCA_VARSCAN2	TCGA-G2-AA3D-01A-11D-A391-08	TCGA-G2-AA3D-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R505G	0.3388	121.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R505G (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TA-01A-12D-A339-08	TCGA-FD-A6TA-10A-21D-A339-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.Q3000H	0.2308	78.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.Q3000H (Missense)	1	BLCA_VARSCAN2	TCGA-G2-A3IE-01A-11D-A20D-08	TCGA-G2-A3IE-10A-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E3007K	0.2471	85.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.E3007K (Missense)	1	BLCA_VARSCAN2	TCGA-G2-A3IE-01A-11D-A20D-08	TCGA-G2-A3IE-10A-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.E97K	0.3953	43.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.E97K (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A6B0-01A-11D-A31L-08	TCGA-DK-A6B0-10A-01D-A31J-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.L57V	0.4857	70.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.L57V (Missense)	0	BLCA_VARSCAN2	TCGA-XF-AAMG-01A-11D-A42E-08	TCGA-XF-AAMG-10A-01D-A42H-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R337H	0.4138	58.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R337H (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A1AG-01A-11D-A13W-08	TCGA-DK-A1AG-10A-01D-A13W-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E2094K	0.2338	154.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.E2094K (Missense)	1	BLCA_VARSCAN2	TCGA-GV-A3QG-01A-11D-A21Z-08	TCGA-GV-A3QG-10A-01D-A21Z-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.R1148Q	0.1815	292.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.R1148Q (Missense)	0	BLCA_VARSCAN2	TCGA-ZF-AA5H-01A-11D-A391-08	TCGA-ZF-AA5H-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.V1352L	0.3741	139.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.V1352L (Missense)	0	BLCA_VARSCAN2	TCGA-4Z-AA84-01A-11D-A391-08	TCGA-4Z-AA84-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.G554R	0.4353	85.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.G554R (Missense)	0	BLCA_VARSCAN2	TCGA-DK-AA6W-01A-12D-A391-08	TCGA-DK-AA6W-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.V939F	0.1781	146.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.V939F (Missense)	0	BLCA_VARSCAN2	TCGA-DK-AA6W-01A-12D-A391-08	TCGA-DK-AA6W-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.F1124L	0.1569	51.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.F1124L (Missense)	0	BLCA_VARSCAN2	TCGA-ZF-AA58-01A-12D-A42E-08	TCGA-ZF-AA58-10A-01D-A42H-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R2973T	0.3433	67.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R2973T (Missense)	1	BLCA_VARSCAN2	TCGA-5N-A9KM-01A-11D-A42E-08	TCGA-5N-A9KM-10A-01D-A42H-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.D520N	0.4	80.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.D520N (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6S-01A-21D-A391-08	TCGA-DK-AA6S-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.D707H	0.2267	75.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.D707H (Missense)	0	BLCA_VARSCAN2	TCGA-XF-A9SZ-01A-11D-A391-08	TCGA-XF-A9SZ-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.D661H	0.1707	41.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.D661H (Missense)	0	BLCA_VARSCAN2	TCGA-XF-A9SZ-01A-11D-A391-08	TCGA-XF-A9SZ-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.I323V	0.125	40.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.I323V (Missense)	1	BLCA_VARSCAN2	TCGA-XF-AAME-01A-12D-A42E-08	TCGA-XF-AAME-10A-01D-A42H-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.P106L	0.5	82.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.P106L (Missense)		BLCA_VARSCAN2	TCGA-DK-A1A7-01A-11D-A13W-08	TCGA-DK-A1A7-10A-01D-A13W-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465C	0.3511	94.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465C (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN1-01A-31D-A42E-08	TCGA-XF-AAN1-10A-01D-A42H-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.S1005C	0.3056	72.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.S1005C (Missense)	0	BLCA_VARSCAN2	TCGA-GC-A4ZW-01A-11D-A26M-08	TCGA-GC-A4ZW-10A-01D-A26K-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.D1705N	0.2015	134.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.D1705N (Missense)	1	BLCA_VARSCAN2	TCGA-XF-A9T8-01A-11D-A391-08	TCGA-XF-A9T8-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R2713K	0.5692	65.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R2713K (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-A9RF-01A-11D-A38G-08	TCGA-ZF-A9RF-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R505G	0.155	129.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R505G (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TF-01A-52D-A32B-08	TCGA-FD-A6TF-10A-21D-A329-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L762V	0.2941	68.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L762V (Missense)	1	BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.D2372N	0.2414	29.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.D2372N (Missense)	1	BLCA_VARSCAN2	TCGA-XF-A9T5-01A-11D-A42E-08	TCGA-XF-A9T5-10A-01D-A42H-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R505G	0.1615	130.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R505G (Missense)		BLCA_VARSCAN2	TCGA-CU-A0YR-01A-12D-A10S-08	TCGA-CU-A0YR-10A-01D-A10S-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.I2888L	0.3776	143.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.I2888L (Missense)	1	BLCA_VARSCAN2	TCGA-CU-A0YR-01A-12D-A10S-08	TCGA-CU-A0YR-10A-01D-A10S-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.D398H	0.1167	60.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.D398H (Missense)	1	BLCA_VARSCAN2	TCGA-UY-A9PB-01A-11D-A38G-08	TCGA-UY-A9PB-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.H1213N	0.4086	93.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.H1213N (Missense)	1	BLCA_VARSCAN2	TCGA-S5-AA26-01A-11D-A38G-08	TCGA-S5-AA26-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R2568G	0.5667	90.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R2568G (Missense)	1	BLCA_VARSCAN2	TCGA-S5-AA26-01A-11D-A38G-08	TCGA-S5-AA26-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.G88A	0.4	65.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.G88A (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA86-01A-11D-A391-08	TCGA-4Z-AA86-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.D395N	0.1266	79.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.D395N (Missense)	0	BLCA_VARSCAN2	TCGA-4Z-AA86-01A-11D-A391-08	TCGA-4Z-AA86-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.V370I	0.2568	74.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.V370I (Missense)	0	BLCA_VARSCAN2	TCGA-XF-A9T6-01A-11D-A42E-08	TCGA-XF-A9T6-10A-01D-A42H-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.T2359N	0.25	44.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.T2359N (Missense)	1	BLCA_VARSCAN2	TCGA-K4-A6MB-01A-11D-A31L-08	TCGA-K4-A6MB-10A-01D-A31J-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.S398F	0.2097	62.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S398F (Missense)		BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Missense	p.E132K	0.3617	47.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.E132K (Missense)	0	BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R505G	0.4565	92.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R505G (Missense)		BLCA_VARSCAN2	TCGA-YC-A9TC-01A-22D-A391-08	TCGA-YC-A9TC-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.Q306E	0.2708	48.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.Q306E (Missense)		BLCA_VARSCAN2	TCGA-YC-A9TC-01A-22D-A391-08	TCGA-YC-A9TC-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.Q2972H	0.4177	79.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.Q2972H (Missense)	1	BLCA_VARSCAN2	TCGA-YC-A9TC-01A-22D-A391-08	TCGA-YC-A9TC-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.D317G	0.3956	91.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.D317G (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A43N-01A-11D-A23U-08	TCGA-FD-A43N-10A-01D-A23U-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.S34L	0.4	50.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.S34L (Missense)	0	BLCA_VARSCAN2	TCGA-ZF-A9R7-01A-11D-A38G-08	TCGA-ZF-A9R7-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.D399H	0.4308	65.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.D399H (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R7-01A-11D-A38G-08	TCGA-ZF-A9R7-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.D399N	0.1739	92.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.D399N (Missense)	0	BLCA_VARSCAN2	TCGA-ZF-A9R7-01A-11D-A38G-08	TCGA-ZF-A9R7-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R505G	0.1905	126.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R505G (Missense)		BLCA_VARSCAN2	TCGA-DK-A3WX-01A-22D-A22Z-08	TCGA-DK-A3WX-10A-01D-A22Z-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Nonsense	p.R1491*	0.325	40.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1491* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A3SM-01A-11D-A22Z-08	TCGA-FD-A3SM-10A-01D-A22Z-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.Q808K	0.156	109.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.Q808K (Missense)	0	BLCA_VARSCAN2	TCGA-YF-AA3L-01A-11D-A38G-08	TCGA-YF-AA3L-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E158Q	0.7529	85.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.E158Q (Missense)	1	BLCA_VARSCAN2	TCGA-BT-A3PH-01A-11D-A21Z-08	TCGA-BT-A3PH-10A-01D-A21Z-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Frameshift	p.A393Ifs*16	0.7778	45.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A393Ifs*16 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-AAMX-01A-11D-A42E-08	TCGA-XF-AAMX-10A-01D-A42H-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.D2889H	0.45	60.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.D2889H (Missense)	1	BLCA_VARSCAN2	TCGA-XF-A8HI-01A-11D-A38G-08	TCGA-XF-A8HI-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.E323K	0.2268	97.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.E323K (Missense)	0	BLCA_VARSCAN2	TCGA-HQ-A5NE-01A-12D-A289-08	TCGA-HQ-A5NE-10A-01D-A289-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.F207L	0.5	18.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.F207L (Missense)	0	BLCA_VARSCAN2	TCGA-CU-A5W6-01A-11D-A289-08	TCGA-CU-A5W6-10A-01D-A289-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.R142C	0.1786	28.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.R142C (Missense)	0	BLCA_VARSCAN2	TCGA-CU-A5W6-01A-11D-A289-08	TCGA-CU-A5W6-10A-01D-A289-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.G517R	0.4478	67.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.G517R (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T2-01A-11D-A42E-08	TCGA-XF-A9T2-10A-01D-A42H-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R505G	0.2027	74.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R505G (Missense)		BLCA_VARSCAN2	TCGA-C4-A0F1-01A-11D-A10S-08	TCGA-C4-A0F1-10A-01D-A10S-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.S207C	0.3651	63.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.S207C (Missense)	1	BLCA_VARSCAN2	TCGA-UY-A9PH-01A-11D-A38G-08	TCGA-UY-A9PH-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.D863N	0.3043	46.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.D863N (Missense)	1	BLCA_VARSCAN2	TCGA-XF-AAML-01A-11D-A42E-08	TCGA-XF-AAML-10A-01D-A42H-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R505G	0.6212	66.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R505G (Missense)		BLCA_VARSCAN2	TCGA-DK-AA75-01A-11D-A391-08	TCGA-DK-AA75-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.F523V	0.5175	143.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.F523V (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L1347V	0.4407	59.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L1347V (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L2005I	0.439	41.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L2005I (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E2164G	0.1149	87.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.E2164G (Missense)	1	BLCA_VARSCAN2	TCGA-K4-A3WS-01A-11D-A22Z-08	TCGA-K4-A3WS-10A-01D-A22Z-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.D864N	0.2364	55.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.D864N (Missense)	0	BLCA_VARSCAN2	TCGA-BT-A20U-01A-11D-A14W-08	TCGA-BT-A20U-11A-11D-A14W-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.Q284P	0.525	40.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.Q284P (Missense)	1	BLCA_VARSCAN2	TCGA-FT-A3EE-01A-11D-A202-08	TCGA-FT-A3EE-10A-01D-A202-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.L498V	0.1225	253.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.L498V (Missense)		BLCA_VARSCAN2	TCGA-S5-A6DX-01A-11D-A31L-08	TCGA-S5-A6DX-10A-01D-A31J-08
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Missense	p.E116K	0.5269	93.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.E116K (Missense)	0	BLCA_VARSCAN2	TCGA-S5-A6DX-01A-11D-A31L-08	TCGA-S5-A6DX-10A-01D-A31J-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.E56Q	0.2667	45.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.E56Q (Missense)		BLCA_VARSCAN2	TCGA-DK-AA71-01A-31D-A391-08	TCGA-DK-AA71-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.S426L	0.2207	299.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S426L (Missense)		BLCA_VARSCAN2	TCGA-BT-A0YX-01A-11D-A10S-08	TCGA-BT-A0YX-10A-01D-A10S-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.G1456D	0.1948	77.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.G1456D (Missense)	1	BLCA_VARSCAN2	TCGA-BT-A0YX-01A-11D-A10S-08	TCGA-BT-A0YX-10A-01D-A10S-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.D280H	0.2424	66.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.D280H (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E2164Q	0.2029	138.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.E2164Q (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.E1378K	0.2013	159.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.E1378K (Missense)	0	BLCA_VARSCAN2	TCGA-GU-AATO-01A-11D-A391-08	TCGA-GU-AATO-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.T385K	0.177	113.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.T385K (Missense)		BLCA_VARSCAN2	TCGA-G2-A2ES-01A-11D-A17V-08	TCGA-G2-A2ES-11A-31D-A17V-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.G182E	0.3582	134.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.G182E (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A1A6-01A-11D-A13W-08	TCGA-DK-A1A6-10A-01D-A13W-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.H470Y	0.3053	131.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.H470Y (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN2-01A-11D-A42E-08	TCGA-XF-AAN2-10A-01D-A42H-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.D140H	0.4844	64.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.D140H (Missense)	1	BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.E542K	0.1132	212.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.E542K (Missense)	0	BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.G844R	0.4118	34.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.G844R (Missense)	1	BLCA_VARSCAN2	TCGA-UY-A8OB-01A-12D-A42E-08	TCGA-UY-A8OB-11A-12D-A42H-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.E1115K	0.379	124.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.E1115K (Missense)	0	BLCA_VARSCAN2	TCGA-UY-A78O-01A-12D-A339-08	TCGA-UY-A78O-10A-01D-A339-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.S546L	0.1327	98.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S546L (Missense)		BLCA_VARSCAN2	TCGA-K4-A3WU-01B-11D-A23M-08	TCGA-K4-A3WU-10A-01D-A23K-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E2884Q	0.2973	37.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.E2884Q (Missense)	1	BLCA_VARSCAN2	TCGA-K4-A3WU-01B-11D-A23M-08	TCGA-K4-A3WU-10A-01D-A23K-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.C95F	0.2381	84.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.C95F (Missense)	0	BLCA_VARSCAN2	TCGA-GU-A42Q-01A-11D-A23U-08	TCGA-GU-A42Q-10A-01D-A23U-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.L1764I	0.5811	74.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.L1764I (Missense)	1	BLCA_VARSCAN2	TCGA-XF-A8HG-01A-11D-A364-08	TCGA-XF-A8HG-10A-01D-A362-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.N526D	0.2712	59.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.N526D (Missense)	0	BLCA_VARSCAN2	TCGA-CU-A3KJ-01A-11D-A21A-08	TCGA-CU-A3KJ-10A-01D-A21A-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.G558V	0.1584	101.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.G558V (Missense)	1	BLCA_VARSCAN2	TCGA-BT-A3PK-01A-21D-A21Z-08	TCGA-BT-A3PK-10A-01D-A21Z-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R2461P	0.1887	53.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R2461P (Missense)	1	BLCA_VARSCAN2	TCGA-BT-A3PK-01A-21D-A21Z-08	TCGA-BT-A3PK-10A-01D-A21Z-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R479G	0.4255	47.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R479G (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7O-01A-31D-A391-08	TCGA-4Z-AA7O-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.E355K	0.3111	45.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.E355K (Missense)	0	BLCA_VARSCAN2	TCGA-ZF-AA4V-01A-11D-A38G-08	TCGA-ZF-AA4V-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.S1947P	0.2982	57.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.S1947P (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-A9RC-01A-11D-A38G-08	TCGA-ZF-A9RC-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465C	0.9868	151.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465C (Missense)		BLCA_VARSCAN2	TCGA-E7-A5KE-01A-11D-A289-08	TCGA-E7-A5KE-10A-01D-A289-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.D642G	0.2162	74.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.D642G (Missense)		BLCA_VARSCAN2	TCGA-GC-A3RD-01A-12D-A22Z-08	TCGA-GC-A3RD-10B-01D-A22Z-08
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Missense	p.G334W	0.1961	51.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.G334W (Missense)	0	BLCA_VARSCAN2	TCGA-DK-AA6L-01A-11D-A391-08	TCGA-DK-AA6L-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.G460D	0.4043	47.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.G460D (Missense)	0	BLCA_VARSCAN2	TCGA-E7-A677-01A-11D-A30E-08	TCGA-E7-A677-10A-01D-A30H-08
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Missense	p.D321E	0.3377	77.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.D321E (Missense)	0	BLCA_VARSCAN2	TCGA-KQ-A41R-01A-21D-A34U-08	TCGA-KQ-A41R-10G-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E2164Q	0.1282	156.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.E2164Q (Missense)	1	BLCA_VARSCAN2	TCGA-G2-AA3B-01A-11D-A391-08	TCGA-G2-AA3B-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.S546L	0.7545	110.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S546L (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AC-01A-11D-A13W-08	TCGA-DK-A1AC-10A-01D-A13W-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.H2038N	0.8261	23.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.H2038N (Missense)	1	BLCA_VARSCAN2	TCGA-E7-A85H-01A-11D-A34U-08	TCGA-E7-A85H-10B-01D-A34X-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.L57V	0.1	110.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.L57V (Missense)	0	BLCA_VARSCAN2	TCGA-2F-A9KO-01A-11D-A38G-08	TCGA-2F-A9KO-11A-12D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R329T	0.4103	39.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R329T (Missense)	1	BLCA_VARSCAN2	TCGA-2F-A9KO-01A-11D-A38G-08	TCGA-2F-A9KO-11A-12D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R505G	0.1562	96.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R505G (Missense)		BLCA_VARSCAN2	TCGA-BL-A13I-01A-11D-A271-08	TCGA-BL-A13I-10A-01D-A271-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R982C	0.4783	46.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R982C (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A3N6-01A-11D-A21A-08	TCGA-FD-A3N6-10A-01D-A21A-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.D1208N	0.2586	58.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.D1208N (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-AA4X-01A-11D-A38G-08	TCGA-ZF-AA4X-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.L903F	0.1724	29.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.L903F (Missense)	0	BLCA_VARSCAN2	TCGA-BT-A20J-01A-11D-A14W-08	TCGA-BT-A20J-11A-11D-A14W-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R1691H	0.4133	75.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R1691H (Missense)		BLCA_VARSCAN2	TCGA-CF-A9FM-01A-11D-A38G-08	TCGA-CF-A9FM-10A-01D-A38J-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.E537D	0.3133	83.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.E537D (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6T-01A-11D-A391-08	TCGA-DK-AA6T-10A-01D-A394-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.L148F	0.1864	59.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.L148F (Missense)		BLCA_VARSCAN2	TCGA-DK-AA76-01A-11D-A391-08	TCGA-DK-AA76-10A-01D-A394-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.L1593V	0.2857	35.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.L1593V (Missense)		BLCA_VARSCAN2	TCGA-GV-A6ZA-01A-12D-A339-08	TCGA-GV-A6ZA-10A-01D-A339-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.E575Q	0.3036	56.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.E575Q (Missense)		BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.D23H	0.2375	80.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.D23H (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN3-01A-11D-A42E-08	TCGA-XF-AAN3-10A-01D-A42H-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.Y85C	0.3158	133.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.Y85C (Missense)		BLCA_VARSCAN2	TCGA-2F-A9KP-01A-11D-A38G-08	TCGA-2F-A9KP-10A-01D-A38J-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R1675C	0.3836	73.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R1675C (Missense)		BLCA_VARSCAN2	TCGA-DK-A3IK-01A-32D-A21A-08	TCGA-DK-A3IK-10A-01D-A21A-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.G178W	0.486	107.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.G178W (Missense)		BLCA_VARSCAN2	TCGA-FJ-A3ZF-01A-11D-A23M-08	TCGA-FJ-A3ZF-10A-01D-A23K-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.R817Q	0.46	100.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.R817Q (Missense)		BLCA_VARSCAN2	TCGA-FJ-A3ZF-01A-11D-A23M-08	TCGA-FJ-A3ZF-10A-01D-A23K-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.E1067K	0.5	18.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.E1067K (Missense)		BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.D1960H	0.2317	82.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.D1960H (Missense)		BLCA_VARSCAN2	TCGA-GD-A2C5-01A-12D-A17V-08	TCGA-GD-A2C5-10A-01D-A17V-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.E2085K	0.2373	59.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.E2085K (Missense)		BLCA_VARSCAN2	TCGA-XF-A9SM-01A-11D-A42E-08	TCGA-XF-A9SM-10A-01D-A42H-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.E311D	0.1067	75.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.E311D (Missense)		BLCA_VARSCAN2	TCGA-FD-A3B6-01A-21D-A20D-08	TCGA-FD-A3B6-10A-01D-A20D-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.D1123H	0.1518	112.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.D1123H (Missense)		BLCA_VARSCAN2	TCGA-DK-AA75-01A-11D-A391-08	TCGA-DK-AA75-10A-01D-A394-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.P286R	0.5135	37.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.P286R (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.A1375V	0.1127	71.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.A1375V (Missense)		BLCA_VARSCAN2	TCGA-LT-A8JT-01A-11D-A364-08	TCGA-LT-A8JT-10A-01D-A362-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.D83H	0.1923	78.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.D83H (Missense)		BLCA_VARSCAN2	TCGA-DK-A3IQ-01A-31D-A20D-08	TCGA-DK-A3IQ-10A-01D-A20D-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.D529N	0.2696	115.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.D529N (Missense)		BLCA_VARSCAN2	TCGA-GC-A6I1-01A-12D-A31L-08	TCGA-GC-A6I1-10A-01D-A31J-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.E1715K	0.4356	225.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.E1715K (Missense)		BLCA_VARSCAN2	TCGA-DK-A1A6-01A-11D-A13W-08	TCGA-DK-A1A6-10A-01D-A13W-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.G1628A	0.4474	152.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.G1628A (Missense)		BLCA_VARSCAN2	TCGA-DK-A1A6-01A-11D-A13W-08	TCGA-DK-A1A6-10A-01D-A13W-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.M1998I	0.2727	165.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.M1998I (Missense)		BLCA_VARSCAN2	TCGA-KQ-A41P-01A-12D-A339-08	TCGA-KQ-A41P-10F-01D-A339-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.E1784K	0.1714	35.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.E1784K (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RC-01A-11D-A38G-08	TCGA-ZF-A9RC-10A-01D-A38J-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.E715D	0.1186	59.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.E715D (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4W-01A-12D-A38G-08	TCGA-ZF-AA4W-10A-01D-A38J-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.H242D	0.303	33.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.H242D (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R0-01A-11D-A38G-08	TCGA-ZF-A9R0-10A-01D-A38J-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.D132N	0.3514	111.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.D132N (Missense)		BLCA_VARSCAN2	TCGA-DK-A6B5-01A-11D-A31L-08	TCGA-DK-A6B5-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.K164Nfs*6	0.5581	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K164Nfs*6 (Frameshift)		BLCA_VARSCAN2	TCGA-E7-A4IJ-01A-31D-A26M-08	TCGA-E7-A4IJ-10A-01D-A26K-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X331_splice	0.8788	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X331_splice (Splice Site)		BLCA_VARSCAN2	TCGA-DK-AA77-01A-11D-A391-08	TCGA-DK-AA77-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193Y	0.3036	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193Y (Missense)		BLCA_VARSCAN2	TCGA-GC-A3OO-01A-11D-A22Z-08	TCGA-GC-A3OO-10C-01D-A22Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.3478	46.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		BLCA_VARSCAN2	TCGA-CF-A47Y-01A-11D-A23U-08	TCGA-CF-A47Y-10A-01D-A23U-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.3333	18.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4N-01A-11D-A38G-08	TCGA-ZF-AA4N-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.E294Sfs*51	0.2875	80.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E294Sfs*51 (Frameshift)		BLCA_VARSCAN2	TCGA-K4-A54R-01A-11D-A26M-08	TCGA-K4-A54R-10A-01D-A26K-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E285K	0.2273	66.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E285K (Missense)		BLCA_VARSCAN2	TCGA-K4-A54R-01A-11D-A26M-08	TCGA-K4-A54R-10A-01D-A26K-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280K	0.55	20.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280K (Missense)		BLCA_VARSCAN2	TCGA-G2-A3IE-01A-11D-A20D-08	TCGA-G2-A3IE-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.678	59.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		BLCA_VARSCAN2	TCGA-K4-A5RI-01A-11D-A289-08	TCGA-K4-A5RI-10A-01D-A289-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.R306Afs*31	0.75	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R306Afs*31 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-AAMG-01A-11D-A42E-08	TCGA-XF-AAMG-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280T	0.375	32.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280T (Missense)		BLCA_VARSCAN2	TCGA-G2-A2EO-01A-11D-A17V-08	TCGA-G2-A2EO-11A-21D-A17V-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L194H	0.15	20.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L194H (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RG-01A-21D-A42E-08	TCGA-ZF-A9RG-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.L35Ffs*7	0.1953	128.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L35Ffs*7 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-AAMJ-01A-11D-A42E-08	TCGA-XF-AAMJ-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H214R	0.3333	24.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H214R (Missense)		BLCA_VARSCAN2	TCGA-XF-A9SX-01A-21D-A391-08	TCGA-XF-A9SX-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q331*	0.7838	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q331* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-AA5H-01A-11D-A391-08	TCGA-ZF-AA5H-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.2442	86.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		BLCA_VARSCAN2	TCGA-FD-A3B7-01A-31D-A20D-08	TCGA-FD-A3B7-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273L	0.6818	22.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273L (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA84-01A-11D-A391-08	TCGA-4Z-AA84-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.A161V	0.3542	48.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A161V (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TD-01A-51D-A339-08	TCGA-FD-A6TD-10A-21D-A339-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.A161S	0.3617	47.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A161S (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TD-01A-51D-A339-08	TCGA-FD-A6TD-10A-21D-A339-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q192*	0.55	20.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q192* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A2I1-01A-11D-A17V-08	TCGA-DK-A2I1-10A-01D-A17V-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.R213Dfs*34	0.8378	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213Dfs*34 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-AA6W-01A-12D-A391-08	TCGA-DK-AA6W-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.A159P	0.85	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A159P (Missense)		BLCA_VARSCAN2	TCGA-FJ-A3ZE-01A-11D-A23M-08	TCGA-FJ-A3ZE-10A-01D-A23K-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.M169I	0.2	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M169I (Missense)		BLCA_VARSCAN2	TCGA-XF-A9SI-01A-11D-A391-08	TCGA-XF-A9SI-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280T	0.3929	28.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280T (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA58-01A-12D-A42E-08	TCGA-ZF-AA58-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G244C	0.75	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G244C (Missense)		BLCA_VARSCAN2	TCGA-E5-A4TZ-01A-11D-A31L-08	TCGA-E5-A4TZ-10B-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P278R	0.9524	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P278R (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RM-01A-11D-A38G-08	TCGA-ZF-A9RM-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E180*	0.2963	54.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E180* (Nonsense)		BLCA_VARSCAN2	TCGA-GU-A766-01A-11D-A32B-08	TCGA-GU-A766-10A-01D-A329-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280T	0.9143	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280T (Missense)		BLCA_VARSCAN2	TCGA-G2-A3VY-01A-11D-A22Z-08	TCGA-G2-A3VY-10A-01D-A22Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E204Q	0.35	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E204Q (Missense)		BLCA_VARSCAN2	TCGA-DK-A3IN-01A-11D-A20D-08	TCGA-DK-A3IN-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.D148N	0.5217	69.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.D148N (Missense)		BLCA_VARSCAN2	TCGA-DK-A3IN-01A-11D-A20D-08	TCGA-DK-A3IN-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.K132N	0.4524	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K132N (Missense)		BLCA_VARSCAN2	TCGA-DK-A3IN-01A-11D-A20D-08	TCGA-DK-A3IN-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.W91*	0.4262	61.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.W91* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-A8HH-01A-11D-A38G-08	TCGA-XF-A8HH-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R158H	0.4286	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R158H (Missense)		BLCA_VARSCAN2	TCGA-GC-A3YS-01A-11D-A23M-08	TCGA-GC-A3YS-10A-01D-A23K-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R156P	0.2619	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R156P (Missense)		BLCA_VARSCAN2	TCGA-XF-A9SZ-01A-11D-A391-08	TCGA-XF-A9SZ-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E336*	0.7368	19.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E336* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-A9RN-01A-11D-A42E-08	TCGA-ZF-A9RN-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.5556	18.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RE-01A-11D-A38G-08	TCGA-ZF-A9RE-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.K132N	0.5455	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K132N (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7Q-01A-11D-A391-08	TCGA-4Z-AA7Q-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R337S	0.2333	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R337S (Missense)		BLCA_VARSCAN2	TCGA-UY-A9PD-01A-11D-A38G-08	TCGA-UY-A9PD-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248G	0.3462	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248G (Missense)		BLCA_VARSCAN2	TCGA-UY-A9PD-01A-11D-A38G-08	TCGA-UY-A9PD-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280T	0.9259	27.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280T (Missense)		BLCA_VARSCAN2	TCGA-GC-A4ZW-01A-11D-A26M-08	TCGA-GC-A4ZW-10A-01D-A26K-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.6667	51.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		BLCA_VARSCAN2	TCGA-DK-A3IL-01A-11D-A20D-08	TCGA-DK-A3IL-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E271Q	0.3214	28.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E271Q (Missense)		BLCA_VARSCAN2	TCGA-K4-AAQO-01A-11D-A38G-08	TCGA-K4-AAQO-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.8	65.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		BLCA_VARSCAN2	TCGA-PQ-A6FI-01A-11D-A31L-08	TCGA-PQ-A6FI-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P152L	0.8837	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P152L (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AD-01A-11D-A13W-08	TCGA-DK-A1AD-10A-01D-A13W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X33_splice	0.7273	143.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X33_splice (Splice Site)		BLCA_VARSCAN2	TCGA-4Z-AA87-01A-11D-A391-08	TCGA-4Z-AA87-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.C229Yfs*10	0.5	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C229Yfs*10 (Frameshift)		BLCA_VARSCAN2	TCGA-FD-A6TF-01A-52D-A32B-08	TCGA-FD-A6TF-10A-21D-A329-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.9286	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		BLCA_VARSCAN2	TCGA-FD-A6TE-01A-12D-A339-08	TCGA-FD-A6TE-10A-21D-A339-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.K132N	0.9655	29.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K132N (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TE-01A-12D-A339-08	TCGA-FD-A6TE-10A-21D-A339-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.C141Afs*29	0.6154	39.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C141Afs*29 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-A9T5-01A-11D-A42E-08	TCGA-XF-A9T5-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.M246T	0.2712	59.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M246T (Missense)		BLCA_VARSCAN2	TCGA-UY-A9PB-01A-11D-A38G-08	TCGA-UY-A9PB-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L111R	0.1379	87.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L111R (Missense)		BLCA_VARSCAN2	TCGA-UY-A9PB-01A-11D-A38G-08	TCGA-UY-A9PB-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C238F	0.8986	69.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C238F (Missense)		BLCA_VARSCAN2	TCGA-C4-A0F7-01A-11D-A10S-08	TCGA-C4-A0F7-10A-01D-A10S-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q331*	0.274	73.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q331* (Nonsense)		BLCA_VARSCAN2	TCGA-K4-A5RJ-01A-11D-A289-08	TCGA-K4-A5RJ-10A-01D-A289-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L194F	0.4194	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L194F (Missense)		BLCA_VARSCAN2	TCGA-BT-A2LB-01A-11D-A18F-08	TCGA-BT-A2LB-10A-01D-A18F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C135Y	0.2222	36.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C135Y (Missense)		BLCA_VARSCAN2	TCGA-GU-A764-01A-11D-A34U-08	TCGA-GU-A764-10B-01D-A34X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280T	0.1389	36.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280T (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA86-01A-11D-A391-08	TCGA-4Z-AA86-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.A161Gfs*3	0.12	50.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A161Gfs*3 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-A9T6-01A-11D-A42E-08	TCGA-XF-A9T6-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.125	48.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		BLCA_VARSCAN2	TCGA-UY-A9PA-01A-11D-A38G-08	TCGA-UY-A9PA-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P278L	0.44	25.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P278L (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN3-01A-11D-A42E-08	TCGA-XF-AAN3-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.64	25.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		BLCA_VARSCAN2	TCGA-E7-A6ME-01A-22D-A32B-08	TCGA-E7-A6ME-10B-01D-A329-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179R	0.7458	59.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179R (Missense)		BLCA_VARSCAN2	TCGA-2F-A9KP-01A-11D-A38G-08	TCGA-2F-A9KP-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.7681	69.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		BLCA_VARSCAN2	TCGA-GV-A3QH-01A-11D-A21Z-08	TCGA-GV-A3QH-10A-01D-A21Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G199V	0.9545	22.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G199V (Missense)		BLCA_VARSCAN2	TCGA-XF-A9ST-01A-11D-A42E-08	TCGA-XF-A9ST-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E336*	0.75	16.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E336* (Nonsense)		BLCA_VARSCAN2	TCGA-K4-A6MB-01A-11D-A31L-08	TCGA-K4-A6MB-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E285K	0.625	48.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E285K (Missense)		BLCA_VARSCAN2	TCGA-UY-A78L-01A-12D-A339-08	TCGA-UY-A78L-10A-01D-A339-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.5699	93.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		BLCA_VARSCAN2	TCGA-DK-A3IK-01A-32D-A21A-08	TCGA-DK-A3IK-10A-01D-A21A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E224D	0.3333	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E224D (Missense)		BLCA_VARSCAN2	TCGA-UY-A78P-01A-12D-A364-08	TCGA-UY-A78P-11A-11D-A362-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E285K	0.9737	76.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E285K (Missense)		BLCA_VARSCAN2	TCGA-FJ-A3ZF-01A-11D-A23M-08	TCGA-FJ-A3ZF-10A-01D-A23K-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G244D	0.9362	47.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G244D (Missense)		BLCA_VARSCAN2	TCGA-GU-A42P-01A-11D-A23U-08	TCGA-GU-A42P-10A-01D-A23U-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q167*	0.7476	103.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q167* (Nonsense)		BLCA_VARSCAN2	TCGA-K4-A4AB-01B-12D-A289-08	TCGA-K4-A4AB-10A-01D-A289-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q331*	0.875	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q331* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-A9T0-01A-11D-A391-08	TCGA-XF-A9T0-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G105C	0.7209	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G105C (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6U-01A-11D-A391-08	TCGA-DK-AA6U-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.7183	71.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		BLCA_VARSCAN2	TCGA-GD-A3OS-01A-12D-A21Z-08	TCGA-GD-A3OS-10A-01D-A21Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R158H	0.4737	57.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R158H (Missense)		BLCA_VARSCAN2	TCGA-XF-A8HF-01A-11D-A364-08	TCGA-XF-A8HF-10A-01D-A362-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H214R	0.7818	55.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H214R (Missense)		BLCA_VARSCAN2	TCGA-FD-A3N5-01A-11D-A21A-08	TCGA-FD-A3N5-10A-01D-A21A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.K139N	0.7826	23.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K139N (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R4-01A-11D-A38G-08	TCGA-ZF-A9R4-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P151H	0.7667	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P151H (Missense)		BLCA_VARSCAN2	TCGA-E5-A2PC-01A-11D-A202-08	TCGA-E5-A2PC-10B-01D-A202-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.8	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		BLCA_VARSCAN2	TCGA-HQ-A2OF-01A-11D-A26M-08	TCGA-HQ-A2OF-10B-01D-A26K-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L257Q	0.1059	85.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L257Q (Missense)		BLCA_VARSCAN2	TCGA-FD-A43N-01A-11D-A23U-08	TCGA-FD-A43N-10A-01D-A23U-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E285K	0.4138	29.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E285K (Missense)		BLCA_VARSCAN2	TCGA-XF-AAMT-01A-11D-A42E-08	TCGA-XF-AAMT-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.A161T	0.9062	32.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A161T (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN7-01A-11D-A42E-08	TCGA-XF-AAN7-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280K	0.9412	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280K (Missense)		BLCA_VARSCAN2	TCGA-KQ-A41O-01A-12D-A34U-08	TCGA-KQ-A41O-10D-01D-A34X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.5161	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6Q-01A-11D-A391-08	TCGA-DK-AA6Q-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248P	0.8511	141.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248P (Missense)		BLCA_VARSCAN2	TCGA-BL-A3JM-01A-12D-A21A-08	TCGA-BL-A3JM-11A-31D-A21A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.6136	88.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		BLCA_VARSCAN2	TCGA-BT-A2LD-01A-12D-A20D-08	TCGA-BT-A2LD-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.K139N	0.7736	53.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K139N (Missense)		BLCA_VARSCAN2	TCGA-BT-A20R-01A-12D-A16O-08	TCGA-BT-A20R-11A-11D-A16O-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220C	0.7619	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220C (Missense)		BLCA_VARSCAN2	TCGA-BL-A13J-01A-11D-A271-08	TCGA-BL-A13J-10A-01D-A10S-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245D	0.5714	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245D (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6M-01A-11D-A391-08	TCGA-DK-AA6M-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.95	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		BLCA_VARSCAN2	TCGA-DK-A3X2-01A-11D-A22Z-08	TCGA-DK-A3X2-10A-01D-A22Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S241F	0.3111	45.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S241F (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4T-01A-11D-A38G-08	TCGA-ZF-AA4T-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q192*	0.9149	94.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q192* (Nonsense)		BLCA_VARSCAN2	TCGA-GV-A3JZ-01A-11D-A21A-08	TCGA-GV-A3JZ-10A-01D-A21A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.L350Pfs*17	0.1389	36.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L350Pfs*17 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A3WX-01A-22D-A22Z-08	TCGA-DK-A3WX-10A-01D-A22Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.L348Wfs*22	0.1304	46.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L348Wfs*22 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A3WX-01A-22D-A22Z-08	TCGA-DK-A3WX-10A-01D-A22Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E271K	0.8636	22.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E271K (Missense)		BLCA_VARSCAN2	TCGA-BT-A3PH-01A-11D-A21Z-08	TCGA-BT-A3PH-10A-01D-A21Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E336*	0.8846	26.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E336* (Nonsense)		BLCA_VARSCAN2	TCGA-4Z-AA7R-01A-11D-A391-08	TCGA-4Z-AA7R-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.G154Afs*16	0.1613	62.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G154Afs*16 (Frameshift)		BLCA_VARSCAN2	TCGA-FD-A62N-01A-11D-A30E-08	TCGA-FD-A62N-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E258K	0.7273	22.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E258K (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TC-01A-21D-A339-08	TCGA-FD-A6TC-10A-21D-A339-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.S183*	0.2195	41.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S183* (Nonsense)		BLCA_VARSCAN2	TCGA-BT-A42F-01A-11D-A23U-08	TCGA-BT-A42F-10A-01D-A23U-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.1224	49.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		BLCA_VARSCAN2	TCGA-BT-A42F-01A-11D-A23U-08	TCGA-BT-A42F-10A-01D-A23U-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.6094	64.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		BLCA_VARSCAN2	TCGA-GD-A2C5-01A-12D-A17V-08	TCGA-GD-A2C5-10A-01D-A17V-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q331*	0.3768	69.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q331* (Nonsense)		BLCA_VARSCAN2	TCGA-G2-A3IB-01A-11D-A20D-08	TCGA-G2-A3IB-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C176F	0.5	62.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C176F (Missense)		BLCA_VARSCAN2	TCGA-G2-A3IB-01A-11D-A20D-08	TCGA-G2-A3IB-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.H178Pfs*3	0.3099	71.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H178Pfs*3 (Frameshift)		BLCA_VARSCAN2	TCGA-ZF-AA52-01A-12D-A391-08	TCGA-ZF-AA52-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C242Y	0.8519	27.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C242Y (Missense)		BLCA_VARSCAN2	TCGA-XF-AAMX-01A-11D-A42E-08	TCGA-XF-AAMX-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E286*	0.2676	71.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E286* (Nonsense)		BLCA_VARSCAN2	TCGA-GC-A3WC-01A-31D-A22Z-08	TCGA-GC-A3WC-10A-01D-A22Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.K132N	0.1692	65.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K132N (Missense)		BLCA_VARSCAN2	TCGA-GC-A3WC-01A-31D-A22Z-08	TCGA-GC-A3WC-10A-01D-A22Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R110L	0.2581	93.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R110L (Missense)		BLCA_VARSCAN2	TCGA-HQ-A5NE-01A-12D-A289-08	TCGA-HQ-A5NE-10A-01D-A289-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E287*	0.4375	32.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E287* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-AA54-01A-11D-A391-08	TCGA-ZF-AA54-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S241F	0.1818	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S241F (Missense)		BLCA_VARSCAN2	TCGA-XF-A9SM-01A-11D-A42E-08	TCGA-XF-A9SM-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E287Q	0.9091	22.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E287Q (Missense)		BLCA_VARSCAN2	TCGA-E7-A7DU-01A-11D-A32B-08	TCGA-E7-A7DU-10A-01D-A329-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.L22Yfs*22	0.4762	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L22Yfs*22 (Frameshift)		BLCA_VARSCAN2	TCGA-HQ-A5ND-01A-11D-A26M-08	TCGA-HQ-A5ND-10A-01D-A26K-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280T	0.6667	24.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280T (Missense)		BLCA_VARSCAN2	TCGA-UY-A78M-01A-21D-A34U-08	TCGA-UY-A78M-10A-01D-A34X-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.3333	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		BLCA_VARSCAN2	TCGA-K4-A4AC-01A-21D-A26M-08	TCGA-K4-A4AC-10A-01D-A26K-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q331*	0.4	45.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q331* (Nonsense)		BLCA_VARSCAN2	TCGA-UY-A9PH-01A-11D-A38G-08	TCGA-UY-A9PH-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245V	0.241	83.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245V (Missense)		BLCA_VARSCAN2	TCGA-FD-A3B6-01A-21D-A20D-08	TCGA-FD-A3B6-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.3953	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		BLCA_VARSCAN2	TCGA-XF-AAML-01A-11D-A42E-08	TCGA-XF-AAML-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R181H	0.3036	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R181H (Missense)		BLCA_VARSCAN2	TCGA-XF-AAML-01A-11D-A42E-08	TCGA-XF-AAML-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R158H	0.2877	73.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R158H (Missense)		BLCA_VARSCAN2	TCGA-GC-A6I3-01A-11D-A31L-08	TCGA-GC-A6I3-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C242F	0.1702	47.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C242F (Missense)		BLCA_VARSCAN2	TCGA-DK-A1A3-01A-11D-A13W-08	TCGA-DK-A1A3-10A-01D-A13W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q192*	0.4286	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q192* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A1A3-01A-11D-A13W-08	TCGA-DK-A1A3-10A-01D-A13W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.D259V	0.3857	70.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.D259V (Missense)		BLCA_VARSCAN2	TCGA-CF-A5U8-01A-11D-A289-08	TCGA-CF-A5U8-10A-01D-A289-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q331*	0.383	47.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q331* (Nonsense)		BLCA_VARSCAN2	TCGA-KQ-A41S-01A-12D-A339-08	TCGA-KQ-A41S-10C-01D-A339-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E285K	0.3654	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E285K (Missense)		BLCA_VARSCAN2	TCGA-DK-A3IU-01A-11D-A20D-08	TCGA-DK-A3IU-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.6905	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		BLCA_VARSCAN2	TCGA-5N-A9KI-01A-31D-A42E-08	TCGA-5N-A9KI-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.3103	29.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		BLCA_VARSCAN2	TCGA-BT-A20U-01A-11D-A14W-08	TCGA-BT-A20U-11A-11D-A14W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.3889	54.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		BLCA_VARSCAN2	TCGA-XF-A8HD-01A-11D-A364-08	TCGA-XF-A8HD-10A-01D-A362-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S241F	0.3714	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S241F (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SJ-01A-12D-A22Z-08	TCGA-FD-A3SJ-10A-01D-A22Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193R	0.1667	36.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193R (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA5P-01A-11D-A391-08	TCGA-ZF-AA5P-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.S15Kfs*27	0.1379	29.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S15Kfs*27 (Frameshift)		BLCA_VARSCAN2	TCGA-ZF-AA56-01A-31D-A391-08	TCGA-ZF-AA56-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E285K	0.375	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E285K (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AB-01A-11D-A13W-08	TCGA-DK-A1AB-10A-01D-A13W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E221*	0.5161	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E221* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A1AB-01A-11D-A13W-08	TCGA-DK-A1AB-10A-01D-A13W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q317*	0.803	66.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q317* (Nonsense)		BLCA_VARSCAN2	TCGA-LT-A5Z6-01A-11D-A289-08	TCGA-LT-A5Z6-10A-01D-A289-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.M237I	0.6786	28.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M237I (Missense)		BLCA_VARSCAN2	TCGA-FD-A5BV-01A-11D-A26M-08	TCGA-FD-A5BV-10A-01D-A26K-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280K	0.6538	26.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280K (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7M-01A-11D-A391-08	TCGA-4Z-AA7M-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.S94*	0.2963	54.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S94* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-AA53-01A-11D-A391-08	TCGA-ZF-AA53-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.A159Hfs*21	0.3617	47.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A159Hfs*21 (Frameshift)		BLCA_VARSCAN2	TCGA-G2-A2EF-01A-12D-A18F-08	TCGA-G2-A2EF-10A-01D-A18F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.T155Sfs*13	0.381	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.T155Sfs*13 (Frameshift)		BLCA_VARSCAN2	TCGA-G2-A2EF-01A-12D-A18F-08	TCGA-G2-A2EF-10A-01D-A18F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C141Y	0.8929	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C141Y (Missense)		BLCA_VARSCAN2	TCGA-GD-A6C6-01A-21D-A31L-08	TCGA-GD-A6C6-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q331*	0.6154	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q331* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A6B6-01A-11D-A30E-08	TCGA-DK-A6B6-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.4462	65.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		BLCA_VARSCAN2	TCGA-GC-A6I1-01A-12D-A31L-08	TCGA-GC-A6I1-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.5091	55.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		BLCA_VARSCAN2	TCGA-GU-AATO-01A-11D-A391-08	TCGA-GU-AATO-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.2347	98.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		BLCA_VARSCAN2	TCGA-DK-A2I2-01A-11D-A17V-08	TCGA-DK-A2I2-10A-01D-A17V-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.5955	89.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		BLCA_VARSCAN2	TCGA-G2-A2ES-01A-11D-A17V-08	TCGA-G2-A2ES-11A-31D-A17V-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E285V	0.4545	66.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E285V (Missense)		BLCA_VARSCAN2	TCGA-GV-A40G-01A-11D-A23M-08	TCGA-GV-A40G-10A-01D-A23K-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.4259	54.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		BLCA_VARSCAN2	TCGA-GV-A40G-01A-11D-A23M-08	TCGA-GV-A40G-10A-01D-A23K-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273S	0.4118	17.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273S (Missense)		BLCA_VARSCAN2	TCGA-CF-A1HS-01A-11D-A13W-08	TCGA-CF-A1HS-10A-01D-A13W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.C124Wfs*25	0.7193	114.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C124Wfs*25 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A1A6-01A-11D-A13W-08	TCGA-DK-A1A6-10A-01D-A13W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.6	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6R-01A-11D-A42E-08	TCGA-DK-AA6R-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.G154Wfs*10	0.3462	26.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G154Wfs*10 (Frameshift)		BLCA_VARSCAN2	TCGA-ZF-A9RL-01A-11D-A38G-08	TCGA-ZF-A9RL-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.S240Kfs*24	0.6957	69.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S240Kfs*24 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A3IS-01A-21D-A21A-08	TCGA-DK-A3IS-10A-01D-A21A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R213Q	0.9565	23.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213Q (Missense)		BLCA_VARSCAN2	TCGA-BT-A2LA-01A-11D-A18F-08	TCGA-BT-A2LA-11A-11D-A18F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280T	0.3421	38.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280T (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SP-01A-31D-A22Z-08	TCGA-FD-A3SP-10A-01D-A22Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.P301Qfs*44	0.475	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P301Qfs*44 (Frameshift)		BLCA_VARSCAN2	TCGA-E7-A97Q-01A-11D-A38G-08	TCGA-E7-A97Q-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280T	0.8478	46.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280T (Missense)		BLCA_VARSCAN2	TCGA-KQ-A41P-01A-12D-A339-08	TCGA-KQ-A41P-10F-01D-A339-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E204*	0.2308	26.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E204* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-A9SK-01A-11D-A42E-08	TCGA-XF-A9SK-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.R209Kfs*6	0.5172	29.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R209Kfs*6 (Frameshift)		BLCA_VARSCAN2	TCGA-UY-A8OB-01A-12D-A42E-08	TCGA-UY-A8OB-11A-12D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E294*	0.525	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E294* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-AA51-01A-21D-A391-08	TCGA-ZF-AA51-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E271Q	0.2174	23.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E271Q (Missense)		BLCA_VARSCAN2	TCGA-UY-A78O-01A-12D-A339-08	TCGA-UY-A78O-10A-01D-A339-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S241F	0.325	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S241F (Missense)		BLCA_VARSCAN2	TCGA-UY-A78O-01A-12D-A339-08	TCGA-UY-A78O-10A-01D-A339-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E294*	0.5698	86.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E294* (Nonsense)		BLCA_VARSCAN2	TCGA-LC-A66R-01A-41D-A30E-08	TCGA-LC-A66R-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E287*	0.5116	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E287* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A3SL-01A-21D-A22Z-08	TCGA-FD-A3SL-10A-01D-A22Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E271K	0.5714	14.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E271K (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RD-01A-11D-A42E-08	TCGA-ZF-A9RD-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245S	0.3077	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245S (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7W-01A-11D-A391-08	TCGA-4Z-AA7W-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E336*	0.6842	38.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E336* (Nonsense)		BLCA_VARSCAN2	TCGA-FJ-A3Z7-01A-12D-A23M-08	TCGA-FJ-A3Z7-10A-01D-A23K-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X331_splice	0.4194	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X331_splice (Splice Site)		BLCA_VARSCAN2	TCGA-GU-A42Q-01A-11D-A23U-08	TCGA-GU-A42Q-10A-01D-A23U-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.8636	22.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		BLCA_VARSCAN2	TCGA-DK-A3IM-01A-11D-A20D-08	TCGA-DK-A3IM-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.A189Dfs*14	0.6061	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A189Dfs*14 (Frameshift)		BLCA_VARSCAN2	TCGA-GU-AATP-01A-11D-A391-08	TCGA-GU-AATP-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.P92Afs*57	0.8958	96.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P92Afs*57 (Frameshift)		BLCA_VARSCAN2	TCGA-GC-A3RB-01A-12D-A21Z-08	TCGA-GC-A3RB-10A-01D-A21Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.A159V	0.7778	81.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A159V (Missense)		BLCA_VARSCAN2	TCGA-CU-A3KJ-01A-11D-A21A-08	TCGA-CU-A3KJ-10A-01D-A21A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280T	0.7391	23.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280T (Missense)		BLCA_VARSCAN2	TCGA-YF-AA3M-01A-11D-A42E-08	TCGA-YF-AA3M-10D-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q144*	0.4429	70.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q144* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A2I6-01A-12D-A18F-08	TCGA-DK-A2I6-10A-01D-A18F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y236C	0.2553	47.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y236C (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RC-01A-11D-A38G-08	TCGA-ZF-A9RC-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.K382Nfs*40	0.4297	128.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K382Nfs*40 (Frameshift)		BLCA_VARSCAN2	TCGA-GC-A3RC-01A-11D-A22Z-08	TCGA-GC-A3RC-10B-01D-A22Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C275Y	1.0	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C275Y (Missense)		BLCA_VARSCAN2	TCGA-C4-A0EZ-01A-21D-A10S-08	TCGA-C4-A0EZ-10A-01D-A10S-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.7581	62.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SS-01A-12D-A22Z-08	TCGA-FD-A3SS-10A-01D-A22Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q192*	0.3261	46.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q192* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A3NA-01A-11D-A21A-08	TCGA-FD-A3NA-10A-01D-A21A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E285K	0.45	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E285K (Missense)		BLCA_VARSCAN2	TCGA-DK-A3IV-01A-22D-A21A-08	TCGA-DK-A3IV-10A-01D-A21A-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X367_splice	0.9661	59.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X367_splice (Splice Site)		BLCA_VARSCAN2	TCGA-G2-A2EL-01A-12D-A18F-08	TCGA-G2-A2EL-10A-01D-A18F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.D228N	0.3462	26.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.D228N (Missense)		BLCA_VARSCAN2	TCGA-FD-A43P-01A-31D-A23U-08	TCGA-FD-A43P-10A-01D-A23U-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S121Y	0.2653	49.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S121Y (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4W-01A-12D-A38G-08	TCGA-ZF-AA4W-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.8553	76.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		BLCA_VARSCAN2	TCGA-GV-A3JX-01A-11D-A20D-08	TCGA-GV-A3JX-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280T	0.3774	53.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280T (Missense)		BLCA_VARSCAN2	TCGA-K4-A6FZ-01A-11D-A31L-08	TCGA-K4-A6FZ-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245V	0.2647	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245V (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6L-01A-11D-A391-08	TCGA-DK-AA6L-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C238F	0.3667	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C238F (Missense)		BLCA_VARSCAN2	TCGA-FD-A62S-01A-11D-A30E-08	TCGA-FD-A62S-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.W146*	0.2069	29.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.W146* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-A9SY-01A-21D-A42E-08	TCGA-XF-A9SY-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P151S	0.4	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P151S (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN0-01A-11D-A42E-08	TCGA-XF-AAN0-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E204*	0.3571	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E204* (Nonsense)		BLCA_VARSCAN2	TCGA-BT-A20X-01A-11D-A16O-08	TCGA-BT-A20X-11A-12D-A16O-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245S	0.5217	46.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245S (Missense)		BLCA_VARSCAN2	TCGA-G2-A2EJ-01A-11D-A17V-08	TCGA-G2-A2EJ-10A-01D-A17V-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C277F	0.4773	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C277F (Missense)		BLCA_VARSCAN2	TCGA-BT-A3PJ-01A-21D-A21Z-08	TCGA-BT-A3PJ-10A-01D-A21Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.C277*	0.5312	32.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C277* (Nonsense)		BLCA_VARSCAN2	TCGA-BT-A20N-01A-11D-A14W-08	TCGA-BT-A20N-11A-11D-A14W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.K319*	0.6061	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K319* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-AAMW-01A-11D-A42E-08	TCGA-XF-AAMW-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.S183*	0.8462	39.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S183* (Nonsense)		BLCA_VARSCAN2	TCGA-G2-AA3B-01A-11D-A391-08	TCGA-G2-AA3B-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q375*	0.7283	92.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q375* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A1AC-01A-11D-A13W-08	TCGA-DK-A1AC-10A-01D-A13W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E271K	0.75	28.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E271K (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AC-01A-11D-A13W-08	TCGA-DK-A1AC-10A-01D-A13W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E285K	0.4286	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E285K (Missense)		BLCA_VARSCAN2	TCGA-E7-A7DV-01A-11D-A339-08	TCGA-E7-A7DV-10A-01D-A339-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.P153Afs*28	0.3415	41.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P153Afs*28 (Frameshift)		BLCA_VARSCAN2	TCGA-G2-AA3F-01A-12D-A42E-08	TCGA-G2-AA3F-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P151H	0.3902	41.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P151H (Missense)		BLCA_VARSCAN2	TCGA-G2-AA3F-01A-12D-A42E-08	TCGA-G2-AA3F-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S241F	0.3704	27.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S241F (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R0-01A-11D-A38G-08	TCGA-ZF-A9R0-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E285K	0.3	50.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E285K (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4X-01A-11D-A38G-08	TCGA-ZF-AA4X-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E68*	0.4171	199.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E68* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-AA4X-01A-11D-A38G-08	TCGA-ZF-AA4X-10A-01D-A38J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.5	28.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		BLCA_VARSCAN2	TCGA-UY-A78K-01A-11D-A339-08	TCGA-UY-A78K-10A-01D-A339-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L257Q	0.2353	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L257Q (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SO-01A-11D-A22Z-08	TCGA-FD-A3SO-10A-01D-A22Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.W53*	0.2737	179.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.W53* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A3SO-01A-11D-A22Z-08	TCGA-FD-A3SO-10A-01D-A22Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280T	0.8	20.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280T (Missense)		BLCA_VARSCAN2	TCGA-E5-A4U1-01A-11D-A31L-08	TCGA-E5-A4U1-10B-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.V73Wfs*50	0.7882	170.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V73Wfs*50 (Frameshift)		BLCA_VARSCAN2	TCGA-UY-A78N-01A-12D-A339-08	TCGA-UY-A78N-10A-01D-A339-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.A161T	0.5	82.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A161T (Missense)		BLCA_VARSCAN2	TCGA-DK-A1A5-01A-11D-A13W-08	TCGA-DK-A1A5-10A-01D-A13W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E271K	0.5	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E271K (Missense)		BLCA_VARSCAN2	TCGA-DK-A3X1-01A-12D-A22Z-08	TCGA-DK-A3X1-10A-01D-A22Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E171K	0.3509	57.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E171K (Missense)		BLCA_VARSCAN2	TCGA-BT-A20J-01A-11D-A14W-08	TCGA-BT-A20J-11A-11D-A14W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.W146S	0.3721	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.W146S (Missense)		BLCA_VARSCAN2	TCGA-BT-A20J-01A-11D-A14W-08	TCGA-BT-A20J-11A-11D-A14W-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Frameshift	p.G279Pfs*69	0.2222	27.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G279Pfs*69 (Frameshift)		BLCA_VARSCAN2	TCGA-FD-A3SR-01A-11D-A22Z-08	TCGA-FD-A3SR-10A-01D-A22Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.A159V	0.2	80.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A159V (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SR-01A-11D-A22Z-08	TCGA-FD-A3SR-10A-01D-A22Z-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R283P	0.4651	86.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R283P (Missense)		BLCA_VARSCAN2	TCGA-K4-A5RH-01A-11D-A30E-08	TCGA-K4-A5RH-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P151A	0.193	57.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P151A (Missense)		BLCA_VARSCAN2	TCGA-PQ-A6FN-01A-11D-A31L-08	TCGA-PQ-A6FN-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V143A	0.4706	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V143A (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T3-01A-11D-A42E-08	TCGA-XF-A9T3-10A-01D-A42H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.A159V	0.8571	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A159V (Missense)		BLCA_VARSCAN2	TCGA-GV-A3JW-01A-11D-A20D-08	TCGA-GV-A3JW-10A-01D-A20D-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E285*	0.5957	47.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E285* (Nonsense)		BLCA_VARSCAN2	TCGA-UY-A9PE-01A-11D-A38G-08	TCGA-UY-A9PE-10A-01D-A38J-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.P628R	0.2907	86.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.P628R (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T6-01A-11D-A42E-08	TCGA-XF-A9T6-10A-01D-A42H-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.D36N	0.2066	121.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.D36N (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA81-01A-11D-A391-08	TCGA-4Z-AA81-10A-01D-A394-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.R874K	0.3158	19.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.R874K (Missense)		BLCA_VARSCAN2	TCGA-DK-A1A3-01A-11D-A13W-08	TCGA-DK-A1A3-10A-01D-A13W-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.E675K	0.4651	43.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.E675K (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SN-01A-12D-A22Z-08	TCGA-FD-A3SN-10A-01D-A22Z-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.H246Y	0.5326	92.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.H246Y (Missense)		BLCA_VARSCAN2	TCGA-BT-A2LA-01A-11D-A18F-08	TCGA-BT-A2LA-11A-11D-A18F-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.K263I	0.1698	53.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.K263I (Missense)		BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.H201Y	0.3188	69.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.H201Y (Missense)		BLCA_VARSCAN2	TCGA-GC-A3RC-01A-11D-A22Z-08	TCGA-GC-A3RC-10B-01D-A22Z-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.S293A	0.4444	36.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.S293A (Missense)		BLCA_VARSCAN2	TCGA-UY-A9PF-01A-11D-A38G-08	TCGA-UY-A9PF-10A-01D-A38J-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.P128L	0.4	95.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.P128L (Missense)		BLCA_VARSCAN2	TCGA-DK-A6B6-01A-11D-A30E-08	TCGA-DK-A6B6-10A-01D-A30H-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.Y134C	0.18	50.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.Y134C (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA89-01A-11D-A391-08	TCGA-4Z-AA89-10A-01D-A394-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.L58V	0.3735	83.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.L58V (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4V-01A-11D-A38G-08	TCGA-ZF-AA4V-10A-01D-A38J-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.M788I	0.2549	51.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.M788I (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RC-01A-11D-A38G-08	TCGA-ZF-A9RC-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.Q593*	0.6923	13.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Q593* (Nonsense)		BLCA_VARSCAN2	TCGA-E7-A4IJ-01A-31D-A26M-08	TCGA-E7-A4IJ-10A-01D-A26K-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.K917*	0.8864	44.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.K917* (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A1AA-01A-11D-A13W-08	TCGA-DK-A1AA-10A-01D-A13W-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.K551*	0.6129	31.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.K551* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A6TA-01A-12D-A339-08	TCGA-FD-A6TA-10A-21D-A339-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.Q914*	0.24	75.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Q914* (Nonsense)		BLCA_VARSCAN2	TCGA-YC-A8S6-01A-31D-A38G-08	TCGA-YC-A8S6-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.E863K	0.3571	70.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.E863K (Missense)		BLCA_VARSCAN2	TCGA-K4-A54R-01A-11D-A26M-08	TCGA-K4-A54R-10A-01D-A26K-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.E902K	0.6613	62.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.E902K (Missense)		BLCA_VARSCAN2	TCGA-BL-A0C8-01A-11D-A271-08	TCGA-BL-A0C8-10A-01D-A271-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.S327Ffs*10	0.7037	54.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.S327Ffs*10 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A6B0-01A-11D-A31L-08	TCGA-DK-A6B0-10A-01D-A31J-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.Y328*	0.9149	47.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Y328* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A6B0-01A-11D-A31L-08	TCGA-DK-A6B0-10A-01D-A31J-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.K330Ifs*8	0.8626	131.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.K330Ifs*8 (Frameshift)		BLCA_VARSCAN2	TCGA-FJ-A3ZE-01A-11D-A23M-08	TCGA-FJ-A3ZE-10A-01D-A23K-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.Q123*	0.9737	38.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Q123* (Nonsense)		BLCA_VARSCAN2	TCGA-E7-A5KF-01A-11D-A289-08	TCGA-E7-A5KF-10A-01D-A289-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Splice Site	p.X699_splice	0.45	80.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.X699_splice (Splice Site)		BLCA_VARSCAN2	TCGA-2F-A9KR-01A-11D-A38G-08	TCGA-2F-A9KR-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.E902K	0.2667	60.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.E902K (Missense)		BLCA_VARSCAN2	TCGA-FD-A62P-01A-32D-A30E-08	TCGA-FD-A62P-10A-01D-A30H-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.G693D	0.3194	72.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.G693D (Missense)		BLCA_VARSCAN2	TCGA-BL-A5ZZ-01A-31D-A30E-08	TCGA-BL-A5ZZ-10A-01D-A30H-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.E902K	0.4706	51.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.E902K (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7Q-01A-11D-A391-08	TCGA-4Z-AA7Q-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.R198Q	0.2137	234.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.R198Q (Missense)		BLCA_VARSCAN2	TCGA-UY-A9PD-01A-11D-A38G-08	TCGA-UY-A9PD-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.R305*	0.25	48.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R305* (Nonsense)		BLCA_VARSCAN2	TCGA-R3-A69X-01A-22D-A30E-08	TCGA-R3-A69X-10A-01D-A30H-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.L405Sfs*20	0.629	62.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.L405Sfs*20 (Frameshift)		BLCA_VARSCAN2	TCGA-H4-A2HQ-01A-11D-A17V-08	TCGA-H4-A2HQ-10A-01D-A17V-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.R309P	0.2128	47.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.R309P (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RF-01A-11D-A38G-08	TCGA-ZF-A9RF-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.Y600Ifs*35	0.8421	38.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Y600Ifs*35 (Frameshift)		BLCA_VARSCAN2	TCGA-PQ-A6FI-01A-11D-A31L-08	TCGA-PQ-A6FI-10A-01D-A31J-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Nonsense	p.Q588*	0.1525	59.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.Q588* (Nonsense)		BLCA_VARSCAN2	TCGA-GV-A6ZA-01A-12D-A339-08	TCGA-GV-A6ZA-10A-01D-A339-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.A760T	0.2091	110.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.A760T (Missense)		BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.E902K	0.3265	49.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.E902K (Missense)		BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.E474K	0.7065	92.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.E474K (Missense)		BLCA_VARSCAN2	TCGA-C4-A0F7-01A-11D-A10S-08	TCGA-C4-A0F7-10A-01D-A10S-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.E860K	0.3396	53.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.E860K (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN3-01A-11D-A42E-08	TCGA-XF-AAN3-10A-01D-A42H-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Frameshift	p.R244Ifs*324	0.5373	67.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.R244Ifs*324 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-A9ST-01A-11D-A42E-08	TCGA-XF-A9ST-10A-01D-A42H-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.E643Lfs*14	0.75	24.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.E643Lfs*14 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-A9ST-01A-11D-A42E-08	TCGA-XF-A9ST-10A-01D-A42H-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Frameshift	p.D432Rfs*13	0.2778	144.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.D432Rfs*13 (Frameshift)		BLCA_VARSCAN2	TCGA-GU-A42P-01A-11D-A23U-08	TCGA-GU-A42P-10A-01D-A23U-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Nonsense	p.Q780*	0.1818	66.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.Q780* (Nonsense)		BLCA_VARSCAN2	TCGA-E7-A7XN-01A-11D-A34U-08	TCGA-E7-A7XN-10A-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Splice Site	p.X274_splice	0.48	50.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.X274_splice (Splice Site)		BLCA_VARSCAN2	TCGA-E5-A2PC-01A-11D-A202-08	TCGA-E5-A2PC-10B-01D-A202-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.Q728*	0.7703	74.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Q728* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A3B5-01A-11D-A20D-08	TCGA-FD-A3B5-10A-01D-A20D-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Frameshift	p.P271Qfs*13	0.6735	49.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.P271Qfs*13 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-AAN7-01A-11D-A42E-08	TCGA-XF-AAN7-10A-01D-A42H-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.E446K	0.4545	110.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.E446K (Missense)		BLCA_VARSCAN2	TCGA-KQ-A41O-01A-12D-A34U-08	TCGA-KQ-A41O-10D-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.Q1029*	0.9608	51.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Q1029* (Nonsense)		BLCA_VARSCAN2	TCGA-KQ-A41O-01A-12D-A34U-08	TCGA-KQ-A41O-10D-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.E1147Dfs*16	0.4878	41.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.E1147Dfs*16 (Frameshift)		BLCA_VARSCAN2	TCGA-BT-A42E-01A-11D-A23U-08	TCGA-BT-A42E-10A-01D-A23U-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.D101Lfs*8	0.9074	54.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.D101Lfs*8 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A3X2-01A-11D-A22Z-08	TCGA-DK-A3X2-10A-01D-A22Z-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.A836D	0.1014	69.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.A836D (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4T-01A-11D-A38G-08	TCGA-ZF-AA4T-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Nonsense	p.Q225*	0.5641	39.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.Q225* (Nonsense)		BLCA_VARSCAN2	TCGA-CF-A27C-01A-11D-A16O-08	TCGA-CF-A27C-10A-01D-A16O-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.Q593*	0.9677	31.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Q593* (Nonsense)		BLCA_VARSCAN2	TCGA-CF-A27C-01A-11D-A16O-08	TCGA-CF-A27C-10A-01D-A16O-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.G1188*	0.6905	42.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.G1188* (Nonsense)		BLCA_VARSCAN2	TCGA-CU-A72E-01A-12D-A339-08	TCGA-CU-A72E-10A-01D-A339-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.T626Nfs*9	0.3545	110.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.T626Nfs*9 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-A8HI-01A-11D-A38G-08	TCGA-XF-A8HI-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.E902K	0.3509	57.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.E902K (Missense)		BLCA_VARSCAN2	TCGA-CU-A5W6-01A-11D-A289-08	TCGA-CU-A5W6-10A-01D-A289-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.Q963*	0.9231	65.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Q963* (Nonsense)		BLCA_VARSCAN2	TCGA-E7-A7DU-01A-11D-A32B-08	TCGA-E7-A7DU-10A-01D-A329-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.Q593*	0.7586	29.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Q593* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-A9T2-01A-11D-A42E-08	TCGA-XF-A9T2-10A-01D-A42H-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.R1012*	1.0	34.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R1012* (Nonsense)		BLCA_VARSCAN2	TCGA-CF-A3MI-01A-11D-A20D-08	TCGA-CF-A3MI-10A-01D-A20D-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.E902K	0.3378	74.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.E902K (Missense)		BLCA_VARSCAN2	TCGA-GV-A3QF-01A-31D-A22Z-08	TCGA-GV-A3QF-10A-01D-A22Z-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.E862K	0.1354	96.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.E862K (Missense)		BLCA_VARSCAN2	TCGA-GD-A3OQ-01A-32D-A21Z-08	TCGA-GD-A3OQ-10A-01D-A21Z-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.A176T	0.2978	178.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.A176T (Missense)		BLCA_VARSCAN2	TCGA-GC-A3BM-01A-11D-A22Z-08	TCGA-GC-A3BM-10A-01D-A22Z-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.N986Sfs*15	0.9412	17.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.N986Sfs*15 (Frameshift)		BLCA_VARSCAN2	TCGA-CF-A5U8-01A-11D-A289-08	TCGA-CF-A5U8-10A-01D-A289-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.E902G	0.5556	36.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.E902G (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4R-01A-11D-A38G-08	TCGA-ZF-AA4R-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.G890D	0.4237	59.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.G890D (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.W495*	0.9796	49.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.W495* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Nonsense	p.Q1063*	0.1012	168.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.Q1063* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-A8HD-01A-11D-A364-08	TCGA-XF-A8HD-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.K870Ifs*21	0.5882	17.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.K870Ifs*21 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-AA71-01A-31D-A391-08	TCGA-DK-AA71-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.E434Q	0.2397	146.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.E434Q (Missense)		BLCA_VARSCAN2	TCGA-LT-A5Z6-01A-11D-A289-08	TCGA-LT-A5Z6-10A-01D-A289-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.M880I	0.3253	83.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.M880I (Missense)		BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S298L	0.1944	108.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S298L (Missense)		BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Nonsense	p.S577*	0.1416	113.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S577* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.E1135Ifs*21	0.1364	44.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.E1135Ifs*21 (Frameshift)		BLCA_VARSCAN2	TCGA-ZF-AA53-01A-11D-A391-08	TCGA-ZF-AA53-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.Y1044Tfs*6	0.8654	52.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Y1044Tfs*6 (Frameshift)		BLCA_VARSCAN2	TCGA-GD-A6C6-01A-21D-A31L-08	TCGA-GD-A6C6-10A-01D-A31J-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.L501*	0.5625	32.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.L501* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A5BX-01A-11D-A26M-08	TCGA-FD-A5BX-10A-01D-A26K-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.Q593*	0.9091	22.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Q593* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A3IS-01A-21D-A21A-08	TCGA-DK-A3IS-10A-01D-A21A-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.N185S	0.4007	277.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.N185S (Missense)		BLCA_VARSCAN2	TCGA-FJ-A871-01A-11D-A34U-08	TCGA-FJ-A871-10A-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.W315*	0.3333	69.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.W315* (Nonsense)		BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.R498W	0.3727	110.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.R498W (Missense)		BLCA_VARSCAN2	TCGA-LC-A66R-01A-41D-A30E-08	TCGA-LC-A66R-10A-01D-A30H-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Frameshift	p.D209Vfs*29	0.625	152.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.D209Vfs*29 (Frameshift)		BLCA_VARSCAN2	TCGA-FD-A3SL-01A-21D-A22Z-08	TCGA-FD-A3SL-10A-01D-A22Z-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.W1038*	0.8409	44.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.W1038* (Nonsense)		BLCA_VARSCAN2	TCGA-4Z-AA89-01A-11D-A391-08	TCGA-4Z-AA89-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.Q847*	0.5932	59.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Q847* (Nonsense)		BLCA_VARSCAN2	TCGA-E7-A6MD-01A-41D-A34U-08	TCGA-E7-A6MD-10B-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.R216*	0.8222	45.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R216* (Nonsense)		BLCA_VARSCAN2	TCGA-E7-A519-01A-11D-A26M-08	TCGA-E7-A519-10A-01D-A26K-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Nonsense	p.Y591*	0.4416	77.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.Y591* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-A9R5-01A-12D-A42E-08	TCGA-ZF-A9R5-10A-01D-A42H-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Nonsense	p.K564*	0.374	123.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.K564* (Nonsense)		BLCA_VARSCAN2	TCGA-CU-A3QU-01A-11D-A22Z-08	TCGA-CU-A3QU-10B-01D-A22Z-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.Q773*	0.9545	22.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Q773* (Nonsense)		BLCA_VARSCAN2	TCGA-CF-A47W-01A-11D-A23U-08	TCGA-CF-A47W-10A-01D-A23U-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.E1029K	0.1532	111.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.E1029K (Missense)		BLCA_VARSCAN2	TCGA-DK-A2I4-01A-11D-A21A-08	TCGA-DK-A2I4-10A-01D-A21A-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.E366K	0.2676	71.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.E366K (Missense)		BLCA_VARSCAN2	TCGA-C4-A0F6-01A-11D-A10S-08	TCGA-C4-A0F6-10A-01D-A10S-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Splice Site	p.X547_splice	0.7838	37.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.X547_splice (Splice Site)		BLCA_VARSCAN2	TCGA-E7-A3Y1-01A-11D-A22Z-08	TCGA-E7-A3Y1-10A-01D-A22Z-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.T834N	0.4138	87.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.T834N (Missense)		BLCA_VARSCAN2	TCGA-E7-A677-01A-11D-A30E-08	TCGA-E7-A677-10A-01D-A30H-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.G543V	0.5538	65.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.G543V (Missense)		BLCA_VARSCAN2	TCGA-KQ-A41R-01A-21D-A34U-08	TCGA-KQ-A41R-10G-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.L518P	0.2429	70.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.L518P (Missense)		BLCA_VARSCAN2	TCGA-E7-A85H-01A-11D-A34U-08	TCGA-E7-A85H-10B-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.Q903P	0.1111	36.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.Q903P (Missense)		BLCA_VARSCAN2	TCGA-G2-AA3F-01A-12D-A42E-08	TCGA-G2-AA3F-10A-01D-A42H-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.D880N	0.1667	24.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.D880N (Missense)		BLCA_VARSCAN2	TCGA-2F-A9KO-01A-11D-A38G-08	TCGA-2F-A9KO-11A-12D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.Y331*	0.8214	84.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Y331* (Nonsense)		BLCA_VARSCAN2	TCGA-E7-A678-01A-11D-A30E-08	TCGA-E7-A678-10A-01D-A30H-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Nonsense	p.S444*	0.2984	258.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S444* (Nonsense)		BLCA_VARSCAN2	TCGA-E5-A4U1-01A-11D-A31L-08	TCGA-E5-A4U1-10B-01D-A31J-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.Q699E	0.7419	31.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.Q699E (Missense)		BLCA_VARSCAN2	TCGA-UY-A78N-01A-12D-A339-08	TCGA-UY-A78N-10A-01D-A339-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.D255N	0.172	157.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.D255N (Missense)		BLCA_VARSCAN2	TCGA-DK-A3X1-01A-12D-A22Z-08	TCGA-DK-A3X1-10A-01D-A22Z-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Nonsense	p.Q512*	0.1741	201.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.Q512* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A3X1-01A-12D-A22Z-08	TCGA-DK-A3X1-10A-01D-A22Z-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.Q593*	0.4211	19.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Q593* (Nonsense)		BLCA_VARSCAN2	TCGA-G2-AA3D-01A-11D-A391-08	TCGA-G2-AA3D-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.E851*	0.1205	83.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.E851* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-A9T3-01A-11D-A42E-08	TCGA-XF-A9T3-10A-01D-A42H-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.L144V	0.6316	19.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.L144V (Missense)		BLCA_VARSCAN2	TCGA-E7-A4IJ-01A-31D-A26M-08	TCGA-E7-A4IJ-10A-01D-A26K-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.D1389N	0.2903	31.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.D1389N (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RG-01A-21D-A42E-08	TCGA-ZF-A9RG-10A-01D-A42H-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.E1001K	0.1277	47.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.E1001K (Missense)		BLCA_VARSCAN2	TCGA-FD-A3B3-01A-12D-A202-08	TCGA-FD-A3B3-10A-01D-A202-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.E1172K	0.125	40.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.E1172K (Missense)		BLCA_VARSCAN2	TCGA-XF-A9SI-01A-11D-A391-08	TCGA-XF-A9SI-10A-01D-A394-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.S271L	0.5	8.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.S271L (Missense)		BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.I666F	0.25	24.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.I666F (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T5-01A-11D-A42E-08	TCGA-XF-A9T5-10A-01D-A42H-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.E889K	0.6364	33.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.E889K (Missense)		BLCA_VARSCAN2	TCGA-BT-A20T-01A-11D-A14W-08	TCGA-BT-A20T-11A-11D-A14W-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.E1042K	0.9355	31.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.E1042K (Missense)		BLCA_VARSCAN2	TCGA-GV-A3JZ-01A-11D-A21A-08	TCGA-GV-A3JZ-10A-01D-A21A-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.S897L	0.9423	52.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.S897L (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.D438N	0.2118	85.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.D438N (Missense)		BLCA_VARSCAN2	TCGA-BT-A0YX-01A-11D-A10S-08	TCGA-BT-A0YX-10A-01D-A10S-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.S18C	0.2414	87.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.S18C (Missense)		BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.R300K	0.1525	59.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.R300K (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TB-01A-12D-A339-08	TCGA-FD-A6TB-10A-21D-A339-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.G183S	0.4457	92.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.G183S (Missense)		BLCA_VARSCAN2	TCGA-2F-A9KW-01A-11D-A38G-08	TCGA-2F-A9KW-10A-01D-A38J-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.S364C	0.1228	57.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.S364C (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6L-01A-11D-A391-08	TCGA-DK-AA6L-10A-01D-A394-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.P483L	0.5208	48.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.P483L (Missense)		BLCA_VARSCAN2	TCGA-KQ-A41R-01A-21D-A34U-08	TCGA-KQ-A41R-10G-01D-A34X-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.D1631N	0.2143	28.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.D1631N (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4X-01A-11D-A38G-08	TCGA-ZF-AA4X-10A-01D-A38J-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.E428G	0.2128	47.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.E428G (Missense)		BLCA_VARSCAN2	TCGA-PQ-A6FN-01A-11D-A31L-08	TCGA-PQ-A6FN-10A-01D-A31J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Splice Site	p.X665_splice	0.3714	35.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.X665_splice (Splice Site)	1	BLCA_VARSCAN2	TCGA-XF-AAMQ-01A-11D-A42E-08	TCGA-XF-AAMQ-10A-01D-A42H-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Nonsense	p.Q636*	0.2821	39.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.Q636* (Nonsense)	1	BLCA_VARSCAN2	TCGA-ZF-AA51-01A-21D-A391-08	TCGA-ZF-AA51-10A-01D-A394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.T2097M	0.2319	69.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.T2097M (Missense)	0	BLCA_VARSCAN2	TCGA-BL-A0C8-01A-11D-A271-08	TCGA-BL-A0C8-10A-01D-A271-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.L30F	0.5	26.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.L30F (Missense)	1	BLCA_VARSCAN2	TCGA-XF-AAMG-01A-11D-A42E-08	TCGA-XF-AAMG-10A-01D-A42H-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E732Q	0.4528	53.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E732Q (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A1AG-01A-11D-A13W-08	TCGA-DK-A1AG-10A-01D-A13W-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.Q957E	0.1307	153.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.Q957E (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-A9RG-01A-21D-A42E-08	TCGA-ZF-A9RG-10A-01D-A42H-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E2343Q	0.2933	75.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E2343Q (Missense)	0	BLCA_VARSCAN2	TCGA-K4-AAQO-01A-11D-A38G-08	TCGA-K4-AAQO-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Frameshift	p.S1720Ffs*7	0.4754	61.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S1720Ffs*7 (Frameshift)	0	BLCA_VARSCAN2	TCGA-ZF-A9RF-01A-11D-A38G-08	TCGA-ZF-A9RF-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.T557K	0.1818	110.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.T557K (Missense)	1	BLCA_VARSCAN2	TCGA-XF-AAMR-01A-31D-A42E-08	TCGA-XF-AAMR-10A-01D-A42H-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.W353C	0.4353	232.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.W353C (Missense)	1	BLCA_VARSCAN2	TCGA-GV-A6ZA-01A-12D-A339-08	TCGA-GV-A6ZA-10A-01D-A339-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E303K	0.506	83.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E303K (Missense)	1	BLCA_VARSCAN2	TCGA-GV-A6ZA-01A-12D-A339-08	TCGA-GV-A6ZA-10A-01D-A339-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.D526N	0.1288	132.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D526N (Missense)	0	BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E84K	0.2125	80.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E84K (Missense)	1	BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.I1136M	0.2373	59.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.I1136M (Missense)	0	BLCA_VARSCAN2	TCGA-UY-A9PB-01A-11D-A38G-08	TCGA-UY-A9PB-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E1210Q	0.5918	49.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E1210Q (Missense)	1	BLCA_VARSCAN2	TCGA-GU-AATQ-01A-11D-A391-08	TCGA-GU-AATQ-10A-01D-A394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.C903S	0.1048	105.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.C903S (Missense)	1	BLCA_VARSCAN2	TCGA-BT-A20W-01A-21D-A14W-08	TCGA-BT-A20W-11A-11D-A14W-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.Q2943E	0.2885	52.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q2943E (Missense)	0	BLCA_VARSCAN2	TCGA-4Z-AA81-01A-11D-A391-08	TCGA-4Z-AA81-10A-01D-A394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.L2753F	0.2442	86.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.L2753F (Missense)	0	BLCA_VARSCAN2	TCGA-BT-A42C-01A-11D-A23M-08	TCGA-BT-A42C-10A-01D-A23K-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.G3086E	0.2237	76.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.G3086E (Missense)	0	BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E1126Q	0.3333	42.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E1126Q (Missense)	0	BLCA_VARSCAN2	TCGA-GV-A3JZ-01A-11D-A21A-08	TCGA-GV-A3JZ-10A-01D-A21A-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.D1386Y	0.2174	46.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D1386Y (Missense)	0	BLCA_VARSCAN2	TCGA-GV-A3JZ-01A-11D-A21A-08	TCGA-GV-A3JZ-10A-01D-A21A-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.R1570T	0.1584	101.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.R1570T (Missense)	0	BLCA_VARSCAN2	TCGA-GV-A3JZ-01A-11D-A21A-08	TCGA-GV-A3JZ-10A-01D-A21A-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E1895K	0.1754	57.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E1895K (Missense)	0	BLCA_VARSCAN2	TCGA-GV-A3JZ-01A-11D-A21A-08	TCGA-GV-A3JZ-10A-01D-A21A-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.D1911N	0.2245	49.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D1911N (Missense)	0	BLCA_VARSCAN2	TCGA-GV-A3JZ-01A-11D-A21A-08	TCGA-GV-A3JZ-10A-01D-A21A-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E572K	0.9574	94.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E572K (Missense)	1	BLCA_VARSCAN2	TCGA-BT-A3PH-01A-11D-A21Z-08	TCGA-BT-A3PH-10A-01D-A21Z-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.L30F	0.2941	34.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.L30F (Missense)	1	BLCA_VARSCAN2	TCGA-4Z-AA7R-01A-11D-A391-08	TCGA-4Z-AA7R-10A-01D-A394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Nonsense	p.E1731*	0.8125	16.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E1731* (Nonsense)	0	BLCA_VARSCAN2	TCGA-XF-AAMX-01A-11D-A42E-08	TCGA-XF-AAMX-10A-01D-A42H-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.M1689I	0.9545	22.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.M1689I (Missense)	1	BLCA_VARSCAN2	TCGA-XF-AAMX-01A-11D-A42E-08	TCGA-XF-AAMX-10A-01D-A42H-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E1581K	0.931	87.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E1581K (Missense)	1	BLCA_VARSCAN2	TCGA-XF-AAMX-01A-11D-A42E-08	TCGA-XF-AAMX-10A-01D-A42H-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.H1332D	0.2308	13.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.H1332D (Missense)	0	BLCA_VARSCAN2	TCGA-HQ-A5ND-01A-11D-A26M-08	TCGA-HQ-A5ND-10A-01D-A26K-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.Q2354E	0.2766	47.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q2354E (Missense)	0	BLCA_VARSCAN2	TCGA-XF-AAML-01A-11D-A42E-08	TCGA-XF-AAML-10A-01D-A42H-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E3043A	0.5366	41.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E3043A (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.N913S	0.4636	110.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.N913S (Missense)	1	BLCA_VARSCAN2	TCGA-LT-A8JT-01A-11D-A364-08	TCGA-LT-A8JT-10A-01D-A362-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.L1764I	0.1667	48.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.L1764I (Missense)	1	BLCA_VARSCAN2	TCGA-K4-A3WS-01A-11D-A22Z-08	TCGA-K4-A3WS-10A-01D-A22Z-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.M192T	0.5488	82.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.M192T (Missense)	0	BLCA_VARSCAN2	TCGA-FT-A3EE-01A-11D-A202-08	TCGA-FT-A3EE-10A-01D-A202-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.R2273K	0.2376	101.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.R2273K (Missense)	0	BLCA_VARSCAN2	TCGA-DK-AA71-01A-31D-A391-08	TCGA-DK-AA71-10A-01D-A394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E1518Q	0.5128	39.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E1518Q (Missense)	0	BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.Q609H	0.1818	22.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q609H (Missense)	0	BLCA_VARSCAN2	TCGA-E7-A541-01A-11D-A26M-08	TCGA-E7-A541-10A-01D-A26K-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.Q649H	0.3333	36.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q649H (Missense)	0	BLCA_VARSCAN2	TCGA-4Z-AA7W-01A-11D-A391-08	TCGA-4Z-AA7W-10A-01D-A394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E832K	0.175	40.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E832K (Missense)	0	BLCA_VARSCAN2	TCGA-4Z-AA7W-01A-11D-A391-08	TCGA-4Z-AA7W-10A-01D-A394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E897K	0.2239	67.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E897K (Missense)	0	BLCA_VARSCAN2	TCGA-4Z-AA7W-01A-11D-A391-08	TCGA-4Z-AA7W-10A-01D-A394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E1126K	0.3182	44.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E1126K (Missense)	0	BLCA_VARSCAN2	TCGA-4Z-AA7W-01A-11D-A391-08	TCGA-4Z-AA7W-10A-01D-A394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.A253T	0.386	57.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.A253T (Missense)	1	BLCA_VARSCAN2	TCGA-4Z-AA89-01A-11D-A391-08	TCGA-4Z-AA89-10A-01D-A394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S708Y	0.2558	43.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S708Y (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A3IM-01A-11D-A20D-08	TCGA-DK-A3IM-10A-01D-A20D-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E3405Q	0.5517	58.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E3405Q (Missense)	0	BLCA_VARSCAN2	TCGA-GU-AATP-01A-11D-A391-08	TCGA-GU-AATP-10A-01D-A394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.L1908V	0.3798	129.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.L1908V (Missense)	0	BLCA_VARSCAN2	TCGA-E7-A6MD-01A-41D-A34U-08	TCGA-E7-A6MD-10B-01D-A34X-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E1726K	0.2667	30.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E1726K (Missense)	0	BLCA_VARSCAN2	TCGA-ZF-AA4V-01A-11D-A38G-08	TCGA-ZF-AA4V-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E1046K	0.1286	70.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E1046K (Missense)	0	BLCA_VARSCAN2	TCGA-ZF-A9RC-01A-11D-A38G-08	TCGA-ZF-A9RC-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Nonsense	p.Q1281*	0.4507	142.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.Q1281* (Nonsense)	0	BLCA_VARSCAN2	TCGA-G2-A2EL-01A-12D-A18F-08	TCGA-G2-A2EL-10A-01D-A18F-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.R446T	0.4103	117.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.R446T (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A1AE-01A-11D-A13W-08	TCGA-DK-A1AE-10A-01D-A13W-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Nonsense	p.Q667*	0.2125	80.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.Q667* (Nonsense)	0	BLCA_VARSCAN2	TCGA-ZF-AA4W-01A-12D-A38G-08	TCGA-ZF-AA4W-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.G2755A	0.5417	24.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.G2755A (Missense)	0	BLCA_VARSCAN2	TCGA-DK-AA6L-01A-11D-A391-08	TCGA-DK-AA6L-10A-01D-A394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.Q1089E	0.2561	82.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q1089E (Missense)	0	BLCA_VARSCAN2	TCGA-G2-AA3B-01A-11D-A391-08	TCGA-G2-AA3B-10A-01D-A394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Nonsense	p.S1383*	0.2727	22.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.S1383* (Nonsense)	0	BLCA_VARSCAN2	TCGA-G2-AA3B-01A-11D-A391-08	TCGA-G2-AA3B-10A-01D-A394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S3014L	0.1667	36.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S3014L (Missense)	0	BLCA_VARSCAN2	TCGA-ZF-A9R0-01A-11D-A38G-08	TCGA-ZF-A9R0-10A-01D-A38J-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E2081Q	0.4262	122.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E2081Q (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A1A5-01A-11D-A13W-08	TCGA-DK-A1A5-10A-01D-A13W-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Nonsense	p.E1004*	0.1923	104.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E1004* (Nonsense)	0	BLCA_VARSCAN2	TCGA-PQ-A6FN-01A-11D-A31L-08	TCGA-PQ-A6FN-10A-01D-A31J-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.D427G	0.3769	130.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D427G (Missense)	0	BLCA_VARSCAN2	TCGA-XF-A9T3-01A-11D-A42E-08	TCGA-XF-A9T3-10A-01D-A42H-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.D160E	0.4268	82.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.D160E (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T6-01A-11D-A42E-08	TCGA-XF-A9T6-10A-01D-A42H-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Splice Site	p.X372_splice	0.2553	47.0	0.0	0.0		Investigate Actionability	Imatinib	KIT inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for imatinib for patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. 	Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.X372_splice (Splice Site)	0	BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Frameshift	p.A377Lfs*16	0.6582	79.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.A377Lfs*16 (Frameshift)		BLCA_VARSCAN2	TCGA-YC-A9TC-01A-22D-A391-08	TCGA-YC-A9TC-10A-01D-A394-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.L376V	0.7838	74.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.L376V (Missense)		BLCA_VARSCAN2	TCGA-YC-A9TC-01A-22D-A391-08	TCGA-YC-A9TC-10A-01D-A394-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.D347N	0.2903	31.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.D347N (Missense)		BLCA_VARSCAN2	TCGA-HQ-A5NE-01A-12D-A289-08	TCGA-HQ-A5NE-10A-01D-A289-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132H	0.3208	106.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132H (Missense)		BLCA_VARSCAN2	TCGA-BT-A0YX-01A-11D-A10S-08	TCGA-BT-A0YX-10A-01D-A10S-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.R132C	0.1667	36.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.R132C (Missense)		BLCA_VARSCAN2	TCGA-E7-A541-01A-11D-A26M-08	TCGA-E7-A541-10A-01D-A26K-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.M291I	0.2105	76.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.M291I (Missense)		BLCA_VARSCAN2	TCGA-FD-A3NA-01A-11D-A21A-08	TCGA-FD-A3NA-10A-01D-A21A-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Nonsense	p.Q228*	0.3906	64.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.Q228* (Nonsense)		BLCA_VARSCAN2	TCGA-BT-A3PJ-01A-21D-A21Z-08	TCGA-BT-A3PJ-10A-01D-A21Z-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.Y390N	0.6333	90.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.Y390N (Missense)	0	BLCA_VARSCAN2	TCGA-DK-AA77-01A-11D-A391-08	TCGA-DK-AA77-10A-01D-A394-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.R1157T	0.1765	68.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.R1157T (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A6TG-01A-11D-A32B-08	TCGA-FD-A6TG-10A-01D-A329-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.E67Q	0.1328	128.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.E67Q (Missense)	0	BLCA_VARSCAN2	TCGA-ZF-A9RG-01A-21D-A42E-08	TCGA-ZF-A9RG-10A-01D-A42H-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.K159E	0.1429	105.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.K159E (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A3B3-01A-12D-A202-08	TCGA-FD-A3B3-10A-01D-A202-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.D1051N	0.2609	161.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.D1051N (Missense)	1	BLCA_VARSCAN2	TCGA-DK-AA6S-01A-21D-A391-08	TCGA-DK-AA6S-10A-01D-A394-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.G289V	0.2941	17.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.G289V (Missense)	1	BLCA_VARSCAN2	TCGA-KQ-A41Q-01A-11D-A339-08	TCGA-KQ-A41Q-10D-01D-A339-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Frameshift	p.E1126Kfs*24	0.3145	124.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.E1126Kfs*24 (Frameshift)	1	BLCA_VARSCAN2	TCGA-2F-A9KR-01A-11D-A38G-08	TCGA-2F-A9KR-10A-01D-A38J-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.E1018K	0.2368	76.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.E1018K (Missense)	0	BLCA_VARSCAN2	TCGA-DK-AA76-01A-11D-A391-08	TCGA-DK-AA76-10A-01D-A394-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.E53Q	0.1667	36.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.E53Q (Missense)	0	BLCA_VARSCAN2	TCGA-GC-A4ZW-01A-11D-A26M-08	TCGA-GC-A4ZW-10A-01D-A26K-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51D	Missense	p.L277V	0.1509	159.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51D p.L277V (Missense)	0	BLCA_VARSCAN2	TCGA-GC-A4ZW-01A-11D-A26M-08	TCGA-GC-A4ZW-10A-01D-A26K-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.E626K	0.2523	111.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.E626K (Missense)	1	BLCA_VARSCAN2	TCGA-K4-AAQO-01A-11D-A38G-08	TCGA-K4-AAQO-10A-01D-A38J-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.P315L	0.11	100.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.P315L (Missense)	0	BLCA_VARSCAN2	TCGA-FD-A6TF-01A-52D-A32B-08	TCGA-FD-A6TF-10A-21D-A329-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.S139C	0.1667	108.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S139C (Missense)	1	BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.D167N	0.4203	69.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.D167N (Missense)	1	BLCA_VARSCAN2	TCGA-BT-A2LB-01A-11D-A18F-08	TCGA-BT-A2LB-10A-01D-A18F-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.Y224H	0.3636	66.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.Y224H (Missense)	1	BLCA_VARSCAN2	TCGA-BT-A2LB-01A-11D-A18F-08	TCGA-BT-A2LB-10A-01D-A18F-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.E1172K	0.9062	96.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.E1172K (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-A9R3-01A-11D-A38G-08	TCGA-ZF-A9R3-10A-01D-A38J-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.I640M	0.12	100.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.I640M (Missense)	1	BLCA_VARSCAN2	TCGA-BT-A42C-01A-11D-A23M-08	TCGA-BT-A42C-10A-01D-A23K-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.P92L	0.3125	32.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.P92L (Missense)	0	BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.E456Q	0.2881	118.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.E456Q (Missense)	0	BLCA_VARSCAN2	TCGA-BT-A20T-01A-11D-A14W-08	TCGA-BT-A20T-11A-11D-A14W-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.D714N	0.1727	110.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.D714N (Missense)	0	BLCA_VARSCAN2	TCGA-XF-A9SP-01A-11D-A391-08	TCGA-XF-A9SP-10A-01D-A394-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.Y224H	0.2703	37.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.Y224H (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A3N5-01A-11D-A21A-08	TCGA-FD-A3N5-10A-01D-A21A-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.Q295E	0.2099	81.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.Q295E (Missense)	1	BLCA_VARSCAN2	TCGA-E7-A7XN-01A-11D-A34U-08	TCGA-E7-A7XN-10A-01D-A34X-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Nonsense	p.S1056*	0.3179	151.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S1056* (Nonsense)	1	BLCA_VARSCAN2	TCGA-BT-A42E-01A-11D-A23U-08	TCGA-BT-A42E-10A-01D-A23U-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.R249C	0.3095	126.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.R249C (Missense)	1	BLCA_VARSCAN2	TCGA-ZF-A9R7-01A-11D-A38G-08	TCGA-ZF-A9R7-10A-01D-A38J-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.S202C	0.3182	22.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.S202C (Missense)	0	BLCA_VARSCAN2	TCGA-GV-A3JZ-01A-11D-A21A-08	TCGA-GV-A3JZ-10A-01D-A21A-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Frameshift	p.T43Kfs*33	0.7852	135.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.T43Kfs*33 (Frameshift)	0	BLCA_VARSCAN2	TCGA-DK-AA6P-01A-11D-A391-08	TCGA-DK-AA6P-10A-01D-A394-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.P21T	0.2899	138.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.P21T (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A5BZ-01A-11D-A289-08	TCGA-FD-A5BZ-10A-01D-A289-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.E837K	0.1667	36.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.E837K (Missense)	0	BLCA_VARSCAN2	TCGA-YF-AA3L-01A-11D-A38G-08	TCGA-YF-AA3L-10A-01D-A38J-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.L84M	0.1494	87.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.L84M (Missense)	1	BLCA_VARSCAN2	TCGA-BT-A20O-01A-21D-A14W-08	TCGA-BT-A20O-11A-11D-A14W-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.E309K	0.5938	64.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.E309K (Missense)	1	BLCA_VARSCAN2	TCGA-GV-A3JV-01A-11D-A21Z-08	TCGA-GV-A3JV-10B-01D-A21Z-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.K231N	0.2995	187.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.K231N (Missense)	0	BLCA_VARSCAN2	TCGA-XF-AAMX-01A-11D-A42E-08	TCGA-XF-AAMX-10A-01D-A42H-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.I633M	0.2736	106.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.I633M (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A43X-01A-11D-A23U-08	TCGA-FD-A43X-10A-01D-A23U-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.H606D	0.2292	48.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.H606D (Missense)	0	BLCA_VARSCAN2	TCGA-FD-A3B6-01A-21D-A20D-08	TCGA-FD-A3B6-10A-01D-A20D-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.P330H	0.2315	108.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.P330H (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A1A3-01A-11D-A13W-08	TCGA-DK-A1A3-10A-01D-A13W-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.R112Q	0.8571	21.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.R112Q (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51D	Missense	p.E104G	0.4085	71.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51D p.E104G (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK1	Missense	p.E432K	0.3846	130.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK1 p.E432K (Missense)	1	BLCA_VARSCAN2	TCGA-LT-A8JT-01A-11D-A364-08	TCGA-LT-A8JT-10A-01D-A362-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51D	Missense	p.Q327P	0.2078	77.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51D p.Q327P (Missense)	0	BLCA_VARSCAN2	TCGA-K4-A3WS-01A-11D-A22Z-08	TCGA-K4-A3WS-10A-01D-A22Z-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.D167N	0.3816	76.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.D167N (Missense)	1	BLCA_VARSCAN2	TCGA-FD-A3SN-01A-12D-A22Z-08	TCGA-FD-A3SN-10A-01D-A22Z-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.L842V	0.2586	58.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.L842V (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.I609M	0.8254	63.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.I609M (Missense)	0	BLCA_VARSCAN2	TCGA-GD-A6C6-01A-21D-A31L-08	TCGA-GD-A6C6-10A-01D-A31J-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.S519C	0.5588	34.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.S519C (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A6B6-01A-11D-A30E-08	TCGA-DK-A6B6-10A-01D-A30H-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.D440G	0.5333	15.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.D440G (Missense)	0	BLCA_VARSCAN2	TCGA-FD-A5BX-01A-11D-A26M-08	TCGA-FD-A5BX-10A-01D-A26K-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.S779L	0.1739	23.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.S779L (Missense)	0	BLCA_VARSCAN2	TCGA-FD-A5BX-01A-11D-A26M-08	TCGA-FD-A5BX-10A-01D-A26K-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.S747C	0.1774	62.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.S747C (Missense)	0	BLCA_VARSCAN2	TCGA-FD-A5BX-01A-11D-A26M-08	TCGA-FD-A5BX-10A-01D-A26K-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.P735A	0.1852	54.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.P735A (Missense)	0	BLCA_VARSCAN2	TCGA-FD-A5BX-01A-11D-A26M-08	TCGA-FD-A5BX-10A-01D-A26K-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Nonsense	p.Q613*	0.2791	43.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.Q613* (Nonsense)	1	BLCA_VARSCAN2	TCGA-FD-A5BX-01A-11D-A26M-08	TCGA-FD-A5BX-10A-01D-A26K-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.S582Y	0.2105	19.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.S582Y (Missense)	0	BLCA_VARSCAN2	TCGA-FD-A5BX-01A-11D-A26M-08	TCGA-FD-A5BX-10A-01D-A26K-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.Q561H	0.1831	71.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.Q561H (Missense)	1	BLCA_VARSCAN2	TCGA-XF-A8HE-01A-11D-A364-08	TCGA-XF-A8HE-10A-01D-A362-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51D	Missense	p.S196F	0.6176	34.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51D p.S196F (Missense)	0	BLCA_VARSCAN2	TCGA-KQ-A41P-01A-12D-A339-08	TCGA-KQ-A41P-10F-01D-A339-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.K197Q	0.439	41.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.K197Q (Missense)	0	BLCA_VARSCAN2	TCGA-ZF-AA51-01A-21D-A391-08	TCGA-ZF-AA51-10A-01D-A394-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.E377K	0.2234	94.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.E377K (Missense)	0	BLCA_VARSCAN2	TCGA-FJ-A3Z7-01A-12D-A23M-08	TCGA-FJ-A3Z7-10A-01D-A23K-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Nonsense	p.S356*	0.2692	52.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.S356* (Nonsense)	0	BLCA_VARSCAN2	TCGA-FJ-A3Z7-01A-12D-A23M-08	TCGA-FJ-A3Z7-10A-01D-A23K-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.H339Y	0.2667	45.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.H339Y (Missense)	0	BLCA_VARSCAN2	TCGA-FJ-A3Z7-01A-12D-A23M-08	TCGA-FJ-A3Z7-10A-01D-A23K-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.D230N	0.3171	41.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.D230N (Missense)	0	BLCA_VARSCAN2	TCGA-E7-A5KE-01A-11D-A289-08	TCGA-E7-A5KE-10A-01D-A289-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.V836I	0.1529	85.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.V836I (Missense)	0	BLCA_VARSCAN2	TCGA-CF-A1HR-01A-11D-A13W-08	TCGA-CF-A1HR-10A-01D-A13W-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.E910Q	0.4757	185.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.E910Q (Missense)	1	BLCA_VARSCAN2	TCGA-G2-A2EJ-01A-11D-A17V-08	TCGA-G2-A2EJ-10A-01D-A17V-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.D772N	0.32	50.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.D772N (Missense)	0	BLCA_VARSCAN2	TCGA-KQ-A41R-01A-21D-A34U-08	TCGA-KQ-A41R-10G-01D-A34X-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.D1112H	0.3385	65.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.D1112H (Missense)	1	BLCA_VARSCAN2	TCGA-E7-A7DV-01A-11D-A339-08	TCGA-E7-A7DV-10A-01D-A339-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Nonsense	p.S653*	0.4556	90.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S653* (Nonsense)	1	BLCA_VARSCAN2	TCGA-4Z-AA7Y-01A-11D-A391-08	TCGA-4Z-AA7Y-10A-01D-A394-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.E367D	0.108	213.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.E367D (Missense)	0	BLCA_VARSCAN2	TCGA-UY-A78K-01A-11D-A339-08	TCGA-UY-A78K-10A-01D-A339-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.D363N	0.1005	398.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.D363N (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A3X1-01A-12D-A22Z-08	TCGA-DK-A3X1-10A-01D-A22Z-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51D	Missense	p.Q319H	0.3836	73.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51D p.Q319H (Missense)	0	BLCA_VARSCAN2	TCGA-BT-A20J-01A-11D-A14W-08	TCGA-BT-A20J-11A-11D-A14W-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.Y676C	0.5833	24.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.Y676C (Missense)	0	BLCA_VARSCAN2	TCGA-XF-A9T3-01A-11D-A42E-08	TCGA-XF-A9T3-10A-01D-A42H-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.S614C	0.1327	113.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.S614C (Missense)	0	BLCA_VARSCAN2	TCGA-XF-AAMG-01A-11D-A42E-08	TCGA-XF-AAMG-10A-01D-A42H-08
Investigate Actionability	FDA-Approved			Somatic Variant	FANCL	Missense	p.I136M	0.1209	91.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	FANCL p.I136M (Missense)	0	BLCA_VARSCAN2	TCGA-FD-A6TD-01A-51D-A339-08	TCGA-FD-A6TD-10A-21D-A339-08
Investigate Actionability	FDA-Approved			Somatic Variant	ATM	Deletion	p.S2860del	0.2174	161.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	ATM p.S2860del (Deletion)	1	BLCA_VARSCAN2	TCGA-FD-A6TI-01A-11D-A32B-08	TCGA-FD-A6TI-10A-01D-A329-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.D296N	0.3514	37.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.D296N (Missense)	0	BLCA_VARSCAN2	TCGA-E5-A4TZ-01A-11D-A31L-08	TCGA-E5-A4TZ-10B-01D-A31J-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Frameshift	p.E95Rfs*29	0.1525	59.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.E95Rfs*29 (Frameshift)	0	BLCA_VARSCAN2	TCGA-G2-A3VY-01A-11D-A22Z-08	TCGA-G2-A3VY-10A-01D-A22Z-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.M415V	0.303	132.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.M415V (Missense)	0	BLCA_VARSCAN2	TCGA-CF-A9FH-01A-11D-A38G-08	TCGA-CF-A9FH-10A-01D-A38J-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.S1142C	0.5246	122.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.S1142C (Missense)	0	BLCA_VARSCAN2	TCGA-UY-A9PD-01A-11D-A38G-08	TCGA-UY-A9PD-10A-01D-A38J-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Frameshift	p.L88Wfs*10	0.32	25.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.L88Wfs*10 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-A9SJ-01A-11D-A391-08	TCGA-XF-A9SJ-10A-01D-A394-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.E98K	0.275	40.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.E98K (Missense)	0	BLCA_VARSCAN2	TCGA-XF-A9T6-01A-11D-A42E-08	TCGA-XF-A9T6-10A-01D-A42H-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.E711K	0.2286	70.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.E711K (Missense)	0	BLCA_VARSCAN2	TCGA-XF-AAN3-01A-11D-A42E-08	TCGA-XF-AAN3-10A-01D-A42H-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Nonsense	p.Q674*	0.2222	36.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.Q674* (Nonsense)		BLCA_VARSCAN2	TCGA-4Z-AA81-01A-11D-A391-08	TCGA-4Z-AA81-10A-01D-A394-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.D514N	0.3871	31.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.D514N (Missense)	0	BLCA_VARSCAN2	TCGA-UY-A78L-01A-12D-A339-08	TCGA-UY-A78L-10A-01D-A339-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD51B	Missense	p.L189Q	0.2969	128.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD51B p.L189Q (Missense)	0	BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.S283L	0.2373	59.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.S283L (Missense)	0	BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.S79L	0.2593	81.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.S79L (Missense)	0	BLCA_VARSCAN2	TCGA-XF-A9T0-01A-11D-A391-08	TCGA-XF-A9T0-10A-01D-A394-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Nonsense	p.S256*	0.3835	133.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.S256* (Nonsense)	0	BLCA_VARSCAN2	TCGA-XF-A9T0-01A-11D-A391-08	TCGA-XF-A9T0-10A-01D-A394-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.E184Q	0.2549	51.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.E184Q (Missense)	0	BLCA_VARSCAN2	TCGA-E7-A7XN-01A-11D-A34U-08	TCGA-E7-A7XN-10A-01D-A34X-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD51B	Missense	p.Q225E	0.1969	127.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD51B p.Q225E (Missense)	0	BLCA_VARSCAN2	TCGA-E7-A7XN-01A-11D-A34U-08	TCGA-E7-A7XN-10A-01D-A34X-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P707S	0.1628	43.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P707S (Missense)	0	BLCA_VARSCAN2	TCGA-ZF-A9R7-01A-11D-A38G-08	TCGA-ZF-A9R7-10A-01D-A38J-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.L1323F	0.505	200.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.L1323F (Missense)	0	BLCA_VARSCAN2	TCGA-GU-A42R-01A-11D-A23M-08	TCGA-GU-A42R-10A-01D-A23K-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.L495F	0.1358	81.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.L495F (Missense)	0	BLCA_VARSCAN2	TCGA-K4-A4AC-01A-21D-A26M-08	TCGA-K4-A4AC-10A-01D-A26K-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD51B	Missense	p.E248A	0.3333	57.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD51B p.E248A (Missense)	0	BLCA_VARSCAN2	TCGA-GC-A6I3-01A-11D-A31L-08	TCGA-GC-A6I3-10A-01D-A31J-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.S1329F	0.4298	114.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.S1329F (Missense)	0	BLCA_VARSCAN2	TCGA-GD-A3OQ-01A-32D-A21Z-08	TCGA-GD-A3OQ-10A-01D-A21Z-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.R13K	0.383	47.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.R13K (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.I272V	0.2917	24.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.I272V (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.E1024K	0.2297	74.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.E1024K (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R344W	0.5455	33.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R344W (Missense)	0	BLCA_VARSCAN2	TCGA-FD-A3SN-01A-12D-A22Z-08	TCGA-FD-A3SN-10A-01D-A22Z-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.P904A	0.3387	62.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.P904A (Missense)	0	BLCA_VARSCAN2	TCGA-5N-A9KI-01A-31D-A42E-08	TCGA-5N-A9KI-10A-01D-A42H-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.S148L	0.2143	98.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.S148L (Missense)	0	BLCA_VARSCAN2	TCGA-BT-A0YX-01A-11D-A10S-08	TCGA-BT-A0YX-10A-01D-A10S-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.L55F	0.2541	122.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.L55F (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.E471Q	0.1	80.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.E471Q (Missense)	0	BLCA_VARSCAN2	TCGA-ZF-AA53-01A-11D-A391-08	TCGA-ZF-AA53-10A-01D-A394-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.S1377L	0.3	60.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.S1377L (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A6B6-01A-11D-A30E-08	TCGA-DK-A6B6-10A-01D-A30H-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Frameshift	p.H791Tfs*29	0.6849	238.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.H791Tfs*29 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A3IS-01A-21D-A21A-08	TCGA-DK-A3IS-10A-01D-A21A-08
Investigate Actionability	FDA-Approved			Somatic Variant	ATM	Deletion	p.Q2314_K2317del	0.1842	38.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	ATM p.Q2314_K2317del (Deletion)	1	BLCA_VARSCAN2	TCGA-E7-A4XJ-01A-11D-A26M-08	TCGA-E7-A4XJ-10A-01D-A26K-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.D459H	0.1778	180.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.D459H (Missense)	0	BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Nonsense	p.Q695*	0.2812	64.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.Q695* (Nonsense)	0	BLCA_VARSCAN2	TCGA-ZF-AA4V-01A-11D-A38G-08	TCGA-ZF-AA4V-10A-01D-A38J-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.E765G	0.1765	51.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.E765G (Missense)	0	BLCA_VARSCAN2	TCGA-C4-A0EZ-01A-21D-A10S-08	TCGA-C4-A0EZ-10A-01D-A10S-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD51B	Missense	p.E168Q	0.2222	117.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD51B p.E168Q (Missense)	0	BLCA_VARSCAN2	TCGA-DK-AA6L-01A-11D-A391-08	TCGA-DK-AA6L-10A-01D-A394-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.E189K	0.2222	36.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.E189K (Missense)	0	BLCA_VARSCAN2	TCGA-G2-A2EC-01A-11D-A17V-08	TCGA-G2-A2EC-10A-01D-A17V-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.E1041K	0.1928	83.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.E1041K (Missense)	0	BLCA_VARSCAN2	TCGA-KQ-A41R-01A-21D-A34U-08	TCGA-KQ-A41R-10G-01D-A34X-08
Investigate Actionability	FDA-Approved			Somatic Variant	FANCL	Missense	p.E209K	0.3909	110.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	FANCL p.E209K (Missense)	0	BLCA_VARSCAN2	TCGA-E7-A85H-01A-11D-A34U-08	TCGA-E7-A85H-10B-01D-A34X-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.S534F	0.1509	106.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.S534F (Missense)	0	BLCA_VARSCAN2	TCGA-2F-A9KO-01A-11D-A38G-08	TCGA-2F-A9KO-11A-12D-A38J-08
Investigate Actionability	FDA-Approved			Somatic Variant	FANCL	Missense	p.T4S	0.4167	24.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	FANCL p.T4S (Missense)	0	BLCA_VARSCAN2	TCGA-XF-A9T3-01A-11D-A42E-08	TCGA-XF-A9T3-10A-01D-A42H-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Splice Site	p.X596_splice	0.5273	55.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.X596_splice (Splice Site)	0	BLCA_VARSCAN2	TCGA-K4-A6MB-01A-11D-A31L-08	TCGA-K4-A6MB-10A-01D-A31J-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.Q417K	0.4235	85.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.Q417K (Missense)		BLCA_VARSCAN2	TCGA-YC-A9TC-01A-22D-A391-08	TCGA-YC-A9TC-10A-01D-A394-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.S466C	0.2553	47.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.S466C (Missense)		BLCA_VARSCAN2	TCGA-BT-A20Q-01A-11D-A14W-08	TCGA-BT-A20Q-11A-11D-A14W-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Nonsense	p.S509*	0.2245	49.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.S509* (Nonsense)		BLCA_VARSCAN2	TCGA-BT-A20Q-01A-11D-A14W-08	TCGA-BT-A20Q-11A-11D-A14W-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.E330K	0.6216	37.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.E330K (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TC-01A-21D-A339-08	TCGA-FD-A6TC-10A-21D-A339-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.E628K	0.1562	32.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.E628K (Missense)		BLCA_VARSCAN2	TCGA-GD-A2C5-01A-12D-A17V-08	TCGA-GD-A2C5-10A-01D-A17V-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Nonsense	p.S584*	0.4769	65.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.S584* (Nonsense)	0	BLCA_VARSCAN2	TCGA-ZF-AA51-01A-21D-A391-08	TCGA-ZF-AA51-10A-01D-A394-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.P989L	0.5385	52.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.P989L (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SL-01A-21D-A22Z-08	TCGA-FD-A3SL-10A-01D-A22Z-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Nonsense	p.S26*	0.2778	126.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.S26* (Nonsense)	0	BLCA_VARSCAN2	TCGA-4Z-AA7W-01A-11D-A391-08	TCGA-4Z-AA7W-10A-01D-A394-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.D768H	0.4375	96.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.D768H (Missense)		BLCA_VARSCAN2	TCGA-GV-A3JX-01A-11D-A20D-08	TCGA-GV-A3JX-10A-01D-A20D-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.K1090N	0.5357	56.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.K1090N (Missense)		BLCA_VARSCAN2	TCGA-GV-A3JX-01A-11D-A20D-08	TCGA-GV-A3JX-10A-01D-A20D-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.E1106Q	0.4321	81.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.E1106Q (Missense)		BLCA_VARSCAN2	TCGA-GV-A3JX-01A-11D-A20D-08	TCGA-GV-A3JX-10A-01D-A20D-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.L426V	0.3846	78.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.L426V (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7Y-01A-11D-A391-08	TCGA-4Z-AA7Y-10A-01D-A394-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Nonsense	p.R102*	0.1176	51.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.R102* (Nonsense)	1	BLCA_VARSCAN2	TCGA-4Z-AA82-01A-11D-A391-08	TCGA-4Z-AA82-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.M1383I	0.1099	91.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.M1383I (Missense)		BLCA_VARSCAN2	TCGA-E7-A4IJ-01A-31D-A26M-08	TCGA-E7-A4IJ-10A-01D-A26K-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.E810K	0.3562	73.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.E810K (Missense)		BLCA_VARSCAN2	TCGA-K4-A54R-01A-11D-A26M-08	TCGA-K4-A54R-10A-01D-A26K-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Frameshift	p.S426Pfs*49	0.2927	123.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S426Pfs*49 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A1AG-01A-11D-A13W-08	TCGA-DK-A1AG-10A-01D-A13W-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.Q779E	0.4545	77.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.Q779E (Missense)		BLCA_VARSCAN2	TCGA-G2-A2EO-01A-11D-A17V-08	TCGA-G2-A2EO-11A-21D-A17V-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Missense	p.D299N	0.5625	32.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.D299N (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA5H-01A-11D-A391-08	TCGA-ZF-AA5H-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Missense	p.R190P	0.8462	39.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.R190P (Missense)		BLCA_VARSCAN2	TCGA-CF-A3MG-01A-11D-A20D-08	TCGA-CF-A3MG-10A-01D-A20D-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Missense	p.S970C	0.594	133.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.S970C (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TD-01A-51D-A339-08	TCGA-FD-A6TD-10A-21D-A339-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.V606F	0.86	50.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.V606F (Missense)		BLCA_VARSCAN2	TCGA-FJ-A3ZE-01A-11D-A23M-08	TCGA-FJ-A3ZE-10A-01D-A23K-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Splice Site	p.X422_splice	0.6667	36.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.X422_splice (Splice Site)		BLCA_VARSCAN2	TCGA-FD-A6TI-01A-11D-A32B-08	TCGA-FD-A6TI-10A-01D-A329-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Splice Site	p.X422_splice	0.375	16.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.X422_splice (Splice Site)		BLCA_VARSCAN2	TCGA-5N-A9KM-01A-11D-A42E-08	TCGA-5N-A9KM-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.E583K	0.3623	69.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E583K (Missense)		BLCA_VARSCAN2	TCGA-DK-A3IN-01A-11D-A20D-08	TCGA-DK-A3IN-10A-01D-A20D-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.T1355A	0.3519	54.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.T1355A (Missense)		BLCA_VARSCAN2	TCGA-BL-A5ZZ-01A-31D-A30E-08	TCGA-BL-A5ZZ-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Missense	p.E1565Q	0.1321	53.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.E1565Q (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R9-01A-11D-A38G-08	TCGA-ZF-A9R9-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X272_splice	0.3929	28.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X272_splice (Splice Site)		BLCA_VARSCAN2	TCGA-4Z-AA7Q-01A-11D-A391-08	TCGA-4Z-AA7Q-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Deletion	p.V593_L594del	0.1375	80.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.V593_L594del (Deletion)		BLCA_VARSCAN2	TCGA-4Z-AA7Q-01A-11D-A391-08	TCGA-4Z-AA7Q-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.E487K	0.2857	42.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.E487K (Missense)		BLCA_VARSCAN2	TCGA-DK-AA76-01A-11D-A391-08	TCGA-DK-AA76-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.S62I	0.5435	46.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.S62I (Missense)		BLCA_VARSCAN2	TCGA-DK-AA76-01A-11D-A391-08	TCGA-DK-AA76-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Nonsense	p.S252*	0.1986	146.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.S252* (Nonsense)		BLCA_VARSCAN2	TCGA-GC-A4ZW-01A-11D-A26M-08	TCGA-GC-A4ZW-10A-01D-A26K-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.L458S	0.4167	48.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.L458S (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RF-01A-11D-A38G-08	TCGA-ZF-A9RF-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Deletion	p.S183_A186del	0.127	63.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.S183_A186del (Deletion)		BLCA_VARSCAN2	TCGA-XF-AAMR-01A-31D-A42E-08	TCGA-XF-AAMR-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Missense	p.I621M	0.1296	54.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.I621M (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TF-01A-52D-A32B-08	TCGA-FD-A6TF-10A-21D-A329-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Missense	p.S1487C	0.36	25.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.S1487C (Missense)		BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Splice Site	p.X36_splice	0.45	20.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.X36_splice (Splice Site)		BLCA_VARSCAN2	TCGA-FD-A3SQ-01A-21D-A22Z-08	TCGA-FD-A3SQ-10A-01D-A22Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Missense	p.A68T	0.1538	26.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.A68T (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T6-01A-11D-A42E-08	TCGA-XF-A9T6-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.T555A	0.3217	143.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.T555A (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T6-01A-11D-A42E-08	TCGA-XF-A9T6-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.D880Y	0.1608	143.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.D880Y (Missense)		BLCA_VARSCAN2	TCGA-BT-A42C-01A-11D-A23M-08	TCGA-BT-A42C-10A-01D-A23K-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Missense	p.Q830H	0.7018	57.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.Q830H (Missense)		BLCA_VARSCAN2	TCGA-XF-A9ST-01A-11D-A42E-08	TCGA-XF-A9ST-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Missense	p.E959K	0.3896	77.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.E959K (Missense)		BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Missense	p.P613L	0.2571	35.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.P613L (Missense)		BLCA_VARSCAN2	TCGA-FD-A5BU-01A-31D-A26M-08	TCGA-FD-A5BU-10A-01D-A26K-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Nonsense	p.Q239*	0.1176	51.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.Q239* (Nonsense)		BLCA_VARSCAN2	TCGA-E7-A7XN-01A-11D-A34U-08	TCGA-E7-A7XN-10A-01D-A34X-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.I1309T	0.2105	76.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.I1309T (Missense)		BLCA_VARSCAN2	TCGA-E5-A2PC-01A-11D-A202-08	TCGA-E5-A2PC-10B-01D-A202-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.Q264H	0.4286	14.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.Q264H (Missense)		BLCA_VARSCAN2	TCGA-HQ-A2OF-01A-11D-A26M-08	TCGA-HQ-A2OF-10B-01D-A26K-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.P1496L	0.1316	38.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.P1496L (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TH-01A-11D-A32B-08	TCGA-FD-A6TH-10A-01D-A329-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.E1132K	0.4275	131.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E1132K (Missense)		BLCA_VARSCAN2	TCGA-BT-A3PH-01A-11D-A21Z-08	TCGA-BT-A3PH-10A-01D-A21Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.E767Q	0.6269	67.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E767Q (Missense)		BLCA_VARSCAN2	TCGA-BT-A3PH-01A-11D-A21Z-08	TCGA-BT-A3PH-10A-01D-A21Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Missense	p.R367W	0.8545	55.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.R367W (Missense)		BLCA_VARSCAN2	TCGA-BT-A3PH-01A-11D-A21Z-08	TCGA-BT-A3PH-10A-01D-A21Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.E731Q	0.6	55.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.E731Q (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TC-01A-21D-A339-08	TCGA-FD-A6TC-10A-21D-A339-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.H826N	0.6463	82.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.H826N (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TC-01A-21D-A339-08	TCGA-FD-A6TC-10A-21D-A339-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.G777E	0.127	126.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.G777E (Missense)		BLCA_VARSCAN2	TCGA-BT-A42F-01A-11D-A23U-08	TCGA-BT-A42F-10A-01D-A23U-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Splice Site	p.X737_splice	0.6324	68.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.X737_splice (Splice Site)		BLCA_VARSCAN2	TCGA-GD-A2C5-01A-12D-A17V-08	TCGA-GD-A2C5-10A-01D-A17V-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Splice Site	p.X798_splice	0.6182	110.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.X798_splice (Splice Site)		BLCA_VARSCAN2	TCGA-GV-A3QF-01A-31D-A22Z-08	TCGA-GV-A3QF-10A-01D-A22Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.D1286N	0.434	53.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.D1286N (Missense)		BLCA_VARSCAN2	TCGA-KQ-A41S-01A-12D-A339-08	TCGA-KQ-A41S-10C-01D-A339-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Nonsense	p.E278*	0.5714	42.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.E278* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R1096C	0.4537	108.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R1096C (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R876C	0.4667	30.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R876C (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.D1049N	0.495	101.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.D1049N (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.T610I	0.4179	67.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.T610I (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Missense	p.D504N	0.3235	34.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.D504N (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SN-01A-12D-A22Z-08	TCGA-FD-A3SN-10A-01D-A22Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.R122L	0.4848	33.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.R122L (Missense)		BLCA_VARSCAN2	TCGA-XF-A8HD-01A-11D-A364-08	TCGA-XF-A8HD-10A-01D-A362-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Nonstop	p.*580Sext*135	0.2374	139.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.*580Sext*135 (Nonstop)		BLCA_VARSCAN2	TCGA-BT-A0YX-01A-11D-A10S-08	TCGA-BT-A0YX-10A-01D-A10S-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.E1049K	0.2121	66.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E1049K (Missense)		BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site	p.X989_splice	0.1905	63.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.X989_splice (Splice Site)		BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Missense	p.R786Q	0.2229	175.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.R786Q (Missense)		BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Missense	p.L830V	0.1698	53.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.L830V (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA80-01A-11D-A391-08	TCGA-4Z-AA80-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.I274M	0.1967	61.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.I274M (Missense)		BLCA_VARSCAN2	TCGA-XF-A8HE-01A-11D-A364-08	TCGA-XF-A8HE-10A-01D-A362-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.E406K	0.2308	78.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E406K (Missense)		BLCA_VARSCAN2	TCGA-XF-A8HE-01A-11D-A364-08	TCGA-XF-A8HE-10A-01D-A362-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.D1325N	0.4466	103.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.D1325N (Missense)		BLCA_VARSCAN2	TCGA-BT-A2LA-01A-11D-A18F-08	TCGA-BT-A2LA-11A-11D-A18F-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Missense	p.Y192H	0.4844	64.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC1 p.Y192H (Missense)		BLCA_VARSCAN2	TCGA-XF-A9SK-01A-11D-A42E-08	TCGA-XF-A9SK-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.M453I	0.2619	42.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.M453I (Missense)		BLCA_VARSCAN2	TCGA-LC-A66R-01A-41D-A30E-08	TCGA-LC-A66R-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Frameshift	p.S404Afs*99	0.2245	49.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S404Afs*99 (Frameshift)		BLCA_VARSCAN2	TCGA-E7-A8O8-01A-11D-A364-08	TCGA-E7-A8O8-10A-01D-A362-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.K1373N	0.1379	116.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.K1373N (Missense)		BLCA_VARSCAN2	TCGA-E7-A6MD-01A-41D-A34U-08	TCGA-E7-A6MD-10B-01D-A34X-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.S716C	0.4167	120.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.S716C (Missense)		BLCA_VARSCAN2	TCGA-E7-A6MD-01A-41D-A34U-08	TCGA-E7-A6MD-10B-01D-A34X-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.N1262D	0.5484	62.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.N1262D (Missense)		BLCA_VARSCAN2	TCGA-GC-A3RC-01A-11D-A22Z-08	TCGA-GC-A3RC-10B-01D-A22Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Deletion	p.T363del	0.1446	83.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.T363del (Deletion)		BLCA_VARSCAN2	TCGA-ZF-AA4W-01A-12D-A38G-08	TCGA-ZF-AA4W-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.R1334W	0.2273	44.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.R1334W (Missense)		BLCA_VARSCAN2	TCGA-K4-A6FZ-01A-11D-A31L-08	TCGA-K4-A6FZ-10A-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Missense	p.S872F	0.26	50.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.S872F (Missense)		BLCA_VARSCAN2	TCGA-K4-A6FZ-01A-11D-A31L-08	TCGA-K4-A6FZ-10A-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.R106T	0.1346	52.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.R106T (Missense)		BLCA_VARSCAN2	TCGA-XF-A9SY-01A-21D-A42E-08	TCGA-XF-A9SY-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Frameshift	p.M438Afs*38	0.4035	57.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.M438Afs*38 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-AAMF-01A-21D-A42E-08	TCGA-XF-AAMF-10A-01D-A42H-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.S585F	0.1	70.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.S585F (Missense)		BLCA_VARSCAN2	TCGA-G2-AA3B-01A-11D-A391-08	TCGA-G2-AA3B-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Nonsense	p.Q698*	0.2857	147.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.Q698* (Nonsense)		BLCA_VARSCAN2	TCGA-2F-A9KT-01A-11D-A38G-08	TCGA-2F-A9KT-10A-01D-A38J-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.Q167E	0.3171	41.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.Q167E (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AV-01A-12D-A30E-08	TCGA-DK-A6AV-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.P239A	0.1277	47.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.P239A (Missense)	0	BLCA_VARSCAN2	TCGA-DK-A3X1-01A-12D-A22Z-08	TCGA-DK-A3X1-10A-01D-A22Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.F689L	0.2411	224.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.F689L (Missense)		BLCA_VARSCAN2	TCGA-DK-A3X1-01A-12D-A22Z-08	TCGA-DK-A3X1-10A-01D-A22Z-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.D543N	0.234	94.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.D543N (Missense)		BLCA_VARSCAN2	TCGA-BT-A20J-01A-11D-A14W-08	TCGA-BT-A20J-11A-11D-A14W-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.A72V	0.3571	14.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.A72V (Missense)	1	BLCA_VARSCAN2	TCGA-K4-A54R-01A-11D-A26M-08	TCGA-K4-A54R-10A-01D-A26K-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.E373K	0.3704	27.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.E373K (Missense)	1	BLCA_VARSCAN2	TCGA-G2-A3VY-01A-11D-A22Z-08	TCGA-G2-A3VY-10A-01D-A22Z-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.L112P	0.5978	92.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.L112P (Missense)	1	BLCA_VARSCAN2	TCGA-UY-A78L-01A-12D-A339-08	TCGA-UY-A78L-10A-01D-A339-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.N372D	0.3659	41.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.N372D (Missense)	1	BLCA_VARSCAN2	TCGA-YC-A9TC-01A-22D-A391-08	TCGA-YC-A9TC-10A-01D-A394-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.E394K	0.3333	30.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.E394K (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.H93R	0.3465	127.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.H93R (Missense)	1	BLCA_VARSCAN2	TCGA-FJ-A871-01A-11D-A34U-08	TCGA-FJ-A871-10A-01D-A34X-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.R233Q	0.2833	60.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R233Q (Missense)	1	BLCA_VARSCAN2	TCGA-DK-A2I6-01A-12D-A18F-08	TCGA-DK-A2I6-10A-01D-A18F-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Frameshift	p.V491Sfs*15	0.3421	152.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.V491Sfs*15 (Frameshift)	0	BLCA_VARSCAN2	TCGA-GV-A3QK-01B-11D-A23M-08	TCGA-GV-A3QK-10A-01D-A23K-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.K1603E	0.1059	85.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.K1603E (Missense)		BLCA_VARSCAN2	TCGA-YC-A8S6-01A-31D-A38G-08	TCGA-YC-A8S6-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.Q1512H	0.3248	157.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1512H (Missense)		BLCA_VARSCAN2	TCGA-K4-A54R-01A-11D-A26M-08	TCGA-K4-A54R-10A-01D-A26K-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S552L	0.133	233.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S552L (Missense)		BLCA_VARSCAN2	TCGA-FD-A3B3-01A-12D-A202-08	TCGA-FD-A3B3-10A-01D-A202-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.R1287T	0.2174	23.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1287T (Missense)		BLCA_VARSCAN2	TCGA-CF-A3MG-01A-11D-A20D-08	TCGA-CF-A3MG-10A-01D-A20D-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Splice Site	p.X451_splice	0.3248	157.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.X451_splice (Splice Site)		BLCA_VARSCAN2	TCGA-FD-A6TI-01A-11D-A32B-08	TCGA-FD-A6TI-10A-01D-A329-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Splice Site	p.X960_splice	0.3478	23.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.X960_splice (Splice Site)		BLCA_VARSCAN2	TCGA-FD-A6TI-01A-11D-A32B-08	TCGA-FD-A6TI-10A-01D-A329-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.C1981Y	0.6696	115.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.C1981Y (Missense)		BLCA_VARSCAN2	TCGA-E5-A4TZ-01A-11D-A31L-08	TCGA-E5-A4TZ-10B-01D-A31J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Deletion	p.N822_A829del	0.1714	35.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.N822_A829del (Deletion)		BLCA_VARSCAN2	TCGA-DK-A3IT-01A-31D-A20D-08	TCGA-DK-A3IT-10A-01D-A20D-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S1000F	0.2703	37.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1000F (Missense)		BLCA_VARSCAN2	TCGA-DK-A3IN-01A-11D-A20D-08	TCGA-DK-A3IN-10A-01D-A20D-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P680T	0.25	64.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P680T (Missense)		BLCA_VARSCAN2	TCGA-KQ-A41Q-01A-11D-A339-08	TCGA-KQ-A41Q-10D-01D-A339-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.L573V	0.1227	383.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.L573V (Missense)		BLCA_VARSCAN2	TCGA-FD-A62P-01A-32D-A30E-08	TCGA-FD-A62P-10A-01D-A30H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.D1912N	0.5217	69.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1912N (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R9-01A-11D-A38G-08	TCGA-ZF-A9R9-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.E1444Q	0.1714	140.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E1444Q (Missense)		BLCA_VARSCAN2	TCGA-GC-A4ZW-01A-11D-A26M-08	TCGA-GC-A4ZW-10A-01D-A26K-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.E654K	0.2051	39.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E654K (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T8-01A-11D-A391-08	TCGA-XF-A9T8-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S1312Y	0.1774	62.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1312Y (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RF-01A-11D-A38G-08	TCGA-ZF-A9RF-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.F1457L	0.1719	64.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.F1457L (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RF-01A-11D-A38G-08	TCGA-ZF-A9RF-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.F1704L	0.175	40.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.F1704L (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RF-01A-11D-A38G-08	TCGA-ZF-A9RF-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S637C	0.3404	47.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S637C (Missense)		BLCA_VARSCAN2	TCGA-GV-A6ZA-01A-12D-A339-08	TCGA-GV-A6ZA-10A-01D-A339-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.Q1650E	0.1667	54.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1650E (Missense)		BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.A2237P	0.2604	288.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.A2237P (Missense)		BLCA_VARSCAN2	TCGA-FJ-A3Z9-01A-11D-A26M-08	TCGA-FJ-A3Z9-10A-01D-A26K-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Nonsense	p.R174*	0.9	40.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.R174* (Nonsense)		BLCA_VARSCAN2	TCGA-S5-AA26-01A-11D-A38G-08	TCGA-S5-AA26-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Splice Site	p.X1367_splice	0.6616	198.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.X1367_splice (Splice Site)		BLCA_VARSCAN2	TCGA-2F-A9KP-01A-11D-A38G-08	TCGA-2F-A9KP-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Deletion	p.R2233_L2238del	0.129	124.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R2233_L2238del (Deletion)		BLCA_VARSCAN2	TCGA-GV-A3QK-01B-11D-A23M-08	TCGA-GV-A3QK-10A-01D-A23K-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.L2011R	0.3243	111.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.L2011R (Missense)		BLCA_VARSCAN2	TCGA-FJ-A3ZF-01A-11D-A23M-08	TCGA-FJ-A3ZF-10A-01D-A23K-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Splice Site	p.X960_splice	0.3939	33.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.X960_splice (Splice Site)		BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Nonsense	p.E83*	0.2857	42.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.E83* (Nonsense)		BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.D1112N	0.3103	29.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.D1112N (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T0-01A-11D-A391-08	TCGA-XF-A9T0-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Splice Site	p.X1368_splice	0.2211	95.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.X1368_splice (Splice Site)		BLCA_VARSCAN2	TCGA-FD-A43N-01A-11D-A23U-08	TCGA-FD-A43N-10A-01D-A23U-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.E2035K	0.4224	116.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E2035K (Missense)		BLCA_VARSCAN2	TCGA-BL-A3JM-01A-12D-A21A-08	TCGA-BL-A3JM-11A-31D-A21A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.Q2188H	0.2733	150.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q2188H (Missense)		BLCA_VARSCAN2	TCGA-BL-A3JM-01A-12D-A21A-08	TCGA-BL-A3JM-11A-31D-A21A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G830A	0.25	44.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G830A (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R7-01A-11D-A38G-08	TCGA-ZF-A9R7-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S1623L	0.3923	130.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1623L (Missense)		BLCA_VARSCAN2	TCGA-GU-A42R-01A-11D-A23M-08	TCGA-GU-A42R-10A-01D-A23K-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S1600F	0.451	51.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1600F (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6P-01A-11D-A391-08	TCGA-DK-AA6P-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.M923I	0.4194	62.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.M923I (Missense)		BLCA_VARSCAN2	TCGA-CU-A5W6-01A-11D-A289-08	TCGA-CU-A5W6-10A-01D-A289-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.Q479E	0.2032	374.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q479E (Missense)		BLCA_VARSCAN2	TCGA-E7-A7DU-01A-11D-A32B-08	TCGA-E7-A7DU-10A-01D-A329-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.H495Y	0.1985	388.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.H495Y (Missense)		BLCA_VARSCAN2	TCGA-E7-A7DU-01A-11D-A32B-08	TCGA-E7-A7DU-10A-01D-A329-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.A955T	0.4474	76.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.A955T (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G1926A	0.2595	185.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G1926A (Missense)		BLCA_VARSCAN2	TCGA-BT-A0YX-01A-11D-A10S-08	TCGA-BT-A0YX-10A-01D-A10S-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.E2000Q	0.2812	64.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E2000Q (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA51-01A-21D-A391-08	TCGA-ZF-AA51-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.E1019Q	0.2745	102.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E1019Q (Missense)		BLCA_VARSCAN2	TCGA-LC-A66R-01A-41D-A30E-08	TCGA-LC-A66R-10A-01D-A30H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S614L	0.3556	45.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S614L (Missense)		BLCA_VARSCAN2	TCGA-CU-A3KJ-01A-11D-A21A-08	TCGA-CU-A3KJ-10A-01D-A21A-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P1605S	0.1379	58.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1605S (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RC-01A-11D-A38G-08	TCGA-ZF-A9RC-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Frameshift	p.K860Nfs*16	0.1818	121.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.K860Nfs*16 (Frameshift)		BLCA_VARSCAN2	TCGA-ZF-AA4W-01A-12D-A38G-08	TCGA-ZF-AA4W-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.E1683Q	0.2059	34.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.E1683Q (Missense)		BLCA_VARSCAN2	TCGA-CF-A1HR-01A-11D-A13W-08	TCGA-CF-A1HR-10A-01D-A13W-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.L2071S	0.3239	71.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.L2071S (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN0-01A-11D-A42E-08	TCGA-XF-AAN0-10A-01D-A42H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P452R	0.3284	268.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P452R (Missense)		BLCA_VARSCAN2	TCGA-DK-A6B5-01A-11D-A31L-08	TCGA-DK-A6B5-10A-01D-A31J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.S715L	0.3333	39.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S715L (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4X-01A-11D-A38G-08	TCGA-ZF-AA4X-10A-01D-A38J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.Q605E	0.1429	84.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q605E (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SR-01A-11D-A22Z-08	TCGA-FD-A3SR-10A-01D-A22Z-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.G1030C	0.4314	51.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.G1030C (Missense)		BLCA_VARSCAN2	TCGA-DK-AA77-01A-11D-A391-08	TCGA-DK-AA77-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R13W	0.1884	69.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R13W (Missense)		BLCA_VARSCAN2	TCGA-DK-A2HX-01A-12D-A18F-08	TCGA-DK-A2HX-10A-01D-A18F-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.S141L	0.2708	48.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.S141L (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TA-01A-12D-A339-08	TCGA-FD-A6TA-10A-21D-A339-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.D190N	0.1091	110.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.D190N (Missense)	0	BLCA_VARSCAN2	TCGA-XF-AAMY-01A-11D-A42E-08	TCGA-XF-AAMY-10A-01D-A42H-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R741K	0.3084	107.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R741K (Missense)		BLCA_VARSCAN2	TCGA-G2-A2EO-01A-11D-A17V-08	TCGA-G2-A2EO-11A-21D-A17V-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.G911D	0.5263	38.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.G911D (Missense)		BLCA_VARSCAN2	TCGA-UY-A8OD-01A-11D-A364-08	TCGA-UY-A8OD-10A-01D-A362-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.D1183H	0.6883	154.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.D1183H (Missense)		BLCA_VARSCAN2	TCGA-FJ-A3ZE-01A-11D-A23M-08	TCGA-FJ-A3ZE-10A-01D-A23K-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.T910M	0.1852	27.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.T910M (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TI-01A-11D-A32B-08	TCGA-FD-A6TI-10A-01D-A329-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.A1186T	0.2264	53.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A1186T (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TI-01A-11D-A32B-08	TCGA-FD-A6TI-10A-01D-A329-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1192C	0.15	60.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1192C (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TI-01A-11D-A32B-08	TCGA-FD-A6TI-10A-01D-A329-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E1083K	0.4885	131.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E1083K (Missense)		BLCA_VARSCAN2	TCGA-G2-A3VY-01A-11D-A22Z-08	TCGA-G2-A3VY-10A-01D-A22Z-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.S641*	0.122	82.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S641* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A3IN-01A-11D-A20D-08	TCGA-DK-A3IN-10A-01D-A20D-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.D1284N	0.1923	26.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.D1284N (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RF-01A-11D-A38G-08	TCGA-ZF-A9RF-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.R14*	0.3077	26.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R14* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-A9T5-01A-11D-A42E-08	TCGA-XF-A9T5-10A-01D-A42H-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E1436D	0.6857	35.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E1436D (Missense)		BLCA_VARSCAN2	TCGA-FJ-A3ZF-01A-11D-A23M-08	TCGA-FJ-A3ZF-10A-01D-A23K-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Frameshift	p.K299Sfs*12	0.2041	49.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.K299Sfs*12 (Frameshift)		BLCA_VARSCAN2	TCGA-YC-A9TC-01A-22D-A391-08	TCGA-YC-A9TC-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.T786N	0.4091	44.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.T786N (Missense)		BLCA_VARSCAN2	TCGA-BT-A20T-01A-11D-A14W-08	TCGA-BT-A20T-11A-11D-A14W-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.E1047K	0.2892	83.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.E1047K (Missense)	0	BLCA_VARSCAN2	TCGA-ZF-A9R7-01A-11D-A38G-08	TCGA-ZF-A9R7-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.R479*	0.4242	66.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R479* (Nonsense)		BLCA_VARSCAN2	TCGA-UY-A9PF-01A-11D-A38G-08	TCGA-UY-A9PF-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Nonsense	p.E662*	0.4844	225.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.E662* (Nonsense)	0	BLCA_VARSCAN2	TCGA-XF-A8HI-01A-11D-A38G-08	TCGA-XF-A8HI-10A-01D-A38J-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E474K	0.1064	47.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E474K (Missense)		BLCA_VARSCAN2	TCGA-GU-A767-01A-11D-A32B-08	TCGA-GU-A767-10A-01D-A329-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.R48W	0.3125	48.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.R48W (Missense)	0	BLCA_VARSCAN2	TCGA-CU-A5W6-01A-11D-A289-08	TCGA-CU-A5W6-10A-01D-A289-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.Q508*	0.2838	74.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.Q508* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-AA75-01A-11D-A391-08	TCGA-DK-AA75-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Splice Site	p.X419_splice	0.625	8.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.X419_splice (Splice Site)	0	BLCA_VARSCAN2	TCGA-DK-AA71-01A-31D-A391-08	TCGA-DK-AA71-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.T417M	0.4909	110.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.T417M (Missense)	0	BLCA_VARSCAN2	TCGA-BT-A0YX-01A-11D-A10S-08	TCGA-BT-A0YX-10A-01D-A10S-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Frameshift	p.E471Kfs*27	0.2367	207.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.E471Kfs*27 (Frameshift)		BLCA_VARSCAN2	TCGA-BT-A0YX-01A-11D-A10S-08	TCGA-BT-A0YX-10A-01D-A10S-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.R278*	0.8056	36.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R278* (Nonsense)		BLCA_VARSCAN2	TCGA-LT-A5Z6-01A-11D-A289-08	TCGA-LT-A5Z6-10A-01D-A289-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E1393K	0.5053	95.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E1393K (Missense)		BLCA_VARSCAN2	TCGA-G2-A2EF-01A-12D-A18F-08	TCGA-G2-A2EF-10A-01D-A18F-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.S678*	0.4796	98.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S678* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A2I2-01A-11D-A17V-08	TCGA-DK-A2I2-10A-01D-A17V-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Frameshift	p.Q581Pfs*24	0.1905	63.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.Q581Pfs*24 (Frameshift)		BLCA_VARSCAN2	TCGA-G2-A2ES-01A-11D-A17V-08	TCGA-G2-A2ES-11A-31D-A17V-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.G33D	0.1765	51.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.G33D (Missense)		BLCA_VARSCAN2	TCGA-G2-A2ES-01A-11D-A17V-08	TCGA-G2-A2ES-11A-31D-A17V-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Nonsense	p.S232*	0.187	123.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.S232* (Nonsense)		BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Nonsense	p.R90*	0.3175	63.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.R90* (Nonsense)		BLCA_VARSCAN2	TCGA-KQ-A41P-01A-12D-A339-08	TCGA-KQ-A41P-10F-01D-A339-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Splice Site	p.X772_splice	0.119	42.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.X772_splice (Splice Site)	0	BLCA_VARSCAN2	TCGA-E7-A541-01A-11D-A26M-08	TCGA-E7-A541-10A-01D-A26K-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.Q127*	0.4848	33.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.Q127* (Nonsense)		BLCA_VARSCAN2	TCGA-GU-A42Q-01A-11D-A23U-08	TCGA-GU-A42Q-10A-01D-A23U-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.K1033N	0.2014	144.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.K1033N (Missense)		BLCA_VARSCAN2	TCGA-CU-A3KJ-01A-11D-A21A-08	TCGA-CU-A3KJ-10A-01D-A21A-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.W321*	0.6346	52.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.W321* (Nonsense)		BLCA_VARSCAN2	TCGA-C4-A0F0-01A-12D-A10S-08	TCGA-C4-A0F0-10A-01D-A10S-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Splice Site	p.X168_splice	0.5833	12.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.X168_splice (Splice Site)		BLCA_VARSCAN2	TCGA-C4-A0F6-01A-11D-A10S-08	TCGA-C4-A0F6-10A-01D-A10S-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Nonsense	p.Q442*	0.3833	60.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.Q442* (Nonsense)	0	BLCA_VARSCAN2	TCGA-4Z-AA7Y-01A-11D-A391-08	TCGA-4Z-AA7Y-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.V588I	0.2549	153.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.V588I (Missense)	0	BLCA_VARSCAN2	TCGA-E5-A4U1-01A-11D-A31L-08	TCGA-E5-A4U1-10B-01D-A31J-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.W365*	0.1298	131.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.W365* (Nonsense)		BLCA_VARSCAN2	TCGA-PQ-A6FN-01A-11D-A31L-08	TCGA-PQ-A6FN-10A-01D-A31J-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Splice Site	p.X68_splice	0.3462	78.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.X68_splice (Splice Site)		BLCA_VARSCAN2	TCGA-K4-A54R-01A-11D-A26M-08	TCGA-K4-A54R-10A-01D-A26K-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Insertion	p.A1437dup	0.2171	175.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.A1437dup (Insertion)		BLCA_VARSCAN2	TCGA-ZF-A9R9-01A-11D-A38G-08	TCGA-ZF-A9R9-10A-01D-A38J-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Nonsense	p.W781*	0.2373	59.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.W781* (Nonsense)		BLCA_VARSCAN2	TCGA-GC-A4ZW-01A-11D-A26M-08	TCGA-GC-A4ZW-10A-01D-A26K-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Nonsense	p.E1599*	0.1129	62.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.E1599* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-A8HD-01A-11D-A364-08	TCGA-XF-A8HD-10A-01D-A362-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Deletion	p.E336_R337del	0.3636	22.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E336_R337del (Deletion)		BLCA_VARSCAN2	TCGA-FD-A5BR-01A-11D-A26M-08	TCGA-FD-A5BR-10A-01D-A26K-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Frameshift	p.K262Nfs*4	0.1702	47.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.K262Nfs*4 (Frameshift)		BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.E322Q	0.4118	17.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.E322Q (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T8-01A-11D-A391-08	TCGA-XF-A9T8-10A-01D-A394-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.A361E	0.4154	65.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.A361E (Missense)		BLCA_VARSCAN2	TCGA-K4-A4AB-01B-12D-A289-08	TCGA-K4-A4AB-10A-01D-A289-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Insertion	p.L55_L57dup	0.1111	36.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.L55_L57dup (Insertion)		BLCA_VARSCAN2	TCGA-DK-A2I6-01A-12D-A18F-08	TCGA-DK-A2I6-10A-01D-A18F-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.K235N	0.1475	61.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.K235N (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4W-01A-12D-A38G-08	TCGA-ZF-AA4W-10A-01D-A38J-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.E589Q	0.7143	21.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.E589Q (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN0-01A-11D-A42E-08	TCGA-XF-AAN0-10A-01D-A42H-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.R34P	0.8667	45.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.R34P (Missense)		BLCA_VARSCAN2	TCGA-K4-A5RI-01A-11D-A289-08	TCGA-K4-A5RI-10A-01D-A289-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.Q161E	0.1364	66.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.Q161E (Missense)		BLCA_VARSCAN2	TCGA-DK-A3IT-01A-31D-A20D-08	TCGA-DK-A3IT-10A-01D-A20D-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.R34G	0.7097	31.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.R34G (Missense)		BLCA_VARSCAN2	TCGA-GU-AATQ-01A-11D-A391-08	TCGA-GU-AATQ-10A-01D-A394-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.R34G	0.3684	57.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.R34G (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN3-01A-11D-A42E-08	TCGA-XF-AAN3-10A-01D-A42H-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Nonsense	p.E423*	0.3858	127.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.E423* (Nonsense)		BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.E35D	0.3594	64.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.E35D (Missense)		BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.K53Q	0.5437	103.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.K53Q (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4U-01A-11D-A38G-08	TCGA-ZF-AA4U-10A-01D-A38J-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.D29H	0.8095	63.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.D29H (Missense)		BLCA_VARSCAN2	TCGA-YC-A9TC-01A-22D-A391-08	TCGA-YC-A9TC-10A-01D-A394-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.T80I	0.2857	28.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.T80I (Missense)		BLCA_VARSCAN2	TCGA-FD-A5BU-01A-31D-A26M-08	TCGA-FD-A5BU-10A-01D-A26K-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.R34G	0.4444	27.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.R34G (Missense)		BLCA_VARSCAN2	TCGA-E5-A2PC-01A-11D-A202-08	TCGA-E5-A2PC-10B-01D-A202-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.R34G	0.6176	68.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.R34G (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6Q-01A-11D-A391-08	TCGA-DK-AA6Q-10A-01D-A394-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.E82D	0.3774	53.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.E82D (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SM-01A-11D-A22Z-08	TCGA-FD-A3SM-10A-01D-A22Z-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.E79Q	0.32	50.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.E79Q (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SM-01A-11D-A22Z-08	TCGA-FD-A3SM-10A-01D-A22Z-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.R34G	0.72	25.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.R34G (Missense)		BLCA_VARSCAN2	TCGA-G2-A3IB-01A-11D-A20D-08	TCGA-G2-A3IB-10A-01D-A20D-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.G81A	0.2281	114.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.G81A (Missense)		BLCA_VARSCAN2	TCGA-G2-AA3C-01A-21D-A391-08	TCGA-G2-AA3C-10A-01D-A394-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.P600R	0.1028	107.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.P600R (Missense)		BLCA_VARSCAN2	TCGA-K4-A3WS-01A-11D-A22Z-08	TCGA-K4-A3WS-10A-01D-A22Z-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.E82V	0.2	30.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.E82V (Missense)		BLCA_VARSCAN2	TCGA-FD-A43Y-01A-21D-A26M-08	TCGA-FD-A43Y-10A-01D-A26K-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.G31R	0.234	47.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.G31R (Missense)		BLCA_VARSCAN2	TCGA-BT-A20U-01A-11D-A14W-08	TCGA-BT-A20U-11A-11D-A14W-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.W24R	0.1111	72.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.W24R (Missense)		BLCA_VARSCAN2	TCGA-BT-A0YX-01A-11D-A10S-08	TCGA-BT-A0YX-10A-01D-A10S-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Deletion	p.L30_S33del	0.225	40.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.L30_S33del (Deletion)		BLCA_VARSCAN2	TCGA-XF-AAN5-01A-11D-A42E-08	TCGA-XF-AAN5-10A-01D-A42H-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.E79K	0.5	80.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.E79K (Missense)		BLCA_VARSCAN2	TCGA-BT-A42B-01A-32D-A23M-08	TCGA-BT-A42B-10A-01D-A23K-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.G31A	0.3509	57.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.G31A (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AE-01A-11D-A13W-08	TCGA-DK-A1AE-10A-01D-A13W-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.K533Q	0.4927	205.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.K533Q (Missense)		BLCA_VARSCAN2	TCGA-C4-A0F6-01A-11D-A10S-08	TCGA-C4-A0F6-10A-01D-A10S-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.E79K	0.3077	39.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.E79K (Missense)		BLCA_VARSCAN2	TCGA-BL-A13I-01A-11D-A271-08	TCGA-BL-A13I-10A-01D-A271-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.D29Y	0.3793	29.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.D29Y (Missense)		BLCA_VARSCAN2	TCGA-FD-A3N6-01A-11D-A21A-08	TCGA-FD-A3N6-10A-01D-A21A-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.V417M	0.2114	175.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.V417M (Missense)		BLCA_VARSCAN2	TCGA-UY-A9PE-01A-11D-A38G-08	TCGA-UY-A9PE-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.E1132K	0.2459	61.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.E1132K (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA84-01A-11D-A391-08	TCGA-4Z-AA84-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.R766K	0.6211	95.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R766K (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA84-01A-11D-A391-08	TCGA-4Z-AA84-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.N69S	0.6667	36.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.N69S (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6W-01A-12D-A391-08	TCGA-DK-AA6W-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.S1382C	0.9038	52.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.S1382C (Missense)		BLCA_VARSCAN2	TCGA-G2-A3VY-01A-11D-A22Z-08	TCGA-G2-A3VY-10A-01D-A22Z-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.R205L	0.5794	107.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.R205L (Missense)		BLCA_VARSCAN2	TCGA-GC-A3YS-01A-11D-A23M-08	TCGA-GC-A3YS-10A-01D-A23K-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.C772R	0.4061	197.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.C772R (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RE-01A-11D-A38G-08	TCGA-ZF-A9RE-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.L776P	0.4516	62.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.L776P (Missense)		BLCA_VARSCAN2	TCGA-E7-A97P-01A-11D-A38G-08	TCGA-E7-A97P-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.K83N	0.2083	24.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.K83N (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T8-01A-11D-A391-08	TCGA-XF-A9T8-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.E1228Q	0.2917	72.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.E1228Q (Missense)		BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Deletion	p.E1187_D1192del	0.1463	41.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.E1187_D1192del (Deletion)		BLCA_VARSCAN2	TCGA-FD-A3SQ-01A-21D-A22Z-08	TCGA-FD-A3SQ-10A-01D-A22Z-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.Q347E	0.2025	158.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.Q347E (Missense)		BLCA_VARSCAN2	TCGA-UY-A9PB-01A-11D-A38G-08	TCGA-UY-A9PB-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.S208Y	0.79	100.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.S208Y (Missense)		BLCA_VARSCAN2	TCGA-E7-A6ME-01A-22D-A32B-08	TCGA-E7-A6ME-10B-01D-A329-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.P1062S	0.378	246.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.P1062S (Missense)		BLCA_VARSCAN2	TCGA-BT-A42C-01A-11D-A23M-08	TCGA-BT-A42C-10A-01D-A23K-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.S704L	0.3636	55.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.S704L (Missense)		BLCA_VARSCAN2	TCGA-BL-A13J-01A-11D-A271-08	TCGA-BL-A13J-10A-01D-A10S-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.E1409Q	0.3667	90.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.E1409Q (Missense)		BLCA_VARSCAN2	TCGA-YF-AA3L-01A-11D-A38G-08	TCGA-YF-AA3L-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.I563M	0.8889	45.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.I563M (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7R-01A-11D-A391-08	TCGA-4Z-AA7R-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Deletion	p.F1397_R1398del	0.3077	13.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.F1397_R1398del (Deletion)		BLCA_VARSCAN2	TCGA-ZF-AA52-01A-12D-A391-08	TCGA-ZF-AA52-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.L432F	0.96	25.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.L432F (Missense)		BLCA_VARSCAN2	TCGA-E7-A7DU-01A-11D-A32B-08	TCGA-E7-A7DU-10A-01D-A329-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.R130I	0.359	39.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.R130I (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T2-01A-11D-A42E-08	TCGA-XF-A9T2-10A-01D-A42H-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Insertion	p.L148_T149insM	0.5583	120.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.L148_T149insM (Insertion)		BLCA_VARSCAN2	TCGA-UY-A78M-01A-21D-A34U-08	TCGA-UY-A78M-10A-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.E1193K	0.2308	78.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.E1193K (Missense)		BLCA_VARSCAN2	TCGA-DK-A1A3-01A-11D-A13W-08	TCGA-DK-A1A3-10A-01D-A13W-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.N986T	1.0	17.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.N986T (Missense)		BLCA_VARSCAN2	TCGA-CF-A5U8-01A-11D-A289-08	TCGA-CF-A5U8-10A-01D-A289-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.S1169Y	0.4819	83.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S1169Y (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.S367I	0.1967	122.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.S367I (Missense)		BLCA_VARSCAN2	TCGA-FD-A43Y-01A-21D-A26M-08	TCGA-FD-A43Y-10A-01D-A26K-08
Investigate Actionability			Guideline	Somatic Variant	ZRSR2	Missense	p.E73K	0.7778	9.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ZRSR2 p.E73K (Missense)		BLCA_VARSCAN2	TCGA-5N-A9KI-01A-31D-A42E-08	TCGA-5N-A9KI-10A-01D-A42H-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.E294K	0.1161	155.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.E294K (Missense)		BLCA_VARSCAN2	TCGA-LT-A5Z6-01A-11D-A289-08	TCGA-LT-A5Z6-10A-01D-A289-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Splice Site	p.X155_splice	0.2407	162.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.X155_splice (Splice Site)		BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.R362K	0.5814	43.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.R362K (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7M-01A-11D-A391-08	TCGA-4Z-AA7M-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.A316V	0.1781	73.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.A316V (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7M-01A-11D-A391-08	TCGA-4Z-AA7M-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R411L	0.1531	98.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R411L (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7M-01A-11D-A391-08	TCGA-4Z-AA7M-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.V301A	0.2105	57.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.V301A (Missense)		BLCA_VARSCAN2	TCGA-FD-A5C0-01A-11D-A289-08	TCGA-FD-A5C0-10A-01D-A289-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.D409H	0.1875	64.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.D409H (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN5-01A-11D-A42E-08	TCGA-XF-AAN5-10A-01D-A42H-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.D311N	0.3959	197.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.D311N (Missense)		BLCA_VARSCAN2	TCGA-DK-A1A6-01A-11D-A13W-08	TCGA-DK-A1A6-10A-01D-A13W-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.E327Q	0.439	164.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.E327Q (Missense)		BLCA_VARSCAN2	TCGA-DK-A1A6-01A-11D-A13W-08	TCGA-DK-A1A6-10A-01D-A13W-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.L260F	0.1012	257.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.L260F (Missense)		BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.D24H	0.3659	82.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.D24H (Missense)		BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.S106C	0.375	56.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.S106C (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA51-01A-21D-A391-08	TCGA-ZF-AA51-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.L207F	0.6209	153.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.L207F (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SL-01A-21D-A22Z-08	TCGA-FD-A3SL-10A-01D-A22Z-08
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.I309M	0.2703	74.0	0.0	0.0																Investigate Actionability	0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PTPN11 p.I309M (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RD-01A-11D-A42E-08	TCGA-ZF-A9RD-10A-01D-A42H-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.M1139I	0.1091	110.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.M1139I (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RD-01A-11D-A42E-08	TCGA-ZF-A9RD-10A-01D-A42H-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.I191M	0.9422	173.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.I191M (Missense)		BLCA_VARSCAN2	TCGA-E7-A8O8-01A-11D-A364-08	TCGA-E7-A8O8-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.H108Y	0.45	60.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.H108Y (Missense)		BLCA_VARSCAN2	TCGA-GU-AATP-01A-11D-A391-08	TCGA-GU-AATP-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.S894R	0.1	170.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S894R (Missense)		BLCA_VARSCAN2	TCGA-XF-A8HG-01A-11D-A364-08	TCGA-XF-A8HG-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.N1343K	0.3115	61.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.N1343K (Missense)		BLCA_VARSCAN2	TCGA-CF-A8HX-01A-11D-A364-08	TCGA-CF-A8HX-10A-01D-A362-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.D351N	0.3793	174.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.D351N (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7O-01A-31D-A391-08	TCGA-4Z-AA7O-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.R370W	0.4444	9.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R370W (Missense)		BLCA_VARSCAN2	TCGA-FD-A3NA-01A-11D-A21A-08	TCGA-FD-A3NA-10A-01D-A21A-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.R130T	0.2069	29.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.R130T (Missense)		BLCA_VARSCAN2	TCGA-FD-A43P-01A-31D-A23U-08	TCGA-FD-A43P-10A-01D-A23U-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.I268S	0.396	101.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.I268S (Missense)		BLCA_VARSCAN2	TCGA-2F-A9KW-01A-11D-A38G-08	TCGA-2F-A9KW-10A-01D-A38J-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.V1279M	0.5738	61.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.V1279M (Missense)		BLCA_VARSCAN2	TCGA-GC-A3RD-01A-12D-A22Z-08	TCGA-GC-A3RD-10B-01D-A22Z-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.S1756F	0.2623	61.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.S1756F (Missense)		BLCA_VARSCAN2	TCGA-KQ-A41R-01A-21D-A34U-08	TCGA-KQ-A41R-10G-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.A214V	0.4771	262.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.A214V (Missense)		BLCA_VARSCAN2	TCGA-KQ-A41R-01A-21D-A34U-08	TCGA-KQ-A41R-10G-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.A107P	0.4872	39.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.A107P (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AC-01A-11D-A13W-08	TCGA-DK-A1AC-10A-01D-A13W-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.R139P	0.2373	59.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.R139P (Missense)		BLCA_VARSCAN2	TCGA-E7-A85H-01A-11D-A34U-08	TCGA-E7-A85H-10B-01D-A34X-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.S1269L	0.2308	78.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S1269L (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SO-01A-11D-A22Z-08	TCGA-FD-A3SO-10A-01D-A22Z-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R1090T	0.2151	93.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R1090T (Missense)		BLCA_VARSCAN2	TCGA-DK-A3X1-01A-12D-A22Z-08	TCGA-DK-A3X1-10A-01D-A22Z-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.D850E	0.119	84.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.D850E (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T3-01A-11D-A42E-08	TCGA-XF-A9T3-10A-01D-A42H-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S352N	0.1458	48.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S352N (Missense)		BLCA_VARSCAN2	TCGA-E7-A4IJ-01A-31D-A26M-08	TCGA-E7-A4IJ-10A-01D-A26K-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Nonsense	p.R1122*	0.4706	17.0	0.0	0.0																Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK2 p.R1122* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A6TA-01A-12D-A339-08	TCGA-FD-A6TA-10A-21D-A339-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Nonsense	p.Q601*	0.5714	21.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.Q601* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A6TA-01A-12D-A339-08	TCGA-FD-A6TA-10A-21D-A339-08
Investigate Actionability			Clinical evidence	Somatic Variant	MC1R	Missense	p.F280L	0.5	18.0	0.0	0.0																Investigate Actionability	0	The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).	Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;	https://doi.org/10.1111/pcmr.12516					MC1R p.F280L (Missense)		BLCA_VARSCAN2	TCGA-XF-AAMG-01A-11D-A42E-08	TCGA-XF-AAMG-10A-01D-A42H-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.A197S	0.2083	24.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.A197S (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA84-01A-11D-A391-08	TCGA-4Z-AA84-10A-01D-A394-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.S823C	0.5312	64.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.S823C (Missense)		BLCA_VARSCAN2	TCGA-E7-A5KF-01A-11D-A289-08	TCGA-E7-A5KF-10A-01D-A289-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.E142K	0.8235	17.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.E142K (Missense)		BLCA_VARSCAN2	TCGA-XF-A9SZ-01A-11D-A391-08	TCGA-XF-A9SZ-10A-01D-A394-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37F	0.3333	45.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37F (Missense)		BLCA_VARSCAN2	TCGA-BL-A5ZZ-01A-31D-A30E-08	TCGA-BL-A5ZZ-10A-01D-A30H-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.P30L	0.3684	19.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.P30L (Missense)		BLCA_VARSCAN2	TCGA-DK-A1A7-01A-11D-A13W-08	TCGA-DK-A1A7-10A-01D-A13W-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Nonsense	p.Q778*	0.7778	9.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.Q778* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-AA76-01A-11D-A391-08	TCGA-DK-AA76-10A-01D-A394-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.E377Q	0.3393	56.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.E377Q (Missense)		BLCA_VARSCAN2	TCGA-PQ-A6FI-01A-11D-A31L-08	TCGA-PQ-A6FI-10A-01D-A31J-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.R910T	0.1048	124.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.R910T (Missense)		BLCA_VARSCAN2	TCGA-XF-AAMZ-01A-11D-A42E-08	TCGA-XF-AAMZ-10A-01D-A42H-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Nonsense	p.R230*	0.3333	9.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.R230* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A6TK-01A-42D-A339-08	TCGA-FD-A6TK-10A-21D-A339-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.D110N	0.1452	62.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.D110N (Missense)		BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.P597S	0.4603	63.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.P597S (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T5-01A-11D-A42E-08	TCGA-XF-A9T5-10A-01D-A42H-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.N599H	0.1127	71.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.N599H (Missense)		BLCA_VARSCAN2	TCGA-BT-A20V-01A-11D-A14W-08	TCGA-BT-A20V-11A-11D-A14W-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Nonsense	p.S43*	0.9565	23.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.S43* (Nonsense)		BLCA_VARSCAN2	TCGA-GU-A42P-01A-11D-A23U-08	TCGA-GU-A42P-10A-01D-A23U-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Frameshift	p.P555Cfs*20	0.5556	36.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.P555Cfs*20 (Frameshift)		BLCA_VARSCAN2	TCGA-K4-A4AB-01B-12D-A289-08	TCGA-K4-A4AB-10A-01D-A289-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D32H	0.1613	31.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D32H (Missense)		BLCA_VARSCAN2	TCGA-HQ-A2OE-01A-11D-A202-08	TCGA-HQ-A2OE-10A-01D-A202-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37C	0.4872	39.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37C (Missense)		BLCA_VARSCAN2	TCGA-BL-A3JM-01A-12D-A21A-08	TCGA-BL-A3JM-11A-31D-A21A-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.D1079N	0.5	64.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.D1079N (Missense)		BLCA_VARSCAN2	TCGA-BT-A3PH-01A-11D-A21Z-08	TCGA-BT-A3PH-10A-01D-A21Z-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.Q1210H	0.2625	80.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.Q1210H (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TC-01A-21D-A339-08	TCGA-FD-A6TC-10A-21D-A339-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.S781L	0.4444	9.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.S781L (Missense)		BLCA_VARSCAN2	TCGA-HQ-A5NE-01A-12D-A289-08	TCGA-HQ-A5NE-10A-01D-A289-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.G921V	0.1935	62.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.G921V (Missense)		BLCA_VARSCAN2	TCGA-GU-A767-01A-11D-A32B-08	TCGA-GU-A767-10A-01D-A329-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.S328C	0.25	48.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.S328C (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA54-01A-11D-A391-08	TCGA-ZF-AA54-10A-01D-A394-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S37C	0.3462	26.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S37C (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T2-01A-11D-A42E-08	TCGA-XF-A9T2-10A-01D-A42H-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S60F	0.5366	41.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S60F (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T2-01A-11D-A42E-08	TCGA-XF-A9T2-10A-01D-A42H-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Nonsense	p.K834*	0.5	42.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.K834* (Nonsense)		BLCA_VARSCAN2	TCGA-C4-A0F1-01A-11D-A10S-08	TCGA-C4-A0F1-10A-01D-A10S-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Nonsense	p.L1088*	0.3962	53.0	0.0	0.0																Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK2 p.L1088* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Nonsense	p.E667*	0.9688	32.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.E667* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Frameshift	p.N214Kfs*2	0.3636	22.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.N214Kfs*2 (Frameshift)		BLCA_VARSCAN2	TCGA-ZF-AA53-01A-11D-A391-08	TCGA-ZF-AA53-10A-01D-A394-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S33F	0.4	45.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S33F (Missense)		BLCA_VARSCAN2	TCGA-FJ-A871-01A-11D-A34U-08	TCGA-FJ-A871-10A-01D-A34X-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.S45F	0.3704	27.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.S45F (Missense)		BLCA_VARSCAN2	TCGA-XF-AAMH-01A-11D-A42E-08	TCGA-XF-AAMH-10A-01D-A42H-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Frameshift	p.Q603Pfs*25	0.5	92.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.Q603Pfs*25 (Frameshift)		BLCA_VARSCAN2	TCGA-E7-A5KE-01A-11D-A289-08	TCGA-E7-A5KE-10A-01D-A289-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.E820K	0.4848	33.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.E820K (Missense)		BLCA_VARSCAN2	TCGA-FD-A3NA-01A-11D-A21A-08	TCGA-FD-A3NA-10A-01D-A21A-08
Investigate Actionability			Clinical evidence	Somatic Variant	MC1R	Missense	p.F257L	0.1562	64.0	0.0	0.0																Investigate Actionability	0	The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).	Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;	https://doi.org/10.1111/pcmr.12516					MC1R p.F257L (Missense)		BLCA_VARSCAN2	TCGA-FD-A43P-01A-31D-A23U-08	TCGA-FD-A43P-10A-01D-A23U-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.R61K	0.3509	57.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.R61K (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN0-01A-11D-A42E-08	TCGA-XF-AAN0-10A-01D-A42H-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.T41A	0.4694	49.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.T41A (Missense)		BLCA_VARSCAN2	TCGA-E7-A677-01A-11D-A30E-08	TCGA-E7-A677-10A-01D-A30H-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.R343C	0.3333	21.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.R343C (Missense)		BLCA_VARSCAN2	TCGA-2F-A9KT-01A-11D-A38G-08	TCGA-2F-A9KT-10A-01D-A38J-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.D699H	0.2763	152.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.D699H (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AV-01A-12D-A30E-08	TCGA-DK-A6AV-10A-01D-A30H-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.K653M	0.4737	38.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.K653M (Missense)		BLCA_VARSCAN2	TCGA-FD-A3N6-01A-11D-A21A-08	TCGA-FD-A3N6-10A-01D-A21A-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.E1157K	0.4333	90.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.E1157K (Missense)		BLCA_VARSCAN2	TCGA-K4-A5RH-01A-11D-A30E-08	TCGA-K4-A5RH-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.H798Y	0.1562	32.0	0.0	0.0																									FGFR1 p.H798Y (Missense)		BLCA_VARSCAN2	TCGA-E7-A4IJ-01A-31D-A26M-08	TCGA-E7-A4IJ-10A-01D-A26K-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.L87M	0.431	58.0	0.0	0.0																									PDGFRB p.L87M (Missense)		BLCA_VARSCAN2	TCGA-DK-AA77-01A-11D-A391-08	TCGA-DK-AA77-10A-01D-A394-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.P314S	0.375	16.0	0.0	0.0																									FLI1 p.P314S (Missense)		BLCA_VARSCAN2	TCGA-DK-AA77-01A-11D-A391-08	TCGA-DK-AA77-10A-01D-A394-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.R22Q	0.3281	64.0	0.0	0.0																									FGFR2 p.R22Q (Missense)		BLCA_VARSCAN2	TCGA-DK-A2HX-01A-12D-A18F-08	TCGA-DK-A2HX-10A-01D-A18F-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.K30N	0.3077	130.0	0.0	0.0																									MTOR p.K30N (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TA-01A-12D-A339-08	TCGA-FD-A6TA-10A-21D-A339-08
Biologically Relevant				Somatic Variant	MLH1	Splice Site	p.X70_splice	0.2353	34.0	0.0	0.0																									MLH1 p.X70_splice (Splice Site)		BLCA_VARSCAN2	TCGA-FD-A6TA-01A-12D-A339-08	TCGA-FD-A6TA-10A-21D-A339-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.S139W	0.25	32.0	0.0	0.0																									MYC p.S139W (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TA-01A-12D-A339-08	TCGA-FD-A6TA-10A-21D-A339-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.P112L	0.4211	19.0	0.0	0.0																									FLI1 p.P112L (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TA-01A-12D-A339-08	TCGA-FD-A6TA-10A-21D-A339-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.T731M	0.466	103.0	0.0	0.0																									NTRK2 p.T731M (Missense)		BLCA_VARSCAN2	TCGA-CF-A47Y-01A-11D-A23U-08	TCGA-CF-A47Y-10A-01D-A23U-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X51_splice	0.7	20.0	0.0	0.0																									CDKN2A p.X51_splice (Splice Site)		BLCA_VARSCAN2	TCGA-ZF-AA4N-01A-11D-A38G-08	TCGA-ZF-AA4N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.D236N	0.4194	62.0	0.0	0.0																									KEAP1 p.D236N (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4N-01A-11D-A38G-08	TCGA-ZF-AA4N-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.E61K	0.3077	26.0	0.0	0.0																									CDKN2A p.E61K (Missense)		BLCA_VARSCAN2	TCGA-K4-A54R-01A-11D-A26M-08	TCGA-K4-A54R-10A-01D-A26K-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.E523K	0.2239	134.0	0.0	0.0																									BRD4 p.E523K (Missense)		BLCA_VARSCAN2	TCGA-K4-A54R-01A-11D-A26M-08	TCGA-K4-A54R-10A-01D-A26K-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.E244K	0.2333	60.0	0.0	0.0																									KEAP1 p.E244K (Missense)		BLCA_VARSCAN2	TCGA-G2-A3IE-01A-11D-A20D-08	TCGA-G2-A3IE-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.E27Q	0.3036	56.0	0.0	0.0																									ERG p.E27Q (Missense)		BLCA_VARSCAN2	TCGA-G2-A3IE-01A-11D-A20D-08	TCGA-G2-A3IE-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.E734K	0.3636	66.0	0.0	0.0																									TACC3 p.E734K (Missense)		BLCA_VARSCAN2	TCGA-XF-AAMG-01A-11D-A42E-08	TCGA-XF-AAMG-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.S225L	0.1304	69.0	0.0	0.0																									RUNX1T1 p.S225L (Missense)		BLCA_VARSCAN2	TCGA-XF-AAMG-01A-11D-A42E-08	TCGA-XF-AAMG-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.R163K	0.3182	44.0	0.0	0.0																									CDK4 p.R163K (Missense)		BLCA_VARSCAN2	TCGA-XF-AAMG-01A-11D-A42E-08	TCGA-XF-AAMG-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R2119T	0.54	100.0	0.0	0.0																									NF1 p.R2119T (Missense)		BLCA_VARSCAN2	TCGA-XF-AAMG-01A-11D-A42E-08	TCGA-XF-AAMG-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.E2193K	0.56	75.0	0.0	0.0																									NF1 p.E2193K (Missense)		BLCA_VARSCAN2	TCGA-XF-AAMG-01A-11D-A42E-08	TCGA-XF-AAMG-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	NF1	Splice Site	p.X2235_splice	0.5429	105.0	0.0	0.0																									NF1 p.X2235_splice (Splice Site)		BLCA_VARSCAN2	TCGA-XF-AAMG-01A-11D-A42E-08	TCGA-XF-AAMG-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.E119K	0.4	35.0	0.0	0.0																									CDKN2A p.E119K (Missense)		BLCA_VARSCAN2	TCGA-G2-A2EO-01A-11D-A17V-08	TCGA-G2-A2EO-11A-21D-A17V-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.D108N	0.3704	27.0	0.0	0.0																									CDKN2A p.D108N (Missense)		BLCA_VARSCAN2	TCGA-G2-A2EO-01A-11D-A17V-08	TCGA-G2-A2EO-11A-21D-A17V-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.S666C	0.128	125.0	0.0	0.0																									NF1 p.S666C (Missense)		BLCA_VARSCAN2	TCGA-G2-A2EO-01A-11D-A17V-08	TCGA-G2-A2EO-11A-21D-A17V-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.E1238K	0.52	25.0	0.0	0.0																									BRD4 p.E1238K (Missense)		BLCA_VARSCAN2	TCGA-G2-A2EO-01A-11D-A17V-08	TCGA-G2-A2EO-11A-21D-A17V-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L199F	0.1061	66.0	0.0	0.0																									ROS1 p.L199F (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RG-01A-21D-A42E-08	TCGA-ZF-A9RG-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.G281S	0.2791	86.0	0.0	0.0																									RUNX1T1 p.G281S (Missense)		BLCA_VARSCAN2	TCGA-UY-A8OD-01A-11D-A364-08	TCGA-UY-A8OD-10A-01D-A362-08
Biologically Relevant				Somatic Variant	RB1	Frameshift		0.2571	35.0	0.0	0.0																									RB1  (Frameshift)		BLCA_VARSCAN2	TCGA-XF-A9SX-01A-21D-A391-08	TCGA-XF-A9SX-10A-01D-A394-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.H83Y	0.4062	32.0	0.0	0.0																									CDKN2A p.H83Y (Missense)		BLCA_VARSCAN2	TCGA-GV-A40E-01A-12D-A23M-08	TCGA-GV-A40E-10A-01D-A23K-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X775_splice	0.4737	19.0	0.0	0.0																									RB1 p.X775_splice (Splice Site)		BLCA_VARSCAN2	TCGA-ZF-AA5H-01A-11D-A391-08	TCGA-ZF-AA5H-10A-01D-A394-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.K765*	0.2857	28.0	0.0	0.0																									RB1 p.K765* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A3B7-01A-31D-A20D-08	TCGA-FD-A3B7-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.S232Y	0.1493	67.0	0.0	0.0																									TMPRSS2 p.S232Y (Missense)		BLCA_VARSCAN2	TCGA-CF-A3MG-01A-11D-A20D-08	TCGA-CF-A3MG-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.E490K	0.3778	45.0	0.0	0.0																									PDGFRB p.E490K (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA84-01A-11D-A391-08	TCGA-4Z-AA84-10A-01D-A394-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.R24G	0.5429	35.0	0.0	0.0																									CDKN2A p.R24G (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA84-01A-11D-A391-08	TCGA-4Z-AA84-10A-01D-A394-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q1010*	0.6333	30.0	0.0	0.0																									NF1 p.Q1010* (Nonsense)		BLCA_VARSCAN2	TCGA-4Z-AA84-01A-11D-A391-08	TCGA-4Z-AA84-10A-01D-A394-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.E106K	0.6667	27.0	0.0	0.0																									LIMK2 p.E106K (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA84-01A-11D-A391-08	TCGA-4Z-AA84-10A-01D-A394-08
Biologically Relevant				Somatic Variant	CCND1	Missense	p.P287R	0.3158	19.0	0.0	0.0																									CCND1 p.P287R (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TD-01A-51D-A339-08	TCGA-FD-A6TD-10A-21D-A339-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.T778Lfs*33	0.2763	152.0	0.0	0.0																									RB1 p.T778Lfs*33 (Frameshift)		BLCA_VARSCAN2	TCGA-FD-A6TD-01A-51D-A339-08	TCGA-FD-A6TD-10A-21D-A339-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R135L	0.5735	68.0	0.0	0.0																									NF1 p.R135L (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6W-01A-12D-A391-08	TCGA-DK-AA6W-10A-01D-A394-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.E684G	0.4634	41.0	0.0	0.0																									COL1A1 p.E684G (Missense)		BLCA_VARSCAN2	TCGA-FJ-A3ZE-01A-11D-A23M-08	TCGA-FJ-A3ZE-10A-01D-A23K-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.R252L	0.5385	26.0	0.0	0.0																									TMPRSS2 p.R252L (Missense)		BLCA_VARSCAN2	TCGA-FJ-A3ZE-01A-11D-A23M-08	TCGA-FJ-A3ZE-10A-01D-A23K-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.8	10.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A6TI-01A-11D-A32B-08	TCGA-FD-A6TI-10A-01D-A329-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X703_splice	0.1053	76.0	0.0	0.0																									RB1 p.X703_splice (Splice Site)		BLCA_VARSCAN2	TCGA-XF-A9SI-01A-11D-A391-08	TCGA-XF-A9SI-10A-01D-A394-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.Q770*	0.2955	44.0	0.0	0.0																									RB1 p.Q770* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-AA58-01A-12D-A42E-08	TCGA-ZF-AA58-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X406_splice	0.8611	72.0	0.0	0.0																									RB1 p.X406_splice (Splice Site)		BLCA_VARSCAN2	TCGA-E5-A4TZ-01A-11D-A31L-08	TCGA-E5-A4TZ-10B-01D-A31J-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R255*	0.7586	29.0	0.0	0.0																									RB1 p.R255* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-AA6T-01A-11D-A391-08	TCGA-DK-AA6T-10A-01D-A394-08
Biologically Relevant				Somatic Variant	NTRK3	Nonsense	p.S477*	0.2941	17.0	0.0	0.0																									NTRK3 p.S477* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A3IT-01A-31D-A20D-08	TCGA-DK-A3IT-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.D108N	0.5	22.0	0.0	0.0																									CDKN2A p.D108N (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6S-01A-21D-A391-08	TCGA-DK-AA6S-10A-01D-A394-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.L31V	0.4783	46.0	0.0	0.0																									CDKN2A p.L31V (Missense)		BLCA_VARSCAN2	TCGA-G2-A3VY-01A-11D-A22Z-08	TCGA-G2-A3VY-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.T1589Rfs*2	0.1485	101.0	0.0	0.0																									NF1 p.T1589Rfs*2 (Frameshift)		BLCA_VARSCAN2	TCGA-G2-A3VY-01A-11D-A22Z-08	TCGA-G2-A3VY-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.S780*	0.4159	113.0	0.0	0.0																									RB1 p.S780* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A3IN-01A-11D-A20D-08	TCGA-DK-A3IN-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.Q395Tfs*11	0.3191	47.0	0.0	0.0																									RB1 p.Q395Tfs*11 (Frameshift)		BLCA_VARSCAN2	TCGA-KQ-A41Q-01A-11D-A339-08	TCGA-KQ-A41Q-10D-01D-A339-08
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.R200Q	0.25	64.0	0.0	0.0																									PDGFB p.R200Q (Missense)		BLCA_VARSCAN2	TCGA-CF-A9FH-01A-11D-A38G-08	TCGA-CF-A9FH-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.M708Kfs*2	0.175	40.0	0.0	0.0																									RB1 p.M708Kfs*2 (Frameshift)		BLCA_VARSCAN2	TCGA-GC-A3YS-01A-11D-A23M-08	TCGA-GC-A3YS-10A-01D-A23K-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.L191*	0.1163	43.0	0.0	0.0																									RB1 p.L191* (Frameshift)		BLCA_VARSCAN2	TCGA-XF-A9SZ-01A-11D-A391-08	TCGA-XF-A9SZ-10A-01D-A394-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R445*	0.1622	37.0	0.0	0.0																									RB1 p.R445* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-A9SZ-01A-11D-A391-08	TCGA-XF-A9SZ-10A-01D-A394-08
Biologically Relevant				Somatic Variant	CD274	Missense	p.R260H	0.2143	56.0	0.0	0.0																									CD274 p.R260H (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RN-01A-11D-A42E-08	TCGA-ZF-A9RN-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	PMS2	Nonsense	p.S270*	0.1884	69.0	0.0	0.0																									PMS2 p.S270* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-A9R9-01A-11D-A38G-08	TCGA-ZF-A9R9-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	FLI1	Nonsense	p.W321*	0.2273	22.0	0.0	0.0																									FLI1 p.W321* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-A9R9-01A-11D-A38G-08	TCGA-ZF-A9R9-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.D86N	0.4048	42.0	0.0	0.0																									TACC3 p.D86N (Missense)		BLCA_VARSCAN2	TCGA-CF-A47X-01A-31D-A23U-08	TCGA-CF-A47X-10A-01D-A23U-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.K346N	0.403	67.0	0.0	0.0																									BRD4 p.K346N (Missense)		BLCA_VARSCAN2	TCGA-CF-A47X-01A-31D-A23U-08	TCGA-CF-A47X-10A-01D-A23U-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.G64A	0.1964	56.0	0.0	0.0																									POT1 p.G64A (Missense)		BLCA_VARSCAN2	TCGA-UY-A9PD-01A-11D-A38G-08	TCGA-UY-A9PD-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	AURKB	Missense	p.I259T	0.2449	49.0	0.0	0.0																									AURKB p.I259T (Missense)		BLCA_VARSCAN2	TCGA-UY-A9PD-01A-11D-A38G-08	TCGA-UY-A9PD-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.K659N	0.2963	81.0	0.0	0.0																									FGFR2 p.K659N (Missense)		BLCA_VARSCAN2	TCGA-DK-AA76-01A-11D-A391-08	TCGA-DK-AA76-10A-01D-A394-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.N188T	0.1053	57.0	0.0	0.0																									NTRK2 p.N188T (Missense)		BLCA_VARSCAN2	TCGA-XF-A9SJ-01A-11D-A391-08	TCGA-XF-A9SJ-10A-01D-A394-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.E746*	0.64	25.0	0.0	0.0																									RB1 p.E746* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-A9SJ-01A-11D-A391-08	TCGA-XF-A9SJ-10A-01D-A394-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.E51*	0.2368	38.0	0.0	0.0																									RB1 p.E51* (Nonsense)		BLCA_VARSCAN2	TCGA-GC-A4ZW-01A-11D-A26M-08	TCGA-GC-A4ZW-10A-01D-A26K-08
Biologically Relevant				Somatic Variant	NTRK2	Frameshift	p.I396Kfs*41	0.4167	24.0	0.0	0.0																									NTRK2 p.I396Kfs*41 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A3IL-01A-11D-A20D-08	TCGA-DK-A3IL-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R552*	0.4146	41.0	0.0	0.0																									RB1 p.R552* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A3IL-01A-11D-A20D-08	TCGA-DK-A3IL-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.E413Q	0.8288	111.0	0.0	0.0																									RB1 p.E413Q (Missense)		BLCA_VARSCAN2	TCGA-E7-A7PW-01A-11D-A34U-08	TCGA-E7-A7PW-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	PAK1	Missense	p.E315K	0.1923	130.0	0.0	0.0																									PAK1 p.E315K (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T8-01A-11D-A391-08	TCGA-XF-A9T8-10A-01D-A394-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.G893A	0.3333	12.0	0.0	0.0																									RB1 p.G893A (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T8-01A-11D-A391-08	TCGA-XF-A9T8-10A-01D-A394-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.V794L	0.283	106.0	0.0	0.0																									ROS1 p.V794L (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA83-01A-11D-A391-08	TCGA-4Z-AA83-10A-01D-A394-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.F989L	0.3684	38.0	0.0	0.0																									MTOR p.F989L (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RF-01A-11D-A38G-08	TCGA-ZF-A9RF-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	EPCAM	Missense	p.K229N	0.1928	83.0	0.0	0.0																									EPCAM p.K229N (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RF-01A-11D-A38G-08	TCGA-ZF-A9RF-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.D604G	0.3182	44.0	0.0	0.0																									RB1 p.D604G (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RF-01A-11D-A38G-08	TCGA-ZF-A9RF-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q1341*	0.2432	148.0	0.0	0.0																									NF1 p.Q1341* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-A9RF-01A-11D-A38G-08	TCGA-ZF-A9RF-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.T1730Pfs*4	0.3506	77.0	0.0	0.0																									NF1 p.T1730Pfs*4 (Frameshift)		BLCA_VARSCAN2	TCGA-ZF-A9RF-01A-11D-A38G-08	TCGA-ZF-A9RF-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.Q217*	0.6528	72.0	0.0	0.0																									RB1 p.Q217* (Nonsense)		BLCA_VARSCAN2	TCGA-PQ-A6FI-01A-11D-A31L-08	TCGA-PQ-A6FI-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.R886Q	0.4444	27.0	0.0	0.0																									BRD4 p.R886Q (Missense)		BLCA_VARSCAN2	TCGA-PQ-A6FI-01A-11D-A31L-08	TCGA-PQ-A6FI-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.E594G	0.4815	27.0	0.0	0.0																									PDGFRB p.E594G (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AD-01A-11D-A13W-08	TCGA-DK-A1AD-10A-01D-A13W-08
Biologically Relevant				Somatic Variant	AURKA	Missense	p.L323F	0.2564	117.0	0.0	0.0																									AURKA p.L323F (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AD-01A-11D-A13W-08	TCGA-DK-A1AD-10A-01D-A13W-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X376_splice	0.3333	93.0	0.0	0.0																									RB1 p.X376_splice (Splice Site)		BLCA_VARSCAN2	TCGA-FD-A6TF-01A-52D-A32B-08	TCGA-FD-A6TF-10A-21D-A329-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.D284N	0.3158	19.0	0.0	0.0																									POT1 p.D284N (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TE-01A-12D-A339-08	TCGA-FD-A6TE-10A-21D-A339-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R455*	0.7895	19.0	0.0	0.0																									RB1 p.R455* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A6TE-01A-12D-A339-08	TCGA-FD-A6TE-10A-21D-A339-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.Q123E	0.1765	68.0	0.0	0.0																									BRD4 p.Q123E (Missense)		BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.D368H	0.1635	159.0	0.0	0.0																									CCNE1 p.D368H (Missense)		BLCA_VARSCAN2	TCGA-SY-A9G5-01A-11D-A38G-08	TCGA-SY-A9G5-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S2326F	0.375	64.0	0.0	0.0																									ROS1 p.S2326F (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T5-01A-11D-A42E-08	TCGA-XF-A9T5-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	CD274	Missense	p.I137M	0.1807	83.0	0.0	0.0																									CD274 p.I137M (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T5-01A-11D-A42E-08	TCGA-XF-A9T5-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R244C	0.1429	42.0	0.0	0.0																									COL1A1 p.R244C (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T5-01A-11D-A42E-08	TCGA-XF-A9T5-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.D232N	0.2029	69.0	0.0	0.0																									COL1A1 p.D232N (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T5-01A-11D-A42E-08	TCGA-XF-A9T5-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.E1113K	0.2083	24.0	0.0	0.0																									BRD4 p.E1113K (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T5-01A-11D-A42E-08	TCGA-XF-A9T5-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	KEAP1	Splice Site	p.X570_splice	0.4667	75.0	0.0	0.0																									KEAP1 p.X570_splice (Splice Site)		BLCA_VARSCAN2	TCGA-CU-A0YR-01A-12D-A10S-08	TCGA-CU-A0YR-10A-01D-A10S-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.Q275K	0.3938	160.0	0.0	0.0																									TPX2 p.Q275K (Missense)		BLCA_VARSCAN2	TCGA-FJ-A3Z9-01A-11D-A26M-08	TCGA-FJ-A3Z9-10A-01D-A26K-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.E691*	0.2373	59.0	0.0	0.0																									RB1 p.E691* (Nonsense)		BLCA_VARSCAN2	TCGA-K4-A5RJ-01A-11D-A289-08	TCGA-K4-A5RJ-10A-01D-A289-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.M53I	0.3008	236.0	0.0	0.0																									SLC45A3 p.M53I (Missense)		BLCA_VARSCAN2	TCGA-BT-A2LB-01A-11D-A18F-08	TCGA-BT-A2LB-10A-01D-A18F-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.I1051V	0.56	25.0	0.0	0.0																									ROS1 p.I1051V (Missense)		BLCA_VARSCAN2	TCGA-BT-A2LB-01A-11D-A18F-08	TCGA-BT-A2LB-10A-01D-A18F-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.V529M	0.1375	80.0	0.0	0.0																									POT1 p.V529M (Missense)		BLCA_VARSCAN2	TCGA-BT-A2LB-01A-11D-A18F-08	TCGA-BT-A2LB-10A-01D-A18F-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q2531*	0.2162	37.0	0.0	0.0																									NF1 p.Q2531* (Nonsense)		BLCA_VARSCAN2	TCGA-BT-A2LB-01A-11D-A18F-08	TCGA-BT-A2LB-10A-01D-A18F-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.R857Qfs*5	0.1628	43.0	0.0	0.0																									RB1 p.R857Qfs*5 (Frameshift)		BLCA_VARSCAN2	TCGA-GU-A764-01A-11D-A34U-08	TCGA-GU-A764-10B-01D-A34X-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.S829*	0.2745	51.0	0.0	0.0																									RB1 p.S829* (Nonsense)		BLCA_VARSCAN2	TCGA-4Z-AA86-01A-11D-A391-08	TCGA-4Z-AA86-10A-01D-A394-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X445_splice	0.5636	55.0	0.0	0.0																									RB1 p.X445_splice (Splice Site)		BLCA_VARSCAN2	TCGA-XF-A9T6-01A-11D-A42E-08	TCGA-XF-A9T6-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.S71C	0.4194	31.0	0.0	0.0																									TACC3 p.S71C (Missense)		BLCA_VARSCAN2	TCGA-KQ-A41N-01A-11D-A339-08	TCGA-KQ-A41N-10D-01D-A339-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.S203L	0.4302	172.0	0.0	0.0																									BRD4 p.S203L (Missense)		BLCA_VARSCAN2	TCGA-KQ-A41N-01A-11D-A339-08	TCGA-KQ-A41N-10D-01D-A339-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.H83Y	0.5833	12.0	0.0	0.0																									CDKN2A p.H83Y (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN3-01A-11D-A42E-08	TCGA-XF-AAN3-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.I374T	0.1852	27.0	0.0	0.0																									ROS1 p.I374T (Missense)		BLCA_VARSCAN2	TCGA-E7-A6ME-01A-22D-A32B-08	TCGA-E7-A6ME-10B-01D-A329-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.C489Vfs*4	0.5833	12.0	0.0	0.0																									RB1 p.C489Vfs*4 (Frameshift)		BLCA_VARSCAN2	TCGA-E7-A6ME-01A-22D-A32B-08	TCGA-E7-A6ME-10B-01D-A329-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.E79Rfs*32	0.2162	74.0	0.0	0.0																									RB1 p.E79Rfs*32 (Frameshift)		BLCA_VARSCAN2	TCGA-4Z-AA81-01A-11D-A391-08	TCGA-4Z-AA81-10A-01D-A394-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.E864*	0.274	73.0	0.0	0.0																									RB1 p.E864* (Nonsense)		BLCA_VARSCAN2	TCGA-4Z-AA81-01A-11D-A391-08	TCGA-4Z-AA81-10A-01D-A394-08
Biologically Relevant				Somatic Variant	MDM2	Missense	p.S246L	0.3286	70.0	0.0	0.0																									MDM2 p.S246L (Missense)		BLCA_VARSCAN2	TCGA-XF-A9ST-01A-11D-A42E-08	TCGA-XF-A9ST-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.A74Efs*4	0.8113	53.0	0.0	0.0																									RB1 p.A74Efs*4 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-A9ST-01A-11D-A42E-08	TCGA-XF-A9ST-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G596A	0.6364	11.0	0.0	0.0																									COL1A1 p.G596A (Missense)		BLCA_VARSCAN2	TCGA-XF-A9ST-01A-11D-A42E-08	TCGA-XF-A9ST-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G263A	0.425	40.0	0.0	0.0																									COL1A1 p.G263A (Missense)		BLCA_VARSCAN2	TCGA-XF-A9ST-01A-11D-A42E-08	TCGA-XF-A9ST-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X840_splice	0.4247	73.0	0.0	0.0																									RB1 p.X840_splice (Splice Site)		BLCA_VARSCAN2	TCGA-UY-A78L-01A-12D-A339-08	TCGA-UY-A78L-10A-01D-A339-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1053R	0.1791	67.0	0.0	0.0																									ROS1 p.P1053R (Missense)		BLCA_VARSCAN2	TCGA-FJ-A3ZF-01A-11D-A23M-08	TCGA-FJ-A3ZF-10A-01D-A23K-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P48L	0.4574	129.0	0.0	0.0																									CDKN2A p.P48L (Missense)		BLCA_VARSCAN2	TCGA-YC-A89H-01A-11D-A364-08	TCGA-YC-A89H-10A-01D-A362-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.F741L	0.3265	98.0	0.0	0.0																									NF1 p.F741L (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T0-01A-11D-A391-08	TCGA-XF-A9T0-10A-01D-A394-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.I392F	0.2444	45.0	0.0	0.0																									LIMK2 p.I392F (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T0-01A-11D-A391-08	TCGA-XF-A9T0-10A-01D-A394-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.8	15.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		BLCA_VARSCAN2	TCGA-GD-A3OS-01A-12D-A21Z-08	TCGA-GD-A3OS-10A-01D-A21Z-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P223R	0.2188	160.0	0.0	0.0																									COL1A1 p.P223R (Missense)		BLCA_VARSCAN2	TCGA-BT-A20Q-01A-11D-A14W-08	TCGA-BT-A20Q-11A-11D-A14W-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.K844*	0.5556	9.0	0.0	0.0																									RB1 p.K844* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A3N5-01A-11D-A21A-08	TCGA-FD-A3N5-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.S303L	0.1607	56.0	0.0	0.0																									POT1 p.S303L (Missense)		BLCA_VARSCAN2	TCGA-E7-A7XN-01A-11D-A34U-08	TCGA-E7-A7XN-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.F31L	0.1909	241.0	0.0	0.0																									POT1 p.F31L (Missense)		BLCA_VARSCAN2	TCGA-E7-A7XN-01A-11D-A34U-08	TCGA-E7-A7XN-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.L78Hfs*41	0.303	33.0	0.0	0.0																									CDKN2A p.L78Hfs*41 (Frameshift)		BLCA_VARSCAN2	TCGA-E7-A7XN-01A-11D-A34U-08	TCGA-E7-A7XN-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.M620I	0.1463	41.0	0.0	0.0																									NTRK2 p.M620I (Missense)		BLCA_VARSCAN2	TCGA-E7-A7XN-01A-11D-A34U-08	TCGA-E7-A7XN-10A-01D-A34X-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.E2049Q	0.5087	173.0	0.0	0.0																									MTOR p.E2049Q (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R4-01A-11D-A38G-08	TCGA-ZF-A9R4-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.E2015Q	0.461	154.0	0.0	0.0																									MTOR p.E2015Q (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R4-01A-11D-A38G-08	TCGA-ZF-A9R4-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.D108N	0.3929	28.0	0.0	0.0																									CDKN2A p.D108N (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R4-01A-11D-A38G-08	TCGA-ZF-A9R4-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.V82M	0.4737	19.0	0.0	0.0																									CDKN2A p.V82M (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R4-01A-11D-A38G-08	TCGA-ZF-A9R4-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.P48Sfs*4	0.1301	146.0	0.0	0.0																									CDKN2A p.P48Sfs*4 (Frameshift)		BLCA_VARSCAN2	TCGA-ZF-A9R4-01A-11D-A38G-08	TCGA-ZF-A9R4-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CDKN2A	Deletion	p.A40_Y44del	0.1915	94.0	0.0	0.0																									CDKN2A p.A40_Y44del (Deletion)		BLCA_VARSCAN2	TCGA-ZF-A9R4-01A-11D-A38G-08	TCGA-ZF-A9R4-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.E360K	0.875	56.0	0.0	0.0																									NTRK3 p.E360K (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R4-01A-11D-A38G-08	TCGA-ZF-A9R4-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.G485A	0.6429	70.0	0.0	0.0																									FGFR1 p.G485A (Missense)		BLCA_VARSCAN2	TCGA-HQ-A2OE-01A-11D-A202-08	TCGA-HQ-A2OE-10A-01D-A202-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.E173K	0.1273	110.0	0.0	0.0																									POT1 p.E173K (Missense)		BLCA_VARSCAN2	TCGA-GD-A3OP-01A-21D-A21Z-08	TCGA-GD-A3OP-10A-01D-A21Z-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.L417V	0.2969	64.0	0.0	0.0																									LIMK2 p.L417V (Missense)		BLCA_VARSCAN2	TCGA-HQ-A2OF-01A-11D-A26M-08	TCGA-HQ-A2OF-10B-01D-A26K-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.P413L	0.2	95.0	0.0	0.0																									FGFR2 p.P413L (Missense)		BLCA_VARSCAN2	TCGA-FD-A3B5-01A-11D-A20D-08	TCGA-FD-A3B5-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G1556R	0.2838	74.0	0.0	0.0																									ROS1 p.G1556R (Missense)		BLCA_VARSCAN2	TCGA-XF-AAMT-01A-11D-A42E-08	TCGA-XF-AAMT-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.S834*	0.8393	56.0	0.0	0.0																									RB1 p.S834* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-AAN7-01A-11D-A42E-08	TCGA-XF-AAN7-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.A102Rfs*14	0.3077	13.0	0.0	0.0																									CDKN2A p.A102Rfs*14 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-AA6Q-01A-11D-A391-08	TCGA-DK-AA6Q-10A-01D-A394-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.Q504*	0.5	8.0	0.0	0.0																									RB1 p.Q504* (Nonsense)		BLCA_VARSCAN2	TCGA-BL-A3JM-01A-12D-A21A-08	TCGA-BL-A3JM-11A-31D-A21A-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.S116C	0.76	50.0	0.0	0.0																									TMPRSS2 p.S116C (Missense)		BLCA_VARSCAN2	TCGA-BL-A3JM-01A-12D-A21A-08	TCGA-BL-A3JM-11A-31D-A21A-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.R717Q	0.3	80.0	0.0	0.0																									MTOR p.R717Q (Missense)		BLCA_VARSCAN2	TCGA-BT-A20R-01A-12D-A16O-08	TCGA-BT-A20R-11A-11D-A16O-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.Q62*	0.1875	32.0	0.0	0.0																									RB1 p.Q62* (Nonsense)		BLCA_VARSCAN2	TCGA-BT-A20R-01A-12D-A16O-08	TCGA-BT-A20R-11A-11D-A16O-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.D609N	0.1176	51.0	0.0	0.0																									NTRK3 p.D609N (Missense)		BLCA_VARSCAN2	TCGA-BT-A20R-01A-12D-A16O-08	TCGA-BT-A20R-11A-11D-A16O-08
Biologically Relevant				Somatic Variant	EPCAM	Missense	p.E101Q	0.3143	35.0	0.0	0.0																									EPCAM p.E101Q (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R7-01A-11D-A38G-08	TCGA-ZF-A9R7-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.G50R	0.3188	552.0	0.0	0.0																									PMS2 p.G50R (Missense)		BLCA_VARSCAN2	TCGA-GU-A42R-01A-11D-A23M-08	TCGA-GU-A42R-10A-01D-A23K-08
Biologically Relevant				Somatic Variant	RB1	Deletion	p.Y454del	0.5789	19.0	0.0	0.0																									RB1 p.Y454del (Deletion)		BLCA_VARSCAN2	TCGA-DK-AA6M-01A-11D-A391-08	TCGA-DK-AA6M-10A-01D-A394-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.N328*	0.8571	28.0	0.0	0.0																									RB1 p.N328* (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A3X2-01A-11D-A22Z-08	TCGA-DK-A3X2-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.E492Lfs*4	0.3529	34.0	0.0	0.0																									RB1 p.E492Lfs*4 (Frameshift)		BLCA_VARSCAN2	TCGA-ZF-AA4T-01A-11D-A38G-08	TCGA-ZF-AA4T-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L836V	0.7692	39.0	0.0	0.0																									ROS1 p.L836V (Missense)		BLCA_VARSCAN2	TCGA-2F-A9KQ-01A-11D-A38G-08	TCGA-2F-A9KQ-11A-11D-A38J-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.E2501*	0.1379	87.0	0.0	0.0																									NF1 p.E2501* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-AA6P-01A-11D-A391-08	TCGA-DK-AA6P-10A-01D-A394-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.M537I	0.2143	56.0	0.0	0.0																									FGFR2 p.M537I (Missense)		BLCA_VARSCAN2	TCGA-FD-A5BZ-01A-11D-A289-08	TCGA-FD-A5BZ-10A-01D-A289-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.K254N	0.4474	38.0	0.0	0.0																									MLH1 p.K254N (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SM-01A-11D-A22Z-08	TCGA-FD-A3SM-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.A140T	0.26	100.0	0.0	0.0																									POT1 p.A140T (Missense)		BLCA_VARSCAN2	TCGA-YF-AA3L-01A-11D-A38G-08	TCGA-YF-AA3L-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X405_splice	0.1132	212.0	0.0	0.0																									RB1 p.X405_splice (Splice Site)		BLCA_VARSCAN2	TCGA-CU-A0YN-01A-21D-A10S-08	TCGA-CU-A0YN-11A-11D-A10S-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X605_splice	0.3364	107.0	0.0	0.0																									RB1 p.X605_splice (Splice Site)		BLCA_VARSCAN2	TCGA-CU-A0YN-01A-21D-A10S-08	TCGA-CU-A0YN-11A-11D-A10S-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.Y728Sfs*19	0.5435	46.0	0.0	0.0																									RB1 p.Y728Sfs*19 (Frameshift)		BLCA_VARSCAN2	TCGA-FD-A6TH-01A-11D-A32B-08	TCGA-FD-A6TH-10A-01D-A329-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.Q384H	0.4796	98.0	0.0	0.0																									ESRP1 p.Q384H (Missense)		BLCA_VARSCAN2	TCGA-BT-A3PH-01A-11D-A21Z-08	TCGA-BT-A3PH-10A-01D-A21Z-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.G865V	0.375	120.0	0.0	0.0																									RB1 p.G865V (Missense)		BLCA_VARSCAN2	TCGA-BT-A3PH-01A-11D-A21Z-08	TCGA-BT-A3PH-10A-01D-A21Z-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q756*	0.9053	190.0	0.0	0.0																									NF1 p.Q756* (Nonsense)		BLCA_VARSCAN2	TCGA-BT-A3PH-01A-11D-A21Z-08	TCGA-BT-A3PH-10A-01D-A21Z-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.D515N	0.1569	102.0	0.0	0.0																									ESRP1 p.D515N (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7R-01A-11D-A391-08	TCGA-4Z-AA7R-10A-01D-A394-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.D108Y	0.8571	35.0	0.0	0.0																									CDKN2A p.D108Y (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7R-01A-11D-A391-08	TCGA-4Z-AA7R-10A-01D-A394-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.D84N	0.9474	19.0	0.0	0.0																									CDKN2A p.D84N (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7R-01A-11D-A391-08	TCGA-4Z-AA7R-10A-01D-A394-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.M385V	0.1158	95.0	0.0	0.0																									ERG p.M385V (Missense)		BLCA_VARSCAN2	TCGA-BT-A20O-01A-21D-A14W-08	TCGA-BT-A20O-11A-11D-A14W-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.R563C	0.1081	37.0	0.0	0.0																									EWSR1 p.R563C (Missense)		BLCA_VARSCAN2	TCGA-BT-A20O-01A-21D-A14W-08	TCGA-BT-A20O-11A-11D-A14W-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.G455E	0.2439	123.0	0.0	0.0																									NF1 p.G455E (Missense)		BLCA_VARSCAN2	TCGA-DK-AA6X-01A-12D-A42E-08	TCGA-DK-AA6X-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X605_splice	0.225	40.0	0.0	0.0																									RB1 p.X605_splice (Splice Site)		BLCA_VARSCAN2	TCGA-FD-A62N-01A-11D-A30E-08	TCGA-FD-A62N-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.S634*	0.2326	43.0	0.0	0.0																									RB1 p.S634* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-A9SW-01A-11D-A42E-08	TCGA-XF-A9SW-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.P759L	0.3889	18.0	0.0	0.0																									BRD4 p.P759L (Missense)		BLCA_VARSCAN2	TCGA-CU-A72E-01A-12D-A339-08	TCGA-CU-A72E-10A-01D-A339-08
Biologically Relevant				Somatic Variant	POT1	Nonsense	p.S250*	0.48	25.0	0.0	0.0																									POT1 p.S250* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A6TC-01A-21D-A339-08	TCGA-FD-A6TC-10A-21D-A339-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.E315*	0.4545	33.0	0.0	0.0																									RB1 p.E315* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A6TC-01A-21D-A339-08	TCGA-FD-A6TC-10A-21D-A339-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.E602K	0.5227	331.0	0.0	0.0																									LIMK2 p.E602K (Missense)		BLCA_VARSCAN2	TCGA-FD-A6TC-01A-21D-A339-08	TCGA-FD-A6TC-10A-21D-A339-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.E754Q	0.2031	64.0	0.0	0.0																									MLH1 p.E754Q (Missense)		BLCA_VARSCAN2	TCGA-GD-A2C5-01A-12D-A17V-08	TCGA-GD-A2C5-10A-01D-A17V-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.S119L	0.1239	113.0	0.0	0.0																									POT1 p.S119L (Missense)		BLCA_VARSCAN2	TCGA-GD-A2C5-01A-12D-A17V-08	TCGA-GD-A2C5-10A-01D-A17V-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.Q119E	0.8462	78.0	0.0	0.0																									NTRK3 p.Q119E (Missense)		BLCA_VARSCAN2	TCGA-XF-AAMX-01A-11D-A42E-08	TCGA-XF-AAMX-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.D153N	0.4583	24.0	0.0	0.0																									SLC45A3 p.D153N (Missense)		BLCA_VARSCAN2	TCGA-UY-A9PF-01A-11D-A38G-08	TCGA-UY-A9PF-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.R116P	0.1618	68.0	0.0	0.0																									KEAP1 p.R116P (Missense)		BLCA_VARSCAN2	TCGA-GC-A3WC-01A-31D-A22Z-08	TCGA-GC-A3WC-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.G513S	0.1515	33.0	0.0	0.0																									IL12RB1 p.G513S (Missense)		BLCA_VARSCAN2	TCGA-GC-A3WC-01A-31D-A22Z-08	TCGA-GC-A3WC-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	CCND1	Missense	p.S41L	0.4394	66.0	0.0	0.0																									CCND1 p.S41L (Missense)		BLCA_VARSCAN2	TCGA-XF-A8HI-01A-11D-A38G-08	TCGA-XF-A8HI-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.E94K	0.1311	61.0	0.0	0.0																									CDK4 p.E94K (Missense)		BLCA_VARSCAN2	TCGA-XF-A9SM-01A-11D-A42E-08	TCGA-XF-A9SM-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.S149*	0.2013	154.0	0.0	0.0																									RB1 p.S149* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-A9SM-01A-11D-A42E-08	TCGA-XF-A9SM-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L2103F	0.44	100.0	0.0	0.0																									NF1 p.L2103F (Missense)		BLCA_VARSCAN2	TCGA-E7-A7DU-01A-11D-A32B-08	TCGA-E7-A7DU-10A-01D-A329-08
Biologically Relevant				Somatic Variant	AURKB	Missense	p.E78Q	0.3333	42.0	0.0	0.0																									AURKB p.E78Q (Missense)		BLCA_VARSCAN2	TCGA-G2-AA3C-01A-21D-A391-08	TCGA-G2-AA3C-10A-01D-A394-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.N549K	0.3488	43.0	0.0	0.0																									FGFR2 p.N549K (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T2-01A-11D-A42E-08	TCGA-XF-A9T2-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.E13K	0.2609	115.0	0.0	0.0																									MLH1 p.E13K (Missense)		BLCA_VARSCAN2	TCGA-C4-A0F1-01A-11D-A10S-08	TCGA-C4-A0F1-10A-01D-A10S-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.Q1866H	0.2128	47.0	0.0	0.0																									MTOR p.Q1866H (Missense)		BLCA_VARSCAN2	TCGA-UY-A9PH-01A-11D-A38G-08	TCGA-UY-A9PH-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.S318C	0.2941	85.0	0.0	0.0																									TMPRSS2 p.S318C (Missense)		BLCA_VARSCAN2	TCGA-UY-A9PH-01A-11D-A38G-08	TCGA-UY-A9PH-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.S567L	0.32	50.0	0.0	0.0																									RB1 p.S567L (Missense)		BLCA_VARSCAN2	TCGA-FD-A3B6-01A-21D-A20D-08	TCGA-FD-A3B6-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.L596V	0.3553	76.0	0.0	0.0																									RB1 p.L596V (Missense)		BLCA_VARSCAN2	TCGA-FD-A3B6-01A-21D-A20D-08	TCGA-FD-A3B6-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.G310*	0.4545	11.0	0.0	0.0																									RB1 p.G310* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-AAML-01A-11D-A42E-08	TCGA-XF-AAML-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.I630T	0.1529	170.0	0.0	0.0																									MLH1 p.I630T (Missense)		BLCA_VARSCAN2	TCGA-GC-A6I3-01A-11D-A31L-08	TCGA-GC-A6I3-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.G89Lfs*30	0.9412	17.0	0.0	0.0																									CDKN2A p.G89Lfs*30 (Frameshift)		BLCA_VARSCAN2	TCGA-GC-A3BM-01A-11D-A22Z-08	TCGA-GC-A3BM-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.D464N	0.2903	155.0	0.0	0.0																									PMS2 p.D464N (Missense)		BLCA_VARSCAN2	TCGA-DK-A1A3-01A-11D-A13W-08	TCGA-DK-A1A3-10A-01D-A13W-08
Biologically Relevant				Somatic Variant	KEAP1	Frameshift	p.Y537Afs*12	0.2333	30.0	0.0	0.0																									KEAP1 p.Y537Afs*12 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A1A3-01A-11D-A13W-08	TCGA-DK-A1A3-10A-01D-A13W-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.E25K	0.2	95.0	0.0	0.0																									KEAP1 p.E25K (Missense)		BLCA_VARSCAN2	TCGA-DK-A1A3-01A-11D-A13W-08	TCGA-DK-A1A3-10A-01D-A13W-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.E649K	0.2119	151.0	0.0	0.0																									TPX2 p.E649K (Missense)		BLCA_VARSCAN2	TCGA-DK-A1A3-01A-11D-A13W-08	TCGA-DK-A1A3-10A-01D-A13W-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.S420L	0.4565	138.0	0.0	0.0																									ERG p.S420L (Missense)		BLCA_VARSCAN2	TCGA-DK-A1A3-01A-11D-A13W-08	TCGA-DK-A1A3-10A-01D-A13W-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1518Q	0.2857	28.0	0.0	0.0																									ROS1 p.E1518Q (Missense)		BLCA_VARSCAN2	TCGA-XF-A8HB-01A-11D-A364-08	TCGA-XF-A8HB-10A-01D-A362-08
Biologically Relevant				Somatic Variant	CD274	Missense	p.R82K	0.4571	35.0	0.0	0.0																									CD274 p.R82K (Missense)		BLCA_VARSCAN2	TCGA-XF-A8HB-01A-11D-A364-08	TCGA-XF-A8HB-10A-01D-A362-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.A425T	0.4677	124.0	0.0	0.0																									NTRK1 p.A425T (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.R269H	0.5938	64.0	0.0	0.0																									SLC45A3 p.R269H (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	EML4	Nonsense	p.E127*	0.3962	53.0	0.0	0.0																									EML4 p.E127* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.R474W	0.4593	172.0	0.0	0.0																									MLH1 p.R474W (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E1348D	0.4444	81.0	0.0	0.0																									ROS1 p.E1348D (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.K646R	0.4789	142.0	0.0	0.0																									ROS1 p.K646R (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.Q520H	0.5429	70.0	0.0	0.0																									ROS1 p.Q520H (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.T257A	0.51	100.0	0.0	0.0																									ROS1 p.T257A (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E238K	0.4955	111.0	0.0	0.0																									RUNX1T1 p.E238K (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.W221*	0.4746	59.0	0.0	0.0																									NF1 p.W221* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R304Q	0.4194	62.0	0.0	0.0																									NF1 p.R304Q (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.E470*	0.4091	22.0	0.0	0.0																									NF1 p.E470* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	AURKA	Missense	p.R189W	0.4217	83.0	0.0	0.0																									AURKA p.R189W (Missense)		BLCA_VARSCAN2	TCGA-DK-A6AW-01A-11D-A30E-08	TCGA-DK-A6AW-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.F7L	0.3297	91.0	0.0	0.0																									MYC p.F7L (Missense)		BLCA_VARSCAN2	TCGA-K4-A3WS-01A-11D-A22Z-08	TCGA-K4-A3WS-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	CCND3	Nonsense	p.Q260*	0.6667	9.0	0.0	0.0																									CCND3 p.Q260* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A3SN-01A-12D-A22Z-08	TCGA-FD-A3SN-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	NF1	Frameshift	p.L952Yfs*19	0.2769	65.0	0.0	0.0																									NF1 p.L952Yfs*19 (Frameshift)		BLCA_VARSCAN2	TCGA-FD-A3SN-01A-12D-A22Z-08	TCGA-FD-A3SN-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.G179R	0.6061	33.0	0.0	0.0																									NTRK1 p.G179R (Missense)		BLCA_VARSCAN2	TCGA-5N-A9KI-01A-31D-A42E-08	TCGA-5N-A9KI-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.M708K	0.2963	54.0	0.0	0.0																									RB1 p.M708K (Missense)		BLCA_VARSCAN2	TCGA-5N-A9KI-01A-31D-A42E-08	TCGA-5N-A9KI-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.S834*	0.3299	97.0	0.0	0.0																									RB1 p.S834* (Nonsense)		BLCA_VARSCAN2	TCGA-5N-A9KI-01A-31D-A42E-08	TCGA-5N-A9KI-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.S18Y	0.3333	39.0	0.0	0.0																									EML4 p.S18Y (Missense)		BLCA_VARSCAN2	TCGA-DK-AA71-01A-31D-A391-08	TCGA-DK-AA71-10A-01D-A394-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.E1266K	0.6667	9.0	0.0	0.0																									BRD4 p.E1266K (Missense)		BLCA_VARSCAN2	TCGA-DK-AA71-01A-31D-A391-08	TCGA-DK-AA71-10A-01D-A394-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.E1183K	0.5556	81.0	0.0	0.0																									BRD4 p.E1183K (Missense)		BLCA_VARSCAN2	TCGA-DK-AA71-01A-31D-A391-08	TCGA-DK-AA71-10A-01D-A394-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.D829N	0.9398	83.0	0.0	0.0																									TACC3 p.D829N (Missense)		BLCA_VARSCAN2	TCGA-BT-A20P-01A-11D-A14W-08	TCGA-BT-A20P-11A-11D-A14W-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.E1889K	0.3514	111.0	0.0	0.0																									NF1 p.E1889K (Missense)		BLCA_VARSCAN2	TCGA-BT-A20P-01A-11D-A14W-08	TCGA-BT-A20P-11A-11D-A14W-08
Biologically Relevant				Somatic Variant	CD274	Missense	p.W57C	0.3137	51.0	0.0	0.0																									CD274 p.W57C (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA56-01A-31D-A391-08	TCGA-ZF-AA56-10A-01D-A394-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.L2209V	0.1705	88.0	0.0	0.0																									MTOR p.L2209V (Missense)		BLCA_VARSCAN2	TCGA-BT-A0YX-01A-11D-A10S-08	TCGA-BT-A0YX-10A-01D-A10S-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P194S	0.213	108.0	0.0	0.0																									ROS1 p.P194S (Missense)		BLCA_VARSCAN2	TCGA-BT-A0YX-01A-11D-A10S-08	TCGA-BT-A0YX-10A-01D-A10S-08
Biologically Relevant				Somatic Variant	AURKB	Missense	p.S37Y	0.1692	65.0	0.0	0.0																									AURKB p.S37Y (Missense)		BLCA_VARSCAN2	TCGA-BT-A0YX-01A-11D-A10S-08	TCGA-BT-A0YX-10A-01D-A10S-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.E1845K	0.4262	61.0	0.0	0.0																									MTOR p.E1845K (Missense)		BLCA_VARSCAN2	TCGA-LT-A5Z6-01A-11D-A289-08	TCGA-LT-A5Z6-10A-01D-A289-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L1937I	0.7073	41.0	0.0	0.0																									ROS1 p.L1937I (Missense)		BLCA_VARSCAN2	TCGA-LT-A5Z6-01A-11D-A289-08	TCGA-LT-A5Z6-10A-01D-A289-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.L387V	0.2	65.0	0.0	0.0																									FIP1L1 p.L387V (Missense)		BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.L311F	0.3077	104.0	0.0	0.0																									FGFR1 p.L311F (Missense)		BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.D543H	0.3226	62.0	0.0	0.0																									RUNX1T1 p.D543H (Missense)		BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Biologically Relevant				Somatic Variant	TMPRSS2	Nonsense	p.W290*	0.25	32.0	0.0	0.0																									TMPRSS2 p.W290* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A3WW-01A-22D-A23M-08	TCGA-DK-A3WW-10A-01D-A23K-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.F90Lfs*30	0.7059	17.0	0.0	0.0																									CDKN2A p.F90Lfs*30 (Frameshift)		BLCA_VARSCAN2	TCGA-FD-A5BV-01A-11D-A26M-08	TCGA-FD-A5BV-10A-01D-A26K-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R2450Q	0.1533	150.0	0.0	0.0																									NF1 p.R2450Q (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7M-01A-11D-A391-08	TCGA-4Z-AA7M-10A-01D-A394-08
Biologically Relevant				Somatic Variant	PDGFRB	Splice Site	p.X969_splice	0.3333	12.0	0.0	0.0																									PDGFRB p.X969_splice (Splice Site)		BLCA_VARSCAN2	TCGA-ZF-AA53-01A-11D-A391-08	TCGA-ZF-AA53-10A-01D-A394-08
Biologically Relevant				Somatic Variant	CCND3	Missense	p.I126M	0.2476	105.0	0.0	0.0																									CCND3 p.I126M (Missense)		BLCA_VARSCAN2	TCGA-G2-A2EF-01A-12D-A18F-08	TCGA-G2-A2EF-10A-01D-A18F-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L447F	0.3095	126.0	0.0	0.0																									NF1 p.L447F (Missense)		BLCA_VARSCAN2	TCGA-GC-A3I6-01A-11D-A20D-08	TCGA-GC-A3I6-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.S1053*	0.2667	15.0	0.0	0.0																									NF1 p.S1053* (Nonsense)		BLCA_VARSCAN2	TCGA-GC-A3I6-01A-11D-A20D-08	TCGA-GC-A3I6-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G2119R	0.127	126.0	0.0	0.0																									ROS1 p.G2119R (Missense)		BLCA_VARSCAN2	TCGA-FT-A61P-01A-11D-A30E-08	TCGA-FT-A61P-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.P2241S	0.2319	69.0	0.0	0.0																									MTOR p.P2241S (Missense)		BLCA_VARSCAN2	TCGA-DK-A6B6-01A-11D-A30E-08	TCGA-DK-A6B6-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.S7L	0.4957	115.0	0.0	0.0																									PMS2 p.S7L (Missense)		BLCA_VARSCAN2	TCGA-DK-A6B6-01A-11D-A30E-08	TCGA-DK-A6B6-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.M53I	0.3235	34.0	0.0	0.0																									CDKN2A p.M53I (Missense)		BLCA_VARSCAN2	TCGA-DK-A6B6-01A-11D-A30E-08	TCGA-DK-A6B6-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.N42Rfs*75	0.2083	192.0	0.0	0.0																									CDKN2A p.N42Rfs*75 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A6B6-01A-11D-A30E-08	TCGA-DK-A6B6-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.E914K	0.2857	14.0	0.0	0.0																									BRD4 p.E914K (Missense)		BLCA_VARSCAN2	TCGA-DK-A6B6-01A-11D-A30E-08	TCGA-DK-A6B6-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.E458*	0.5294	17.0	0.0	0.0																									RB1 p.E458* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A5C0-01A-11D-A289-08	TCGA-FD-A5C0-10A-01D-A289-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.P175L	0.2667	45.0	0.0	0.0																									EML4 p.P175L (Missense)		BLCA_VARSCAN2	TCGA-GC-A6I1-01A-12D-A31L-08	TCGA-GC-A6I1-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S808L	0.129	155.0	0.0	0.0																									ROS1 p.S808L (Missense)		BLCA_VARSCAN2	TCGA-GU-AATO-01A-11D-A391-08	TCGA-GU-AATO-10A-01D-A394-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.S391*	0.686	242.0	0.0	0.0																									RB1 p.S391* (Nonsense)		BLCA_VARSCAN2	TCGA-GU-AATO-01A-11D-A391-08	TCGA-GU-AATO-10A-01D-A394-08
Biologically Relevant				Somatic Variant	COL1A1	Nonsense	p.Q1304*	0.1586	145.0	0.0	0.0																									COL1A1 p.Q1304* (Nonsense)		BLCA_VARSCAN2	TCGA-GU-AATO-01A-11D-A391-08	TCGA-GU-AATO-10A-01D-A394-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q756*	0.2727	44.0	0.0	0.0																									NF1 p.Q756* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-AAN5-01A-11D-A42E-08	TCGA-XF-AAN5-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.S788Pfs*14	0.1064	47.0	0.0	0.0																									RB1 p.S788Pfs*14 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-AAMQ-01A-11D-A42E-08	TCGA-XF-AAMQ-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X51_splice	0.52	25.0	0.0	0.0																									CDKN2A p.X51_splice (Splice Site)		BLCA_VARSCAN2	TCGA-G2-A2ES-01A-11D-A17V-08	TCGA-G2-A2ES-11A-31D-A17V-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.R828Nfs*5	0.6047	43.0	0.0	0.0																									RB1 p.R828Nfs*5 (Frameshift)		BLCA_VARSCAN2	TCGA-GV-A40G-01A-11D-A23M-08	TCGA-GV-A40G-10A-01D-A23K-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X888_splice	0.2577	97.0	0.0	0.0																									RB1 p.X888_splice (Splice Site)		BLCA_VARSCAN2	TCGA-GV-A40G-01A-11D-A23M-08	TCGA-GV-A40G-10A-01D-A23K-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.E125Q	0.3143	70.0	0.0	0.0																									RAF1 p.E125Q (Missense)		BLCA_VARSCAN2	TCGA-FD-A5BX-01A-11D-A26M-08	TCGA-FD-A5BX-10A-01D-A26K-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.R464T	0.2167	60.0	0.0	0.0																									EWSR1 p.R464T (Missense)		BLCA_VARSCAN2	TCGA-FD-A5BX-01A-11D-A26M-08	TCGA-FD-A5BX-10A-01D-A26K-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.A430T	0.1739	46.0	0.0	0.0																									ERG p.A430T (Missense)		BLCA_VARSCAN2	TCGA-XF-A8HE-01A-11D-A364-08	TCGA-XF-A8HE-10A-01D-A362-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.L554F	0.6441	1169.0	0.0	0.0																									TACC3 p.L554F (Missense)		BLCA_VARSCAN2	TCGA-DK-A3IS-01A-21D-A21A-08	TCGA-DK-A3IS-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	PDGFRB	Splice Site	p.X968_splice	0.5952	84.0	0.0	0.0																									PDGFRB p.X968_splice (Splice Site)		BLCA_VARSCAN2	TCGA-DK-A3IS-01A-21D-A21A-08	TCGA-DK-A3IS-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.E53*	0.2628	137.0	0.0	0.0																									RB1 p.E53* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-AAN2-01A-11D-A42E-08	TCGA-XF-AAN2-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.Q850*	0.9118	34.0	0.0	0.0																									RB1 p.Q850* (Nonsense)		BLCA_VARSCAN2	TCGA-BT-A2LA-01A-11D-A18F-08	TCGA-BT-A2LA-11A-11D-A18F-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.E717Q	0.1034	58.0	0.0	0.0																									MLH1 p.E717Q (Missense)		BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S829F	0.1429	49.0	0.0	0.0																									ROS1 p.S829F (Missense)		BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.I736M	0.3529	51.0	0.0	0.0																									ROS1 p.I736M (Missense)		BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.H139Y	0.2222	126.0	0.0	0.0																									PMS2 p.H139Y (Missense)		BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.E667*	0.7179	39.0	0.0	0.0																									RB1 p.E667* (Nonsense)		BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.D1490Y	0.2109	128.0	0.0	0.0																									NF1 p.D1490Y (Missense)		BLCA_VARSCAN2	TCGA-MV-A51V-01A-11D-A26M-08	TCGA-MV-A51V-10A-01D-A26K-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.P554S	0.3784	37.0	0.0	0.0																									ESRP1 p.P554S (Missense)		BLCA_VARSCAN2	TCGA-XF-A9SK-01A-11D-A42E-08	TCGA-XF-A9SK-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S1524L	0.3548	31.0	0.0	0.0																									ROS1 p.S1524L (Missense)		BLCA_VARSCAN2	TCGA-UY-A8OB-01A-12D-A42E-08	TCGA-UY-A8OB-11A-12D-A42H-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.D735H	0.8125	16.0	0.0	0.0																									FGFR1 p.D735H (Missense)		BLCA_VARSCAN2	TCGA-UY-A8OB-01A-12D-A42E-08	TCGA-UY-A8OB-11A-12D-A42H-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.R1170S	0.2105	19.0	0.0	0.0																									COL1A1 p.R1170S (Missense)		BLCA_VARSCAN2	TCGA-UY-A78O-01A-12D-A339-08	TCGA-UY-A78O-10A-01D-A339-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.V470I	0.3538	65.0	0.0	0.0																									NTRK2 p.V470I (Missense)		BLCA_VARSCAN2	TCGA-CU-A3YL-01A-11D-A22Z-08	TCGA-CU-A3YL-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.D270Rfs*6	0.3065	62.0	0.0	0.0																									RB1 p.D270Rfs*6 (Frameshift)		BLCA_VARSCAN2	TCGA-LC-A66R-01A-41D-A30E-08	TCGA-LC-A66R-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.E210V	0.2051	117.0	0.0	0.0																									NTRK2 p.E210V (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SL-01A-21D-A22Z-08	TCGA-FD-A3SL-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.I744Rfs*7	0.225	40.0	0.0	0.0																									RB1 p.I744Rfs*7 (Frameshift)		BLCA_VARSCAN2	TCGA-FD-A3SL-01A-21D-A22Z-08	TCGA-FD-A3SL-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.M761L	0.1579	57.0	0.0	0.0																									RB1 p.M761L (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SL-01A-21D-A22Z-08	TCGA-FD-A3SL-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	POLE2	Missense	p.R470I	0.4634	82.0	0.0	0.0																									POLE2 p.R470I (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7S-01A-11D-A391-08	TCGA-4Z-AA7S-10A-01D-A394-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.Y44*	0.52	100.0	0.0	0.0																									CDKN2A p.Y44* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-A9RD-01A-11D-A42E-08	TCGA-ZF-A9RD-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	CCND1	Missense	p.P199S	0.2568	74.0	0.0	0.0																									CCND1 p.P199S (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7W-01A-11D-A391-08	TCGA-4Z-AA7W-10A-01D-A394-08
Biologically Relevant				Somatic Variant	CD274	Frameshift	p.E188Vfs*18	0.3043	69.0	0.0	0.0																									CD274 p.E188Vfs*18 (Frameshift)		BLCA_VARSCAN2	TCGA-4Z-AA89-01A-11D-A391-08	TCGA-4Z-AA89-10A-01D-A394-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.5385	13.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		BLCA_VARSCAN2	TCGA-GU-A42Q-01A-11D-A23U-08	TCGA-GU-A42Q-10A-01D-A23U-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.S45F	0.36	75.0	0.0	0.0																									KEAP1 p.S45F (Missense)		BLCA_VARSCAN2	TCGA-GU-A42Q-01A-11D-A23U-08	TCGA-GU-A42Q-10A-01D-A23U-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.K143Sfs*2	0.6852	54.0	0.0	0.0																									RB1 p.K143Sfs*2 (Frameshift)		BLCA_VARSCAN2	TCGA-DK-A3IM-01A-11D-A20D-08	TCGA-DK-A3IM-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	CCND1	Missense	p.P220L	0.1636	110.0	0.0	0.0																									CCND1 p.P220L (Missense)		BLCA_VARSCAN2	TCGA-E7-A8O8-01A-11D-A364-08	TCGA-E7-A8O8-10A-01D-A362-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.I547M	0.4231	52.0	0.0	0.0																									ROS1 p.I547M (Missense)		BLCA_VARSCAN2	TCGA-GU-AATP-01A-11D-A391-08	TCGA-GU-AATP-10A-01D-A394-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.S309L	0.3147	143.0	0.0	0.0																									CCNE1 p.S309L (Missense)		BLCA_VARSCAN2	TCGA-GU-AATP-01A-11D-A391-08	TCGA-GU-AATP-10A-01D-A394-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.E777K	0.1173	179.0	0.0	0.0																									FGFR2 p.E777K (Missense)		BLCA_VARSCAN2	TCGA-E7-A6MD-01A-41D-A34U-08	TCGA-E7-A6MD-10B-01D-A34X-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X405_splice	0.2545	55.0	0.0	0.0																									RB1 p.X405_splice (Splice Site)		BLCA_VARSCAN2	TCGA-ZF-AA4V-01A-11D-A38G-08	TCGA-ZF-AA4V-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	PAK1	Frameshift	p.R105Afs*39	0.3673	49.0	0.0	0.0																									PAK1 p.R105Afs*39 (Frameshift)		BLCA_VARSCAN2	TCGA-E7-A519-01A-11D-A26M-08	TCGA-E7-A519-10A-01D-A26K-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.K192Nfs*9	0.4615	39.0	0.0	0.0																									RB1 p.K192Nfs*9 (Frameshift)		BLCA_VARSCAN2	TCGA-YF-AA3M-01A-11D-A42E-08	TCGA-YF-AA3M-10D-01D-A42H-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.S194C	0.5294	34.0	0.0	0.0																									RB1 p.S194C (Missense)		BLCA_VARSCAN2	TCGA-YF-AA3M-01A-11D-A42E-08	TCGA-YF-AA3M-10D-01D-A42H-08
Biologically Relevant				Somatic Variant	CCND3	Missense	p.P265T	0.3243	37.0	0.0	0.0																									CCND3 p.P265T (Missense)		BLCA_VARSCAN2	TCGA-DK-A2I6-01A-12D-A18F-08	TCGA-DK-A2I6-10A-01D-A18F-08
Biologically Relevant				Somatic Variant	CCND3	Missense	p.E75D	0.4795	73.0	0.0	0.0																									CCND3 p.E75D (Missense)		BLCA_VARSCAN2	TCGA-DK-A2I6-01A-12D-A18F-08	TCGA-DK-A2I6-10A-01D-A18F-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.N234Y	0.1569	102.0	0.0	0.0																									NTRK2 p.N234Y (Missense)		BLCA_VARSCAN2	TCGA-DK-A2I6-01A-12D-A18F-08	TCGA-DK-A2I6-10A-01D-A18F-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.R344T	0.2155	116.0	0.0	0.0																									EML4 p.R344T (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RC-01A-11D-A38G-08	TCGA-ZF-A9RC-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.E5K	0.2222	63.0	0.0	0.0																									PMS2 p.E5K (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RC-01A-11D-A38G-08	TCGA-ZF-A9RC-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.H352Y	0.1404	57.0	0.0	0.0																									FGFR1 p.H352Y (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RC-01A-11D-A38G-08	TCGA-ZF-A9RC-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.E163K	0.2143	70.0	0.0	0.0																									ESRP1 p.E163K (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9RC-01A-11D-A38G-08	TCGA-ZF-A9RC-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P1131R	0.375	48.0	0.0	0.0																									COL1A1 p.P1131R (Missense)		BLCA_VARSCAN2	TCGA-E7-A5KE-01A-11D-A289-08	TCGA-E7-A5KE-10A-01D-A289-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.P370A	0.4909	275.0	0.0	0.0																									TPX2 p.P370A (Missense)		BLCA_VARSCAN2	TCGA-FD-A62O-01A-11D-A30E-08	TCGA-FD-A62O-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.S332F	0.1915	47.0	0.0	0.0																									FGFR1 p.S332F (Missense)		BLCA_VARSCAN2	TCGA-GC-A3RC-01A-11D-A22Z-08	TCGA-GC-A3RC-10B-01D-A22Z-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.E1020K	0.4615	78.0	0.0	0.0																									NF1 p.E1020K (Missense)		BLCA_VARSCAN2	TCGA-GC-A3RC-01A-11D-A22Z-08	TCGA-GC-A3RC-10B-01D-A22Z-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X405_splice	0.55	120.0	0.0	0.0																									RB1 p.X405_splice (Splice Site)		BLCA_VARSCAN2	TCGA-C4-A0F0-01A-12D-A10S-08	TCGA-C4-A0F0-10A-01D-A10S-08
Biologically Relevant				Somatic Variant	CCND3	Missense	p.L32R	0.7	10.0	0.0	0.0																									CCND3 p.L32R (Missense)		BLCA_VARSCAN2	TCGA-CU-A3QU-01A-11D-A22Z-08	TCGA-CU-A3QU-10B-01D-A22Z-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.D38N	0.2414	29.0	0.0	0.0																									NTRK1 p.D38N (Missense)		BLCA_VARSCAN2	TCGA-DK-A2I4-01A-11D-A21A-08	TCGA-DK-A2I4-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.D491Y	0.2985	67.0	0.0	0.0																									SLC45A3 p.D491Y (Missense)		BLCA_VARSCAN2	TCGA-DK-A2I4-01A-11D-A21A-08	TCGA-DK-A2I4-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.R2825T	0.15	60.0	0.0	0.0																									NF1 p.R2825T (Missense)		BLCA_VARSCAN2	TCGA-FD-A3NA-01A-11D-A21A-08	TCGA-FD-A3NA-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X405_splice	0.3696	46.0	0.0	0.0																									RB1 p.X405_splice (Splice Site)		BLCA_VARSCAN2	TCGA-DK-A3IV-01A-22D-A21A-08	TCGA-DK-A3IV-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.Q850*	1.0	40.0	0.0	0.0																									RB1 p.Q850* (Nonsense)		BLCA_VARSCAN2	TCGA-G2-A2EL-01A-12D-A18F-08	TCGA-G2-A2EL-10A-01D-A18F-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.D417N	0.125	40.0	0.0	0.0																									FIP1L1 p.D417N (Missense)		BLCA_VARSCAN2	TCGA-FD-A43P-01A-31D-A23U-08	TCGA-FD-A43P-10A-01D-A23U-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R320*	0.3448	58.0	0.0	0.0																									RB1 p.R320* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A43P-01A-31D-A23U-08	TCGA-FD-A43P-10A-01D-A23U-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P1667S	0.2338	77.0	0.0	0.0																									ROS1 p.P1667S (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4W-01A-12D-A38G-08	TCGA-ZF-AA4W-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.R448H	0.1077	65.0	0.0	0.0																									ESRP1 p.R448H (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4W-01A-12D-A38G-08	TCGA-ZF-AA4W-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P114T	0.2917	24.0	0.0	0.0																									CDKN2A p.P114T (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4W-01A-12D-A38G-08	TCGA-ZF-AA4W-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CDK4	Deletion	p.G48del	0.1385	65.0	0.0	0.0																									CDK4 p.G48del (Deletion)		BLCA_VARSCAN2	TCGA-ZF-AA4W-01A-12D-A38G-08	TCGA-ZF-AA4W-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.Q132H	0.3261	46.0	0.0	0.0																									TPX2 p.Q132H (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4W-01A-12D-A38G-08	TCGA-ZF-AA4W-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.Q217*	0.8049	82.0	0.0	0.0																									RB1 p.Q217* (Nonsense)		BLCA_VARSCAN2	TCGA-GV-A3JX-01A-11D-A20D-08	TCGA-GV-A3JX-10A-01D-A20D-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X376_splice	0.3333	99.0	0.0	0.0																									RB1 p.X376_splice (Splice Site)		BLCA_VARSCAN2	TCGA-K4-A6FZ-01A-11D-A31L-08	TCGA-K4-A6FZ-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.E522Q	0.3444	180.0	0.0	0.0																									TACC3 p.E522Q (Missense)		BLCA_VARSCAN2	TCGA-C4-A0F6-01A-11D-A10S-08	TCGA-C4-A0F6-10A-01D-A10S-08
Biologically Relevant				Somatic Variant	CDKN2A	Frameshift	p.A102Rfs*19	0.32	25.0	0.0	0.0																									CDKN2A p.A102Rfs*19 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-A9SY-01A-21D-A42E-08	TCGA-XF-A9SY-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.E559*	0.7209	43.0	0.0	0.0																									RB1 p.E559* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-AAMF-01A-21D-A42E-08	TCGA-XF-AAMF-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S125C	0.1698	53.0	0.0	0.0																									ROS1 p.S125C (Missense)		BLCA_VARSCAN2	TCGA-XF-AAN0-01A-11D-A42E-08	TCGA-XF-AAN0-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.R798Tfs*17	0.3889	72.0	0.0	0.0																									RB1 p.R798Tfs*17 (Frameshift)		BLCA_VARSCAN2	TCGA-XF-AAN0-01A-11D-A42E-08	TCGA-XF-AAN0-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S1581C	0.2105	38.0	0.0	0.0																									ROS1 p.S1581C (Missense)		BLCA_VARSCAN2	TCGA-G2-A2EJ-01A-11D-A17V-08	TCGA-G2-A2EJ-10A-01D-A17V-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.E218Q	0.2	20.0	0.0	0.0																									KEAP1 p.E218Q (Missense)		BLCA_VARSCAN2	TCGA-G2-A2EJ-01A-11D-A17V-08	TCGA-G2-A2EJ-10A-01D-A17V-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.L86R	0.2146	219.0	0.0	0.0																									RAF1 p.L86R (Missense)		BLCA_VARSCAN2	TCGA-BT-A3PJ-01A-21D-A21Z-08	TCGA-BT-A3PJ-10A-01D-A21Z-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.T271Nfs*5	0.4355	62.0	0.0	0.0																									RB1 p.T271Nfs*5 (Frameshift)		BLCA_VARSCAN2	TCGA-BT-A3PJ-01A-21D-A21Z-08	TCGA-BT-A3PJ-10A-01D-A21Z-08
Biologically Relevant				Somatic Variant	ERG	Missense	p.G401W	0.3758	157.0	0.0	0.0																									ERG p.G401W (Missense)		BLCA_VARSCAN2	TCGA-BT-A3PJ-01A-21D-A21Z-08	TCGA-BT-A3PJ-10A-01D-A21Z-08
Biologically Relevant				Somatic Variant	TACC3	Frameshift	p.S787Pfs*30	0.24	25.0	0.0	0.0																									TACC3 p.S787Pfs*30 (Frameshift)		BLCA_VARSCAN2	TCGA-BT-A20N-01A-11D-A14W-08	TCGA-BT-A20N-11A-11D-A14W-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.D108Y	0.825	40.0	0.0	0.0																									CDKN2A p.D108Y (Missense)		BLCA_VARSCAN2	TCGA-E7-A677-01A-11D-A30E-08	TCGA-E7-A677-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.S611L	0.1528	72.0	0.0	0.0																									ESRP1 p.S611L (Missense)		BLCA_VARSCAN2	TCGA-KQ-A41R-01A-21D-A34U-08	TCGA-KQ-A41R-10G-01D-A34X-08
Biologically Relevant				Somatic Variant	CRKL	Missense	p.R21C	0.4167	60.0	0.0	0.0																									CRKL p.R21C (Missense)		BLCA_VARSCAN2	TCGA-KQ-A41R-01A-21D-A34U-08	TCGA-KQ-A41R-10G-01D-A34X-08
Biologically Relevant				Somatic Variant	PAK1	Missense	p.E417Q	0.5	58.0	0.0	0.0																									PAK1 p.E417Q (Missense)		BLCA_VARSCAN2	TCGA-G2-AA3B-01A-11D-A391-08	TCGA-G2-AA3B-10A-01D-A394-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.K355I	0.2022	89.0	0.0	0.0																									POT1 p.K355I (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AC-01A-11D-A13W-08	TCGA-DK-A1AC-10A-01D-A13W-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.E238K	0.1327	196.0	0.0	0.0																									RUNX1T1 p.E238K (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AC-01A-11D-A13W-08	TCGA-DK-A1AC-10A-01D-A13W-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.S780L	0.281	121.0	0.0	0.0																									FGFR2 p.S780L (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AC-01A-11D-A13W-08	TCGA-DK-A1AC-10A-01D-A13W-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.V86M	0.2524	103.0	0.0	0.0																									FGFR2 p.V86M (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AC-01A-11D-A13W-08	TCGA-DK-A1AC-10A-01D-A13W-08
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.S69C	0.2381	42.0	0.0	0.0																									PDGFB p.S69C (Missense)		BLCA_VARSCAN2	TCGA-DK-A1AC-01A-11D-A13W-08	TCGA-DK-A1AC-10A-01D-A13W-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.P5S	0.3908	87.0	0.0	0.0																									POT1 p.P5S (Missense)		BLCA_VARSCAN2	TCGA-4Z-AA7Y-01A-11D-A391-08	TCGA-4Z-AA7Y-10A-01D-A394-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.L53F	0.2716	81.0	0.0	0.0																									NTRK3 p.L53F (Missense)		BLCA_VARSCAN2	TCGA-E7-A85H-01A-11D-A34U-08	TCGA-E7-A85H-10B-01D-A34X-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.D49N	0.4677	201.0	0.0	0.0																									COL1A1 p.D49N (Missense)		BLCA_VARSCAN2	TCGA-E7-A85H-01A-11D-A34U-08	TCGA-E7-A85H-10B-01D-A34X-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.R273W	0.3659	41.0	0.0	0.0																									POT1 p.R273W (Missense)		BLCA_VARSCAN2	TCGA-2F-A9KT-01A-11D-A38G-08	TCGA-2F-A9KT-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	MLH1	Splice Site	p.X264_splice	0.1493	67.0	0.0	0.0																									MLH1 p.X264_splice (Splice Site)		BLCA_VARSCAN2	TCGA-2F-A9KO-01A-11D-A38G-08	TCGA-2F-A9KO-11A-12D-A38J-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.D298H	0.1786	84.0	0.0	0.0																									EWSR1 p.D298H (Missense)		BLCA_VARSCAN2	TCGA-2F-A9KO-01A-11D-A38G-08	TCGA-2F-A9KO-11A-12D-A38J-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.E398K	0.295	139.0	0.0	0.0																									NTRK3 p.E398K (Missense)		BLCA_VARSCAN2	TCGA-FD-A3N6-01A-11D-A21A-08	TCGA-FD-A3N6-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.R503W	0.4255	47.0	0.0	0.0																									EWSR1 p.R503W (Missense)		BLCA_VARSCAN2	TCGA-FD-A3N6-01A-11D-A21A-08	TCGA-FD-A3N6-10A-01D-A21A-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.E2049K	0.2287	223.0	0.0	0.0																									MTOR p.E2049K (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R0-01A-11D-A38G-08	TCGA-ZF-A9R0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.E2032K	0.2884	215.0	0.0	0.0																									MTOR p.E2032K (Missense)		BLCA_VARSCAN2	TCGA-ZF-A9R0-01A-11D-A38G-08	TCGA-ZF-A9R0-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.S816*	0.5814	43.0	0.0	0.0																									RB1 p.S816* (Nonsense)		BLCA_VARSCAN2	TCGA-ZF-AA4X-01A-11D-A38G-08	TCGA-ZF-AA4X-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.L259V	0.2903	124.0	0.0	0.0																									CCNE1 p.L259V (Missense)		BLCA_VARSCAN2	TCGA-ZF-AA4X-01A-11D-A38G-08	TCGA-ZF-AA4X-10A-01D-A38J-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R251*	0.2615	65.0	0.0	0.0																									RB1 p.R251* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A3SO-01A-11D-A22Z-08	TCGA-FD-A3SO-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.S834*	0.2358	106.0	0.0	0.0																									RB1 p.S834* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A3SO-01A-11D-A22Z-08	TCGA-FD-A3SO-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.S1078*	0.55	40.0	0.0	0.0																									NF1 p.S1078* (Nonsense)		BLCA_VARSCAN2	TCGA-E5-A4U1-01A-11D-A31L-08	TCGA-E5-A4U1-10B-01D-A31J-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.F31C	0.4491	216.0	0.0	0.0																									POT1 p.F31C (Missense)		BLCA_VARSCAN2	TCGA-UY-A78N-01A-12D-A339-08	TCGA-UY-A78N-10A-01D-A339-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R275L	0.4889	45.0	0.0	0.0																									RUNX1T1 p.R275L (Missense)		BLCA_VARSCAN2	TCGA-GV-A3QI-01A-11D-A21Z-08	TCGA-GV-A3QI-10A-01D-A21Z-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.S12*	0.3947	38.0	0.0	0.0																									CDKN2A p.S12* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A3X1-01A-12D-A22Z-08	TCGA-DK-A3X1-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.S397*	0.1094	192.0	0.0	0.0																									RB1 p.S397* (Nonsense)		BLCA_VARSCAN2	TCGA-DK-A3X1-01A-12D-A22Z-08	TCGA-DK-A3X1-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	CCND1	Missense	p.S41L	0.2	80.0	0.0	0.0																									CCND1 p.S41L (Missense)		BLCA_VARSCAN2	TCGA-BT-A20J-01A-11D-A14W-08	TCGA-BT-A20J-11A-11D-A14W-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.K447M	0.1875	192.0	0.0	0.0																									NTRK1 p.K447M (Missense)		BLCA_VARSCAN2	TCGA-FD-A3SR-01A-11D-A22Z-08	TCGA-FD-A3SR-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	BRD4	Nonsense	p.E555*	0.1489	47.0	0.0	0.0																									BRD4 p.E555* (Nonsense)		BLCA_VARSCAN2	TCGA-FD-A3SR-01A-11D-A22Z-08	TCGA-FD-A3SR-10A-01D-A22Z-08
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.V419Gfs*9	0.3824	68.0	0.0	0.0																									RB1 p.V419Gfs*9 (Frameshift)		BLCA_VARSCAN2	TCGA-K4-A5RH-01A-11D-A30E-08	TCGA-K4-A5RH-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X888_splice	0.2389	113.0	0.0	0.0																									RB1 p.X888_splice (Splice Site)		BLCA_VARSCAN2	TCGA-PQ-A6FN-01A-11D-A31L-08	TCGA-PQ-A6FN-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	CDKN2C	Missense	p.G103E	0.2195	41.0	0.0	0.0																									CDKN2C p.G103E (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T3-01A-11D-A42E-08	TCGA-XF-A9T3-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.C853*	0.2692	26.0	0.0	0.0																									RB1 p.C853* (Nonsense)		BLCA_VARSCAN2	TCGA-XF-A9T3-01A-11D-A42E-08	TCGA-XF-A9T3-10A-01D-A42H-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.S382P	0.4167	60.0	0.0	0.0																									NF1 p.S382P (Missense)		BLCA_VARSCAN2	TCGA-XF-A9T3-01A-11D-A42E-08	TCGA-XF-A9T3-10A-01D-A42H-08
Biologically Relevant				Microsatellite Stability	Supporting variants		MLH1 p.X70_splice (Splice Site), POLE p.X68_splice (Splice Site), MSH3 p.S220* (Nonsense), PMS2 p.S270* (Nonsense), POLE p.A1437dup (Insertion), MSH6 p.S252* (Nonsense), DOCK3 p.K589* (Nonsense), JAK1 p.R174* (Nonsense), JAK1 p.E83* (Nonsense), DOCK3 p.Q1965* (Nonsense), MSH2 p.Q239* (Nonsense), DOCK3 p.L125Kfs*17 (Frameshift), MSH2 p.E278* (Nonsense), POLE p.E1599* (Nonsense), JAK1 p.K860Nfs*16 (Frameshift), MSH6 p.T363del (Deletion), PRDM2 p.Q1654* (Nonsense), MSH6 p.Q698* (Nonsense), MLH1 p.X264_splice (Splice Site)																													Supporting variants: MLH1 p.X70_splice (Splice Site), POLE p.X68_splice (Splice Site), MSH3 p.S220* (Nonsense), PMS2 p.S270* (Nonsense), POLE p.A1437dup (Insertion), MSH6 p.S252* (Nonsense), DOCK3 p.K589* (Nonsense), JAK1 p.R174* (Nonsense), JAK1 p.E83* (Nonsense), DOCK3 p.Q1965* (Nonsense), MSH2 p.Q239* (Nonsense), DOCK3 p.L125Kfs*17 (Frameshift), MSH2 p.E278* (Nonsense), POLE p.E1599* (Nonsense), JAK1 p.K860Nfs*16 (Frameshift), MSH6 p.T363del (Deletion), PRDM2 p.Q1654* (Nonsense), MSH6 p.Q698* (Nonsense), MLH1 p.X264_splice (Splice Site)		BLCA_VARSCAN2		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.229																													COSMIC Signature (version 2) 1 (23%)		BLCA_VARSCAN2		
Biologically Relevant				Mutational Signature	COSMIC Signature 13	version 2	0.252																													COSMIC Signature (version 2) 13 (25%)		BLCA_VARSCAN2		
